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1.1. Environmental concerns regarding veterinary medicines 
 
In the late nineteenth century, the study of the relation between ecosystems and 
(micro) nutrients was an integral part of the science of life (Wells et al., 1930). The impact of 
man-made substances on ecosystems was however never considered1, until the mid-1950’s 
and 1960’s when populations of birds of prey alarmingly declined (up to 91%) in Europe and 
the USA. These declines in reproduction success, as well as field observations of bird 
mortalities, were attributed to insecticides, substances for seed treatment, and rodent baits, 
applied in agriculture for crop protection (Cramp, 1963; Koeman et al., 1972; Mendenhall 
and Pank, 1980; Hill and Fleming, 1982). Regulatory responses to these particular findings 
involved, amongst others, the ban on certain pesticides, and the establishment of an 
environmental risk assessment scheme for the registration of pesticides (see e.g. EU Directive 
79/117/EEC and Luttik (2003)). 
In some incidents with bird mortalities, the substances involved had not been applied 
widespread as pesticides on crops. The organophosphate substances DDVP and famphur 
were applied as veterinary medicines to cattle, either by feed or by pour-on applications 
(Ludke and Locke, 1976; Hill and Mendenhall, 1980; Henny et al., 1985). Also the use of 
organophosphate sheep-dips in Scotland to combat scab and other parasites caused surface 
water contamination and fish mortality (McVeigh et al., 1997). These observations show that 
the medicinal use of pesticides has caused environmental damage comparable to that caused 
by their use in crop protection.   
These examples suggest that measures taken for pesticides used as plant protection 
products2 with respect to environmental risk, should also be taken for the pesticides and 
(related) substances used as veterinary medicines. There are, in fact, several classes of 
substances that are used both as veterinary medicines and as pesticides. Several insecticides 
(e.g. lindane, coumaphos, cypermethrin, avermectin, and imidacloprid) are used both in 
veterinary medicine and in crop protection. Moxidectin and milbemectin are both 
fermentation products from the soil actinomycete Streptomyces sp.. Moxidectin is used as an 
anthelminthic (a substance that expels or destroys intestinal worms) in animals, and 
milbemectin is used as an insecticide in crops. Thiabendazole is an anthelminthic in animals 
that is also approved for post-harvest treatment of citrus fruits against fungi. The fungicide 
trifluralin is applied both in crop protection and in shrimp cultivation. The antibiotic 
oxytetracyclin and streptomycin are applied as veterinary medicines in animals and as foliage 
                                                 
1 Pollution associated with the use and mining of metals has occurred throughout history. Development of the chemical 
industry began in the second half of the nineteenth century. For example, Bayer began the production of dye-stuffs in 
1863. 
2 A substance used for crop protection is generally denoted either a plant protection product or a pesticide. A pesticide used 
to fight pests in non-crop applications, such as buildings, industrial systems, and construction materials, is generally 





pesticides in crops. Some sulfonylurea substances are used to treat diabetes in pets, and other 
sulfonylurea substances are used as herbicides in crops. Copper is a micro-nutrient, and also a 
medicine for treatment of footrot and ringworm in animals. It is also a well-known fungicide 
in crops, and is used for wood preservation and in anti-fouling paint.  
Paracelsus’ theorem "All substances are poisons: there is none that is not a poison. 
The right dose differentiates a poison and a remedy.” provides reason to extend the risk-
based approach applied to pesticides to perhaps all veterinary medicines. Two illustrative 
examples of this concept are warfarin and paracetamol. Therapeutic medicinal use of 
warfarin prevents thromboembolism, while the same compound used as a rodenticide very 
effectively kills rats and mice. Paracetamol is a well-known pain reliever, that also effectively 
controls Brown Tree snakes when applied in baits (Johnston et al., 2002). Considering this 
theorem in combination with the fact that the environment contains countless organisms with 
different sensitivities leads to the hypothesis that veterinary medicines that are not pesticides 
may also pose a risk for the environment.  
This hypothesis has already been substantiated. An alarming decline of vulture 
populations (up to 95%) occurred in Pakistan in the late 1990’s. Recently, research has 
attributed this decline to the use of the anti-inflammatory drug diclofenac in cattle (Oaks et 
al., 2004). Incidental mortalities of bald eagles in the USA have been attributed to the use of 
the anaesthetic pentobarbital in pet animals (Krueger and Krueger, 2003). In general 
however, too little is known about effects of veterinary medicines and their metabolites 
(Boxall et al., 2003).  
The reported environmental damages and the intrinsic pharmacological properties of 
veterinary medicines warrant an environmental risk assessment of the use of veterinary 
medicines.  
 
The marketing of veterinary medicinal products is actively regulated in the European 
Union by Directive 2001/82/EC, amended by Directive 2004/28/EC, with the intent to protect 
the environment, next to animal health, consumers, and professional users3. An 
environmental risk assessment is to be performed at registration, and a clear policy and 
regulatory infrastructure exists to deal with this issue, as well as a number of regulatory 
guidance documents on the environmental risk assessment (EMEA, 1997; VICH, 2000; DG 
Enterprise, 2000).  
Environmental risk assessment is a scientific discipline that investigates the possible 
damage that certain activities, such as the use of veterinary medicines, have for the 
                                                                                                                                                        
biocides under Directive 98/8/EC. In the Netherlands, both are regulated by a single law (Bestrijdingsmiddelenwet, 1962) 
and are specified with the same noun (‘bestrijdingsmiddel’). 
3 The use of veterinary medicines (and other products containing chemicals) is also regulated by European environmental 
legislation. Typical examples are the Directives on water pollution 76/464/EEC, and on groundwater protection 
80/86/EEC. This type of legislation operates from the starting point that all actions that may lead to pollution are forbidden 
unless a permit is granted by the national competent authority. The permit ought to regulate emission (e.g. by prescribing 
application or purification techniques) as well as the maximum permissible concentration of the substance in the 
environment (Van Rijswick, 2001). This legislation addresses different authorities than the Directive 2001/82/EC, and the 
implications for risk assessment in these frameworks are not explored in this thesis. They do provide, however, important 





environment. It is a way of structuring and interpreting information on behaviour and effects 
of substances with the aim of creating a new type of information, namely estimations on the 
likelihood of the occurrence of effects (Rodricks, 1992). In general, environmental risk 
assessment addresses an overall level of protection, in most instances that of no effect (SSC, 
2003). The aim of risk assessment in the registration process is to eliminate the no-risk 
situations from further regulatory actions. Risk assessment is most commonly used to 
elaborate on (which means to downsize) identified hazards in hierarchic levels, from 
screening level to advanced levels. If a risk in a lower level is deemed acceptable, no further 
assessment is made.  
In the EU Directive 2004/28/EC, amending the Directive 2001/82/EC, Article 30 
states that marketing authorisation is denied if the risk-benefit balance of the product is, 
under the authorised conditions of use, unfavourable. A risk/benefit balance is defined as: ‘an 
evaluation of the positive therapeutic effects of the veterinary medicinal product in relation to 
the risks’. In Article 33, it is stipulated that a mutual recognition of a marketing authorisation 
can be denied if there are concerns for a potential serious risk to human or animal health or 
for the environment. Another response to an identified environmental risk is to mitigate the 
predicted risk to an acceptable level by addressing the user of the veterinary medicine 
through the information that accompanies the product (Koschorreck et al., 2002). This 
response has the intention of establishing a code of conduct that is reaching further than the 
Good Agricultural Practice taken as a starting point in the risk assessment. Risk mitigation 
through product labelling is held in high esteem, since it is explicitly worded in Article 12.3.j 
of the 2004/28/EC Directive and the recital. This option sets requirements towards the 
environmental risk assessment methodology, by which the effect of the precaution is to be 
demonstrated, and to the user of the product. One way or the other, the risk assessment 
methodology plays a crucial role both in the protection of the environment and in the 
sustainability of agricultural practice. 
The focus in this thesis will be on the validation of the environmental risk assessment 
methodology4 for the marketing authorisation of veterinary medicines in the European Union. 
Validation is a process of formulating and substantiating explicit claims about the 
applicability and accuracy of predictions, with reference to the intended purpose as well as 
the natural system that is represented (Dee, 1995). With respect to the regulatory objectives 
of the environmental risk assessment, validation contributes to a better understanding of the 
information generated in the risk assessment. 
 
1.2.  A definition of veterinary medicines 
 
Before we begin an in depth look at the environmental risk assessment for veterinary 
medicines, we must define which compounds are considered veterinary medicines. Any 
substance or combination of substances presented for treating or preventing disease in 
                                                 





animals is a veterinary medicine. Any substance or combination of substances, which may be 
administered to animals with a view to making a medical diagnosis or to restoring, correcting 
or modifying physiological functions in animals is likewise considered a veterinary medicinal 
product. These are the definitions given in the EU Directive 2001/82/EC on the marketing 
authorisation for veterinary medicines5. Substances are defined as any matter irrespective of 
the origin, which may be: e.g. blood and blood products, micro-organisms, parts of organs, 
whole animals, toxins, plants, extracts of plants, or chemicals, elements, naturally occurring 
chemicals or synthetic chemicals.  
In short, veterinary medicines are substances for specific purposes, and are regulated 
and approved through special Community regulation. In a broader understanding, substances 
that are no longer authorised, or that are (or have been) used without authorisation on 
animals, are also named veterinary medicines. 
This definition excludes certain substances in their applications, such as substances 
beneficial to, but not used on, or in, animals. Typical examples are disinfectants for animal 
housing and products to treat indoor surfaces against fleas or bacteria. The substance 
phenoxyethanol, when applied as a disinfectant on animals, is labelled as a veterinary 
medicine, and when applied on surfaces (e.g. floors, walls), it classifies as a biocide.  
There are applications that can be considered either medicinal or biocidal. Some 
Member States register teat dips for dairy cows as biocides, others as medicines, provided a 
therapeutic claim is made (EC, 2002b; VMRF, 2003). Anti-parasitic substances used on 
animals appear to be on the borderline between pesticides and veterinary medicines6, but in 
the European Union, the substances in these applications are defined as veterinary medicines.  
Substances that are added to animal feed in order to increase animal production 
without preventing any specific illness are included with feed additives. Substances that are 
used for treating, diagnosing, or preventing disease, or restoring, correcting or modifying 
physiological functions, in man, are classified as human medicines. For these two product 
classes special regulation exists7. 
Comprehensive classification of veterinary medicines is determined primarily by their 
mode of action and also by their use category (CVMP, 2000). Factors upon which groups and 
categories are based include, amongst others: 
- Origin: blood products, micro-organisms, chemicals 
                                                 
5 The first EU Directive on medicines dates from 1965, and has been amended numerous times. Comprehensive reviews 
resulted in new Directives on veterinary medicines in 1981 (81/852/EEC), in 2001 (2001/82/EC), and recently in 2004 
(2004/28/EC). 
6 In Australia these products are regulated by a single regulation. In New Zealand the definition used is set for an 
‘agricultural compound’: a generic term for any substance or mixture of substances, or biological compounds, used or 
intended for use in the direct management of plants or animals or to be applied to the land or water on or in which the 
plants or animals are managed, for the purposes of managing pests, or plant or animal productivity, or diagnosing or 
preventing or treating the condition of animals, and includes any pesticide and veterinary medicine. The term pesticide 
includes fungicides, herbicides, insecticide, and chemicals which may be administered to animals for the control of 
ectoparasites (Vannoort, 2003). 
7 I.e. the Directive 2001/79/EC for feed additives and the Directive 2001/83/EC for human medicines. Although many 
substances (and emission routes) are shared with veterinary medicines, the environmental risks of the use of these products 





- Route of application: topical (on the skin), oral, intra-ruminal (placed in the rumen), sub-
cutane, intra-muscular or intra-venal by injection 
- Type of treatment: prophylactic, curative, immune-stimulant (vaccine), homeopathic 
medicine, regular medicine 
- Target species classes: mammals, fish, birds 
- Target animal categories: companion animals, animals (not) destined for human 
consumption, major and minor species, major and minor use in major species, 
aquaculture, stabled animals, grazing animals 
- Mode of action, or therapeutic class: antibacterial (antibiotics), antiprotozoal, antimyotic, 
anthelmintic, antiparasitic, anti-inflammatory, and agents acting on nervous systems, on 
reproductive systems, on the gastrointestinal system, and on the immune system 
- Chemical classes. 
The environmental fate and effects of such diverse substances included in the 
definition of veterinary medicines are, most likely, very different. Considering the difference 
between microorganisms and chemicals in this context is an illustrative example. Where most 
chemicals are expected to degrade in the environment, micro-organisms may multiply 
(EMEA, 1996; Montforts, 2000; Jones et al., 2003). Only chemicals will be considered 
further in these investigations. When referring to veterinary medicines, terms like 
pharmaceuticals, drug substances, drugs, and chemicals, compounds, and substances, are 
used interchangeably.  
 
1.3. The extent of the consumption of veterinary medicines  
 
By expressing the annual consumption of veterinary medicines in monetary value or 
weight, one gets an idea of the importance of these substances for society and the 
environment. Let us also consider the scale of animal husbandry operations, the consumption 
of human medicines, and the consumption of pesticides. The Dutch society of producers and 
importers of veterinary medicines (FIDIN) estimated the annual turnover reported by their 
members in 2001 at 165 million Euro, 6% of the European turnover (FIDIN, 2002). Table 1-1 
shows the distribution over the therapeutic classes in 2001.  
 
Table 1-1 Relative consumption of veterinary medicines by animal husbandry and companion animals in 










Antibiotic 41 5 30 
Vaccine 33 20 29 
Other 13 18 17 
Antiparasitic 12 31 17 






Table 1-2 Consumption of antibiotics in the Netherlands in 1999 and 2002 (MARAN, 2002). 
Classes of antibiotics kg (x 1000) 
in 2002 
veterinary use 
kg (x 1000) 
in 1999 
veterinary use 
kg (x 1000) 
in 1999 
human use 
Penicillines/cephalosporines 40 40 25 
Tetracyclines 225 186 4 
Macrolides 20 10 3 
Fluoroquinolones 6 7 5 
Trimethoprim/sulpha’s 94 80 2 
Other 21 27 1 
Total  402 350 40 
 
 
More specific consumption data on veterinary medicines are only available for 
antibiotics. Historical surveys have revealed that veterinary antibiotic consumption in the 
Netherlands has increased from 275 tonnes in 1990 to 402 tonnes in 2002. Only 2 tonnes 
were used for companion animals. Table 1-2 illustrates the relative importance of substance 
classes (MARAN, 2002).  
In 2002, the animal population distribution in the Netherlands comprised of cattle (3.9 
million), pigs (1.7 million), and poultry (101 million)8. A rough estimate of the total animal 
body weight amounts to 3 million tonnes in 2002. The average consumption of antibiotics by 
animals amounted to 150 mg per kilogram body weight in 2002.  
 
The human consumption of non-immunological medicines is estimated at 400 tonnes 
in 1999 in the Netherlands (Tolls, 2001). For the antibiotics my estimate is 40 tonnes based 
on data from the SFK9 and from (Janknegt et al., 2000) and (Baart and De Neeling, 2001).  
The antibiotic consumption by man amounted to an approximate 50 mg per kilogram 
body weight per year in 1999. There is also a marked difference in the type of antibiotics 
used for veterinary and human treatment (Table 1-2). 
The ratio between consumption of antibiotics for veterinary and human purposes in 
the Netherlands in 1999 was 9 : 1. In Denmark, another small country with intensive animal 
husbandry, the ratio was about 5 : 5, in the European Union the overall ratio is 3 : 7 (Halling-
Sørensen et al., 1998; FEDESA, 2001).  
 
In the Netherlands, pesticide consumption amounted to 8000 tonnes in 2002 (RIVM, 
2003). Compared to this figure, the consumption of veterinary medicines, represented by the 
antibiotics, is rather small. Veterinary medicines are used in larger quantities than human 
medicines, especially the antibiotics. Potential ecological consequences or impacts depend, 
                                                 
8 Aquaculture in the Netherlands is a small contributor. The production amounts to about 0.2% of the production of animal 
husbandry (Kamstra and Van der Heul, 1995; Luiten, 2002). 
9 Stichting Farmaceutische Kengetallen. Data on hospital use of antibiotics are from 1996; the same ratio between the use 





however, on the typical use, the distribution and fate, and the toxicological profile of the 
substances classified as veterinary medicines.  
 
1.4. Environmental risk assessment and management for veterinary 
medicines  
 
Since it is impossible to assess the risks of all combinations of substances, uses, and 
environment, there is a well-established need to model the real world. Two levels of 
modelling are discerned in this thesis:  
1. the exposure and effect assessment, and  
2. the overall process of risk assessment at registration.  
The objective of every individual exposure and effect model is to predict accurate 
exposure or effect concentrations. Exposure models describe transport, partitioning, and 
degradation processes, and enable us to predict concentrations in soil or water as a result of 
the use of a veterinary medicine. Effect models elucidate effects in model organisms or 
systems as a result of exposure to a veterinary medicine. These model results need to be 
translated to the situation of interest.  
The objective of the overall risk model is to provide comprehensive information on all 
environmental risks related to the use of the veterinary medicines in order to optimise the 
risk-based decision (Di Fabio, 1994; Cranor, 1997). The level of the overall process includes 
all activities employed in the risk assessment procedure at registration. The integral collection 
of protection goals, exposure and effect models, and the conventions to apply the models and 
to harmonise their results, is by itself a model to assess the risk of the use of veterinary 
medicines. In Figure 1-1 the overall process of risk assessment is represented by the sub-
levels hazard identification, exposure and effects assessment and risk characterisation. The 
rectangular boxes, from risk classification down to monitoring, describe the stages of risk 
management (Van Leeuwen, 1995).  
 
Hazard identification is the stage at which possible effects (hazards) are 
characterised. In this stage questions are asked such as: Is the activity of concern (here, the 
use of veterinary medicines) sufficiently explored using available science?  
 
Exposure assessment begins with the emission of the product from the source to the 
various compartments in the environment. It addresses all possible exposure and distribution 
routes, using emission and exposure models, as well as monitoring data. Underestimation of 
the exposure in a compartment can be avoided by making realistic worst-case assumptions. 
Research questions relating to exposure assessment focus on modelling approaches of 
distribution processes, the use of substance properties (sorption, degradation), the handling of 
variability and uncertainty in environmental parameters, and the definition of reference 
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Exposure  assessment Effects assessment 
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Figure 1-1 The basic framework of risk management. Hazard identification, exposure and effects 
assessment and risk characterisation are components of environmental risk assessment. Risk 
classification, risk-benefit analysis, risk reduction and monitoring are additional methods aiming at risk 
management. 
 
Effect assessment or dose-response assessment is the estimation of the relationship 
between the level of exposure to a substance, and the incidence and severity of an effect. In 
environmental risk assessment (ERA) millions of species and processes may be exposed to 
contaminants by a variety of pathways. Effect assessment addresses all hazards identified, 
using dose-effect models and monitoring data, as well as the integration of the various effect 
model results, in e.g. predicted no effect concentrations (PNEC) or in probabilities (Posthuma 
et al., 2002). Research questions relating to effect assessment focus on the use of substance 
properties, the selection of relevant test species, test data and endpoints, the handling of 
uncertainty in these data, the justifications of extrapolation methods to unknown species, and 
harmonisation of endpoints to endpoints in other compartments. 
 
Risk characterisation combines the information gathered, for example in a Risk 
Characterisation Ratio (RCR) that expresses the ratio of the predicted exposure 
concentrations (PEC) over predicted no-effect-concentrations (PNEC): PEC/PNEC. The 
modelling approach in the exposure assessment should relate to the mode of application of 
the veterinary medicine and should be harmonised with the effect assessment endpoint. 
Research questions in this stage relate to this harmonisation of data.  
 
Risk classification is based on the total set of RCRs. Criteria that define the groups 
have to be agreed upon. Research questions relate to the choice of endpoints that are 
classified (for what compartments and hazards have RCR (not) been derived?) and the way 






Risk-benefit analysis. Decisions regarding classification or individual RCRs rely on 
regulatory choices that either dictate or exempt further assessment or risk mitigation 
measures. This choice will depend on uncertainty in the models as well as on the political or 
economic implications of mitigation measures (risk-benefit analysis) (Di Fabio, 1994). Risk-
benefit analysis is not further addressed within the scope of this thesis. 
 
Risk mitigation encompasses all the regulatory actions intended to diminish the 
environmental impact of the use of veterinary medicines. These measures may be directed to 
either the competent authorities that are responsible for the quality of soil, surface water, or 
drinking water, or to the users of the medicinal product. This research investigates which 
mitigation measures might be included in the methodology for the registration of veterinary 
medicines, as far as they are substantiated by the risk assessment.  
 
Monitoring. This is the stage in risk management that aims to generate information 
on the accuracy of the risk assessment, and of the risk mitigation measures. Typically, for the 
authorisation of veterinary medicines and human medicines, a system of monitoring was 
created to respond adequately to unexpected effects of the use of medicines. According to 
Article 73 of Directive 2001/82/EC, member states are required ‘to establish a veterinary 
pharmacovigilance system that takes into account any available information related to 
investigations on potential environmental problems’. This final stage in risk assessment is not 
further explored in this thesis. 
 
The administrative process of the registration of medicines is mandated to the 
European Agency for the Evaluation of Medicinal Products (EMEA)10. The EMEA consists 
of a board, formed by two representatives from each member state, two from the European 
Commission, and two from the European Parliament (EP), and a staff. The EMEA functions 
among others as the secretariat to the scientific Committee for Veterinary Medicinal 
Products. The CVMP consists of independent scientists (two from each Member State) and 
formulates opinions on requests for registration with respect to quality, efficacy and safety 
(environment included) of the products. CVMP and EMEA also produce guidance documents 
on risk assessment. The first guidance document was released in 1997 and provided a 
comprehensive risk assessment methodology. After the release of the EMEA (1997) 
guidance, an international harmonisation of the guidance between the EU, USA and Japan 
was initiated by the International Co-operation on Harmonisation of Technical Requirements 
for Registration of Veterinary Medicinal Products (VICH)11 to which both the European 
Commission and the EMEA are committed (DG Enterprise, 2000). The guidance document 
on Phase I was implemented by July 1st 2001 in the European Union and United States 
(VICH, 2000) and replaced the EMEA 1997 guidance on Phase I, the phase predominated by 
the exposure assessment. Currently (April 2004), the draft VICH guidance on Phase II, the 
                                                 
10 Commonly referred to as the European Medicines Evaluation Agency. The name is changed by the Regulation (EC) 
726/2004 to European Medicines Agency. 





phase in which the risk assessment is conducted, is still engaged in the consultative process. 
For this reason this guidance document is not considered here. 
 
In this thesis, the risk assessment methodology used in the registration framework of 
veterinary medicines is validated against the risk approach presented above. Validation is a 
word that is frequently misinterpreted. The word suggests a search for truth and through 
combinations of models it gives the impression of being all about creating the perfect model. 
Validation is not about creating models. Validation is a process of substantiating explicit 
claims on the applicability of predictions with reference to the intended purpose of the model. 
Validation is also concerned with the accuracy of these predictions for the system that is 
represented (Dee, 1995). All models are, by their nature, incomplete representations of the 
system they are intended to model, but, in spite of this limitation, models can be useful. 
Strictly speaking, a model cannot be validated in the sense that the validation proves that the 
model is true, only whether the model is well founded and applicable (Addiscott, 1998). 
Some models cannot be validated, but components or modules of the model can be validated 
on an individual basis. Dee (1995) has identified four major aspects associated with model 
validation, as follows: 
1. Conceptual validation 
2. Validation of algorithms 
3. Validation of software code 
4. Empirical validation of the functionality. 
Conceptual validation contributes to a better understanding of the information generated in 
the risk assessment and to the transparency of the decision making process. Conceptual 
validation concerns the question of whether the model accurately represents the system under 
study. Was the simplification of the underlying process in model steps realistic; i.e. were the 
model assumptions credible? Usually, conceptual validation is largely qualitative, although 
experimental or observational data in support of the principles and assumptions can be 
integrated. Conceptual validation makes the consequences of the choices on what variables 
and relationships in the natural system are formalised in the model, explicit.  
Algorithm validation concerns the translation of model concepts into mathematical 
formulae. Software code validation concerns the implementation of mathematical formulae in 
computer language. These aspects of validation are of marginal concern here.  
Most validation studies do not refer to the way a model is assembled, but regard it as a 
black box: an input-output function, which might represent the system of interest. This 
approach, where empirical observations are compared to model predictions, is denoted 
functional or empirical validation. 
 
Typical of risk assessment is utilisation of both scientific data and normative 
assumptions, and that both scientists and regulators determine the outcome of the risk 
assessment process. On one hand, regulators must indicate what should be assessed (hazard 
identification), what levels of protection should be taken as protection goals, and are 





regulators are supposed to take into account must be objective and of high calibre12. On the 
other hand, scientists are required not only to provide information on the relevance of these 
hazards, but also to assess the fate and effects of the substances in a way that addresses the 
concerns, the standards, and the uncertainties13.  
The validation exercise performed here addresses the quality of the (modelling) 
science applied, including the use of this science in a regulatory context. Two levels of 
modelling were discerned in this thesis: the level of individual fate and effect models used in 
exposure and effect assessment, and the integral level of the assessment methodology for the 
environmental risk arising from the use of veterinary medicines. The validation is 
predominantly of a conceptual nature, but where possible, empirical validation of individual 
exposure models is performed. A profound research has recently been performed in a similar 
way on the uncertainty in environmental quality standards (Ragas, 2000).  
A broader view on the strategic arena in which science is applied to develop guidance 
on environmental risk assessment and to execute assessments is necessary. Concerning the 
aspect of objectivity of science, there are potential controversies that require a carefully 
designated playing field, where science can be impartial and authoritative. One is at the 
demarcation line between science and regulation: who decides what should be investigated or 
protected? When is this protection goal achieved? The second is the choice of scientific 
disciplines: what science is allowed, whose scientists are selected? The third is the actual 
weight science is given in the process of decision making (Cranor, 1997; Joerges et al., 1997; 
Heyvaert, 1999a; Heyvaert, 1999b; Breyer and Heyvaert, 2000; Halffman, 2003).  
The following research topics on model validation and on the interaction between 
science and regulation are addressed in this thesis. 
 
1. Harmonisation of protection goals and risk assessment methodology 
- What relevant environmental protection goals can be considered? 
- Does the integral risk model address the protection goals? 
2. The conceptual and empirical validation of models and precautionary labelling 
- Are screening level exposure models for surface water in aquaculture, for dung 
excreted by grazing animals, and for soil and water in intensive animal husbandry 
well founded and applicable? 
- Is the soil trigger value based on effect data functional and validated? 
- Can the efficacy of mitigation measures be demonstrated by the methodology used to 
predict the risk? 
3. The use of science in the registration framework 
- Is science applied transparently and impartially in the development of risk assessment 
methodology and in the decision making for product registration?  
                                                 
12 Based on the rulings of the European Court of Justice (ECJ) in case C-41/93 PCP [1994] ECR I-1829 (Joerges et al., 1997  
p. 319) 
13 According to the European Court of Justice (case C212-91 Angelopharm): "the Scientific Committee is the only party 
involved in the policy-making process that is competent to make those scientific and technical assessments on which the 





1.5. Readers guide 
 
The following chapters are publications submitted to or published in peer-reviewed 
journals or books. The publications cover one or more of the stages in the risk assessment 
process, and address one or more of the research questions outlined above. The relation 
between the contents of the chapter, the research questions and the other publications, is 
described in the short introductions below.  
 
Methodological aspects concerning the environmental risk assessment for 
medicinal products: research challenges 
This chapter takes the European legislation and guidance documents for the risk 
assessment, as a starting point in a conceptual validation exercise on the relation between 
protection goals, risk models and methodology. It provides a basis for this exercise, that will 
be continued, studied in depth, and repeated in the following chapters, by highlighting 
possible hazards and regulatory protection goals, and introducing concepts on risk assessment 
and harmonisation of models and effect endpoints.  
The particular case of the human medicines is outside the scope of this thesis. 
However, the observations made are suitable as case studies for veterinary medicines as well. 
The chapter focuses on remaining research needs for the environmental risk model of 
human and veterinary pharmaceuticals; in other words, on those items that may be considered 
to invalidate the risk model in the relation between protection goals, methodology and risk 
mitigation.  
 
The exposure assessment of veterinary medicinal products 
This chapter highlights a selection of exposure models for considering effects of 
veterinary medicines related to the following animal sources and receiving compartments: 
aquaculture and surface water and soil, grazing animals and dung, and stabled animals and 
slurry and soil. It investigates the selection of parameter values, such as number of 
applications, storage time and degradation rate. The implications of these findings are 
discussed in the light of the risk model set by the European Guidance document in 1997. 
Some other features in this risk model are discussed and considered for further research. It is 
a first step in the conceptual validation of the exposure assessment methodology that 
questions the high calibre of the science applied and the implications of choices made. 
 
Validation of the exposure assessment of veterinary medicinal products 
This chapter investigates the validity of exposure and distribution models for soil, 
groundwater and surface water, applied for veterinary medicines that reach the soil by 
contaminated slurry. The removal efficiency of substances in settling tanks, used in the 
previous paper, was verified with data from mushroom and flower bulb industries. Transport 
(mass transfer), concentration and impact of substances are influenced both by the 
environment and the substance. Environmental factors such as soil and climate are subject to 





validate the models: Do the models predict the field results? This represents a second step in 
the conceptual validation of the methodology: Is the methodology well founded, and what are 
the implications of choices made? The second objective of this chapter was to develop 
scenarios for the exposure assessment under different European conditions, incorporating 
information on agricultural and veterinary practice, land use, geomorphology and climate. 
Using the scenarios it will be possible to facilitate national, mutual, and central registration 
procedures, and European harmonisation of risk assessment methodology for chemicals. 
 
Effect assessment at the base of an exposure trigger in soil – a critical appraisal 
In the EU guidance documents a limited environmental risk assessment is foreseen for 
veterinary medicines with a presumed negligible exposure level in the soil compartment. The 
regulatory trigger value has been substantiated with a scientific assessment of 
ecotoxicological data. The science of ecotoxicology offers various tools to assess the 
presented data. This article focuses on the selection of tools and the scientific argumentation 
used, and will demonstrate that with the same information and tools, trigger values in a range 
of up to three orders of magnitude are justifiable. 
 
European medicines and feed additives regulation are not in compliance with 
environmental legislation and policy 
This chapter investigates transparent application of science in the drafting of 
environmental risk assessment methodology for veterinary products, and how science is used 
in the decision-making. The interactions between science and regulation in the drafting of the 
guidance document for the Phase I assessment are explored. 
 
Legal constraints on special precautions in product labelling to mitigate the 
environmental risk of the use of veterinary medicines in the EU 
This chapter concludes the validation of exposure models, of the use of science, and 
of the relation between science and regulation. It investigates what possibilities and 
obligations are created within the registration framework to bind authorities, applicants, and 
users to instructions and prohibitions. Effective risk mitigation measures could remove the 
need for refusal of product authorisation, or of risk-benefit analyses. This chapter analyses 
the contributing factors to effectiveness of mitigation measures. Risk mitigation is part of the 
risk management process, but as far as mitigation measures are (suggested to be) based on 
exposure or effect assessments, there is a direct relevance for the risk model.  
 
Discussion 
The findings from the presented research are summarised and discussed in coherence. 
First, the degree of harmonisation of protection goals and risk assessment methodology is 
discussed. Next, the implications of the conceptual and empirical validation of models and 
precautionary labelling are considered. Finally I present considerations on the use of science 
in this registration framework. In the light of recent developments in the risk assessment 









2. Methodological aspects concerning the environmental risk 
assessment for medicinal products; research challenges 
 
Published as chapter 32 in: K. Kümmerer (Editor) Pharmaceuticals in the environment. Second 
enlarged edition, Springer Verlag, 2004.  
2.1. Introduction 
 
The fate and behaviour of pharmaceuticals in the environment have been studied since 
several decades (Zondek and Sulman, 1943; Soulides et al., 1962; Tabak and Bunch, 1970), 
and the presence and effects of residues in the environment is a concern that has been 
identified not long after that (Berland and Maestrini, 1969; Manten, 1971; Blume et al., 1976; 
Rurainski et al., 1977; Patten et al., 1980). More recently several reviews on use, emission, 
fate, occurrences and effects of pharmaceuticals have been published and at national and 
supra-national regulatory levels the environmental risks of pharmaceuticals are on the agenda 
(Roij and De Vries, 1980; Römbke et al., 1996; Ternes, 1999; Jorgensen and Halling-
Sørensen, 2000; Daughton and Jones-Lepp, 2001; Kümmerer, 2001; Halling-Sørensen et al., 
2002; Dietrich, 2002; Boxall et al., 2004).  
The environmental risk of the use of medicinal products is currently assessed at 
registration. The methodology has not been finalised yet (EMEA, 1997; EMEA, 2000; VICH, 
2000) and suggestions for risk assessment methodology are given by several authors 
(Spaepen et al., 1997; Daughton and Jones-Lepp, 2001; Römbke et al., 2001a; Römbke et al., 
2001b; Länge and Dietrich, 2002; Koschorreck et al., 2002; Schowanek and Webb, 2002). 
The proposed risk assessment procedure at registration of human medicines and veterinary 
medicines is discussed by several authors (Gärtner, 1998; De Knecht and Montforts, 2001; 
Montforts and De Knecht, 2002; Koschorreck et al., 2002; Long and Crane, 2003). 
Considerations on the assessment of pharmaceutical feed additives are given by Jorgensen et 
al. (1998). 
This chapter focuses on research needs for the environmental risks of human and 
veterinary pharmaceuticals. National and European regulators are involved in managing 
environmental risks of pharmaceuticals from two perspectives. One is the regulation of 
pharmaceutical products, and the other is the management of a good environmental quality 
(Montforts and De Knecht, 2002). The chapter takes the registration assessment of medicinal 
products as a starting point in a validation exercise on the relation between protection goals, 
risk models and methodology, and will highlight research challenges. 
 
The terms medicine, pharmaceutical, and drug will be used interchangeably here, but 
please note that registration has concerns for a product: a veterinary or human 
pharmaceutical, containing active ingredients (substances) and excipients, and that 
environmental quality policy deals with substances in compartments, and activities of legal 




certain intended use, whereas a drug in the environmental quality policy is a substance (be it 
a parent compound, pro-drug, or metabolite) emitted to, or present in, an environmental 
compartment.  
 
2.2. Protection goals 
 
Medicines are regulated in order to protect animal health, consumers, professional 
users, the environment as well as the internal market. The framework of the registration 
procedure and assessments for both the applicant and regulator consists of a European 
Commission and Council directive, European policy, and case law, as well as global (trade) 
agreements. As a general observation it is stated here that the primary goal of any 
environmental assessment should be risk mitigation and risk management. In order to 
mitigate or accept risks, a risk assessment has to be performed, both for products (e.g. drugs) 
and for activities (e.g. emission of drug residues). At registration it is possible to lay the 
burden of proof on the applicant (the principle that the polluter pays). The decision-making 
process and the risk models used should optimise (reduce) the costs to society in terms of 
environmental damage (due to false negatives implying registration of harmful products) and 
economic damage (due to false positives implying refusal of harmless products). Also the 
assessment process itself should neither hamper product development nor timely action 
(Cranor, 1997). Should the assessment remain inconclusive on the acceptability of the risk, 
further action depends on the cost-benefit analysis. Risk assessment is a key process in which 
both regulators and scientist determine the outcome (Joerges et al., 1997). On one hand, 
regulators have to indicate what should be assessed (hazard identification) and what level of 
protection should be taken as protection goals, and have to make risk-benefit decisions. On 
the other hand, scientists are required not only to provide information on the relevance of 
these hazards, but also to assess the fate and effects of the substances in a way that addresses 
the concerns, the standards, and provides suitable information for the risk-benefit analysis.  
 
A risk assessment can only be performed, once the protection goals and the assessment 
methodology have been developed. The Directives 2001/82/EC and 2001/83/EC on the 
registration of pharmaceuticals do not contain explicit environmental protection goals, only 
procedural directions. Only the EU Directive 2001/82/EC on veterinary medicinal products 
contains some directions on the risk assessment model and decision making approach. It is 
stated that the assessment shall normally be conducted in two phases. In phase I, the 
investigator shall assess the potential extent of exposure to the environment of the product, its 
active substances or relevant metabolites, taking into account: 
• the target species, and the proposed pattern of use (for example, mass-medication or 
individual animal medication), 
• the method of administration, in particular the likely extent to which the product will enter 




• the possible excretion of the product, its active substances or relevant metabolites into the 
environment by treated animals; persistence in such excreta, 
• the disposal of unused or waste product. 
 
In phase II, having regard to the extent of exposure of the product to the environment, 
and the available information about the physical/chemical, pharmacological and/or 
toxicological properties of the compound which has been obtained during the conduct of the 
other tests and trials required by this Directive, the investigator shall then consider whether 
further specific investigation of the effects of the product on particular eco-systems is 
necessary. As appropriate, further investigation may be required of: 
• fate and behaviour in soil, 
• fate and behaviour in water and air, 
• effects on aquatic organisms, 
• effects on other non-target organisms. 
These further investigations shall be carried out in accordance with the test protocols 
laid down in Annex V of Council Directive 67/548/EEC of 27 June 1967 on the 
approximation of laws, regulations and administrative provisions relating to the classification, 
packaging and labelling of dangerous substances, or where an end point is not adequately 
covered by these protocols, in accordance with other internationally recognised protocols on 
the veterinary medicinal product and/or the active substance(s) and/or the excreted 
metabolites as appropriate. The number and types of tests and the criteria for their evaluation 
shall depend upon the state of scientific knowledge at the time the application is submitted. 
Commission Directive 93/67/EEC elaborates further on these protocols.  
The decision making scheme (decision tree) has been fixed on a general level, and it is 
indicated that both fate and effects of drugs should be assessed. It is left to the scientific 
community to decide what information is to be generated and when the assessment is 
ended14.  
 
Important sources of information on protection goals are the legislation and policy 
documents concerning environmental quality (Heyvaert, 1999b). Focusing on the legislation 
for environmental quality, following the precautionary principle laid down in the Water 
Framework Directive (2000/60/EC), surface water and groundwater must be regarded as 
natural resources, which should be protected in their own rights. The EU included in the 6th 
Environmental Action Programme an outline for a future "thematic strategy on soil 
protection", which should lead to a European soil protection policy with adequate legislation 
in place. Most member states (if not all) have national legislation on soil quality. All this 
legislation operates from the starting point that all actions that may lead to pollution are 
forbidden unless a permit is granted by the competent authority. Thus, to emit or spread 
residues of medicines one needs a permit. The permit ought to regulate emission (e.g. 
                                                 
14 On the European level this scientific community (CPMP and CVMP) consists of independent scientists appointed by the 




prescribing application techniques) as well as the maximum permissible concentration of the 
substance in the environment. The competent authorities should thus derive these quality 
standards for every substance of interest. Also, they have to develop action plans for the local 
resource management15 (Van Rijswick, 2001).  
It is very well possible that existing European directives on the environmental quality 
of water already contain standards for medicines, even though the product group ‘medicines’ 
is not named in the environmental directives 76/464/EC and 80/68/EC. The use of the terms 
‘pesticide’ and ‘biocide’ in these directives do not refer to the product categories, but to the 
nature of the substances reaching environmental compartments after production, use or 
disposal of products (Montforts and De Knecht, 2002). Once in the environment, the 
competent authority is not concerned with the intended use of the compound, but with the 
compound itself. Medicines could be qualified as ‘biocidal’, because they are biologically 
active. Several compounds are actually registered as pesticide and as medicine, for example 
streptomycin, oxytetracyclin, 4-aminopyridine, paracetamol, warfarin, and cypermethrin.  
The quality of drinking water is protected under the Directive 98/83/EC. This directive 
aims at protecting public health by setting quality criteria to drinking water. Within the 
Netherlands it has been environmental policy since 1989 that with respect to xenobiotics also 
groundwater should comply with the standards for drinking water, as it often concerns 
soluble compounds that cannot, or insufficiently, be removed using common purification 
techniques (TK, 1989). To all substances that qualify as such, a numeric standard is already 
available for drinking water (for ‘pesticides’ 0.1 µg/L), and at least in the Netherlands, also 
for groundwater.  
 
The registration process of products should thus primarily be concerned with the level 
of no effect (maximum permissible concentration) and the risk that this level will be 
exceeded. It applies to water (surface water and sediment, groundwater, drinking water) 
based on European legislation, and to soil based on national legislation. When a level of no 
effect (predicted no effect concentration PNEC), or an acceptable effect concentration, is 
reached is open for scientific and political debate. For example in the Netherlands, the level 
of no effect is considered to be eminent at the ecosystem level, and is defined at a level at 
which 95% of the species are protected at the no-observed effect concentration (NOEC). This 
analysis assumes a certain distribution of toxicity data representing the ecosystem sensitivity 
to the given substance (ECB, 1996; Crommentuijn et al., 2000; Forbes and Calow, 2002c). 
Ecosystem functionality and structure are thus protected when critical concentrations 
affecting population dynamics (growth, reproduction, and mortality) are not surpassed. 
Process parameters at population level such as C- or N-cycling, or resistance development, 
can be incorporated in deriving the critical concentration (Traas, 2001; Wösten et al., 2001).  
 
                                                 





2.3. Research challenges  
 
As stated above, the risk assessment targets a desired level of quality. The assessment 
methodologies translate the protection goals in quantities: for example probabilities, 
concentrations, dosages, and risks. The protection goal (no effect) is generally pursued by 
assessing a reasonable worst case situation, thus assuming that either the chance on a 
negative impact is reasonably small and/or that the affected fraction of the area (e.g. nation, 
water catchment) and the impact itself are acceptably small. When this reasonable worst case 
exposure leads to concentrations below the maximum permissible concentrations, the risk 
that the level of no effect will be exceeded is considered acceptable.  
Methodology, protection goals and decision making are strongly interconnected. The 
environment is at risk when a product reaches the environment. Transport (mass transfer), 
transformation, concentration, and impact of substances are influenced both by the 
environment, the substance, and the receptor (e.g. the species or populations). Environmental 
variables such as soil, climate, and receptors are subject to a considerable spatial and 
temporal variation. Because it is impossible to assess the risks of all combinations of 
substances and environment, there is a well-established need to predict fate and exposure 
concentrations and risks. In order to do so, generic models of the environment and values for 
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Figure 2-1 The basic framework of risk management. Hazard identification, exposure and effects 
assessment and risk characterisation are components of environmental risk assessment. Risk 





Two levels of modelling are discerned: the level of the complete risk model covering 
the environmental risk assessment process, and the sub-level of the fate and effect models. 
The risk model includes all activities employed in the risk assessment process, including their 
harmonisation. It addresses the overall protection level: no effect. In Figure 2.1 the risk 
model is represented by the ovals containing hazard identification, exposure and effects 
assessment and risk characterisation.  
Hazard identification is the stage at which possible effects (hazards) are characterised. 
Exposure assessment starts from the emission of the product to the different compartment and 
addresses all exposure routes, using emission and exposure models, and monitoring data. 
Effect assessment addresses all hazards identified, using dose-effect models and monitoring 
data, as well as the integration of the effect model results. Risk characterisation combines the 
information gathered. The risk model is as good as the weakest link in the model, be it an 
exposure model, an effect model, unidentified exposures or effect, the interpretation of effect 
data or the integration of exposure and effect. The rectangular boxes, from risk classification 
down to monitoring, belong the stage of risk management. 
Ultimately, the quality of the assessment that can be achieved will depend upon the 
adequacy of available data as well as a suitable choice of model and modelling parameters 
(Dee, 1994; WRc-NSF, 2001). It is important to note that the model capabilities should have 
been reflected in the decision making process, e.g. in applying a worst-case scenario or in the 
use of safety factors (Brouwer et al., 1994; Resseler et al., 1997; Uffink and Van der Linden, 
1998; Van der Linden and Van Beek, 1999). Modelling at levels of no concern requires a 
rigorous understanding of all relevant transport, fate and effect processes, or requires 
sufficient safety factors. Evidently, there should be good agreement between the protection 
goal and the methodology used to assess the impact, in the sense that it should be clear what 
situations the methodology represents, and what level of certainty the predictions have (cf. 
Forbes and Calow (2002a) and Tarazona et al. (2002)). In an ideal situation, the assessment at 
registration functions as a tool in maintaining a good environmental quality. 
Below the risk models for veterinary and human medicines are presented and 
regulatory needs and research challenges are indicated.  
 
Veterinary medicines: protection goals and risk models 
The European Agency for the Evaluation of Medicinal Products (EMEA)16 has 
published guidance on the environmental risk assessment (ERA) of veterinary medicinal 
products (VMPs), and this assessment was implemented in 1997 (EMEA, 1997). The 
assessment scheme takes the use of the product and the properties of the products into 
account in the assessment (phase I or II), the emission routes (slurry-soil, water, and pasture) 
and the data requirements. After the final draft of the EMEA (1997) guidance, an 
international harmonisation between the EU, USA and Japan was started by the International 
Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary 
                                                 




Medicinal Products (VICH)17 to which both the European Commission and the EMEA are 
committed (DG Enterprise, 2000). The guidance document on Phase I was implemented by 
July 1st 2001 in the European Union and United States (VICH, 2000) and replaced the 
EMEA 1997 guidance on Phase I. This guidance document is at this moment leading for the 
registration procedure. 
Within the VICH guidance document a limited assessment is foreseen for substances 
with a generally accepted low hazard (e.g. vitamins, electrolytes), and with a presumed 
negligible emission and exposure level. The exposure level that is considered negligible for 
the total environment is quantified both for effluent and soil for some groups of compounds 
and several routes of emission: 1 µg/L and 100 µg/kg, respectively (Phase I), for residues 
reaching waste water through confined fish rearing facilities or reaching soil via manure 
application. These triggers are substantiated with an assessment of a dataset of toxicity values 
of several antibiotics, although the assessment to determine the value of the trigger is 
criticised from an ecotoxicological point of view (De Knecht and Montforts, 2001). It is 
crucial to note that the soil trigger is based on soil toxicity data, but also determines the 
eventual assessment of groundwater and surface water exposed through soil.  
The triggers apply to a total residue, regardless of the actual substances in the residue 
(mixture of metabolites and active ingredients). Using this concept, the Phase I assessment 
addresses the entire product. However, a further use of substance related fate and effect data 
in exposure or effect assessment is questionable, because it is not defined what compound 
should be modelled. 
Not just these exposure trigger values define the desired level of quality for soil and 
effluent. Should the Phase I triggers be breached, or should the product be applied to grazing 
animals or open water facilities, a further assessment in Phase II, as published by (EMEA, 
1997), is risk based, and both exposure and effect are assessed. The VICH Phase I assessment 
does not seamlessly connect to the EMEA Phase II assessment. Phase II defines the 
substances and the environmental criteria that need to be assessed: substance persistency and 
bioaccumulation, and risks to soil, groundwater and surface water. Both intrinsic substance 
properties (insecticidal activity) and a risk quotient for earthworms define the extent of data 
requirements for grazing animals. Toxicity to grassland invertebrates and predators is also to 
be assessed. Whenever the soil is reached, persistency and sorption may trigger further 
standards and data requirements. Phase II makes use of several acceptability triggers: 
• Specific risk ratios for taxonomic groups (plants, earthworms, micro-organisms)  
• effect levels for single dose tests (arthropods and dung fauna) 
• persistency levels for soil 
• PEC/PNEC risk ratio for aquatic systems 
• Expert judgement for bioaccumulation. 
Breaching these acceptability triggers leads to a further refinement of the risk 
assessment on the trigger of concern. 
                                                 




The risk model challenges research on different aspects of the model. Some of these are 
addressed below. The risk model employed does not systematically address all environmental 
concerns identified above (i.e. groundwater), but leaves ample room for scientific input and 
assessment of e.g. persistency and bioaccumulation properties. The protection goal is 
addressed in several risk and hazard based endpoints, both for the terrestrial and aquatic 
compartment. The protection goals have not been characterised to an extent that boundary 
agreements for exposure and effect models have been set (e.g. time frame).  
If the assessment aims to establish conditions under which an acceptable risk is present, 
model and data requirements may differ from those in a risk model that identifies the worst 
case. For example, the load of a residue in manure or slurry to soil is driven by the amount of 
manure applied. Under the Nitrate directive 91/676/EC vulnerable areas in river catchments 
are assigned, and in those areas immission standards for the nitrate in the slurry apply. A risk 
assessment for these areas establishes acceptable risks, but not worst case risks. 
Degradation of the veterinary drug in the target animal and/or during storage of 
manure, and/or in soil are aspects of the environmental risk assessment that were mentioned 
in the Phase II guidance as information that may be considered in refining the PEC. The 
guidance does not provide the details on for example, standardisation of laboratory test 
results, repetitions in exposure, and time intervals, thus leaving these refinements to expert 
judgement. In Phase II all active ingredients and all metabolites formed >20% at metabolism 
or in environmental compartments are to be assessed. The guidance is unclear whether 
information on transformation (animal-slurry-soil-water) is compulsory or not after phase I.  
Following a total residue approach a challenge lies in the assessment of the fate and 
effects of the residues through manure and soil. The total residue has no intrinsic properties 
(e.g. sorption, degradation) that can be determined and plugged into models that require this 
information. The different compounds in the residue probably cover a large range of 
properties: persistent to readily degradable, strongly adsorbing to weakly adsorbing, high 
impact to no effect. There are no directions how to determine the properties, or model 
compounds, that should be used to refine or advance the assessment of the total residue. 
The impact on nitrification processes in soil is assessed at registration, but effects of 
some antibiotics on nitrification and decomposition in soil have been reviewed and the few 
studies available indicate effects at rather high concentrations only (Jensen, 2001; Thiele-
Bruhn, 2003). Test duration and test type may play an important role however (Backhaus et 
al., 1997; Halling-Sørensen, 2001). The effects of antibiotics on the microbial community can 
range from simple parameters like a decrease in biomass, respiration rate or denitrification 
rate, to more complex parameters like the survival of genetically engineered micro-organisms 
(Landi et al., 1993; Badalucco et al., 1994; Da Gloria Britto De Oliveira et al., 1995). 
Therapeutic doses of chlortetracycline in cattle have been found to alter the rumen 
microflora, hence the possibility exist that it alters the nature and activities of the microflora 
participating in the decomposition process both in dung and in slurry (Elmund et al., 1971; 
Patten et al., 1980; Poels et al., 1984; Sommer and Bibby, 2002). Could other effect models 
and effect assessment approaches provide more relevant information (Van Beelen and 




The survival of adapted bacteria in absence of the compound that the bacteria have 
adapted to, is usually said to be limited, but the acquired functionality (e.g. resistance genes) 
remains present at low levels (Cooke, 1983; Stappen et al., 1989; Zuidema and Klein, 1993; 
Séveno et al., 2002; Park et al., 2003). The costs for resistance can however be compensated 
for (Björkman et al., 2000). An additional concern is hence found from the perspective of 
resistance development and transfer. This process is triggered at the Minimum Effect 
Concentration (MEC) at which growth is reduced (O'Reilly and Smith, 1999), which is 
tenfold below the Minimum Inhibitory Concentration (MIC), the endpoint used by EMEA to 
derive a safe exposure level in soil for antibiotics at phase I (AHI, 1997). This indicates that 
at and below the MIC level a selection pressure for resistance is present. Thus, even at 
concentrations below the Phase I trigger, resistance genes may be favoured, which can be 
transferred from manure to soil and groundwater (Chee-Sanford et al., 2001; Halling-
Sørensen et al., 2002; Sengeløv et al., 2003). The management of resistance development in 
water and sediment face comparable challenges (Grabow et al., 1976; Cooke, 1983; Linton et 
al., 1988; Rodgers, 2001; O'Reilly and Smith, 2001). Should resistance development be 
identified as a hazard? And if so, how can it be used in decision making, knowing that it also 
applies to antimicrobial products used as pesticide and biocide (Séveno et al., 2002; Mcbain 
et al., 2002; Russel, 2002)?  
 
Human medicines: protection goals and risk models 
The EMEA has published a draft guidance on the environmental risk assessment of 
human medicines, but this guidance was not yet implemented in 2003 (EMEA, 2000). 
Emission to the environment is primarily foreseen through wastewater. In phase I a trigger of 
10 ng/L in surface water was proposed to proceed to risk based assessment providing for a 
PEC/PNEC risk ratio for aquatic systems. Breaching this acceptability trigger leads to a 
further refinement of the risk assessment.  
The predicted exposure concentration (PEC) is based on a simple dilution model, in 
which the total annual consumption is diluted over the total amount of wastewater produced. 
The concentration in wastewater is further diluted to surface water using a default dilution 
factor of 10. Retention in wastewater treatment plants (WWTPs) can be accounted for. The 
predicted no effect concentration is derived from a base set of aquatic toxicity data in 
accordance with Directive 67/548/EEC, and assessment factors according to the Technical 
Guidance Document for New and Existing Substances (TGD) (ECB, 1996). 
The protection goal is narrowed down to, or represented by, the aquatic environment, 
which is exposed through wastewater. Before a risk assessment is performed, an exposure 
level has to surpass an action limit. The calculation of the exposure level is guided, not 
prescribed. It depends on the interpretation of the input data what outcome is generated, as 
indicated below: 
• annual consumption: should seasonal and regional differences be taken into account 




• how is a removal percentage in WWTPs determined: how can one translate the result of 
fate models (laboratory of field scale) to the representative exposure model (Tabak et al., 
1981; Kümmerer et al., 2000; Balcioglu and Ötker, 2003). 
• are WWTPs expected to be present in all urbanised areas (EC, 2001d)?;  
• what is an appropriate dilution factor for effluent to surface water? In the Netherlands, 40% 
of all WWTPs (n=466) have a dilution factor of 1-10 within 100 metres. In the 
Netherlands, 40 out of 83 of the domestic WWTPs at tributaries (48%) and 48 out of 126 
of the domestic WWTPs at polders (38%) have a dilution factor of 1-5 within 100 metres. 
About 60 of these domestic WWTPs (c. 20%) have a dilution factor of 2 within 100 
metres; an extrapolated number of 15 (c. 5%) is expected to have a dilution factor of 1. In 
trench-like waters, owing to the low flow, only poorly developed turbulence is likely to 
occur from time to time. Hence, in polder waters and the like, it is to be expected that 
noticeable lengths of these channels be gradually filled with poorly diluted effluent. In 
these situations, at least about 20% of all domestic WWTPs in the Netherlands, a dilution 
factor of 1 is very well be applicable (De Greef and De Nijs, 1990). 
If a risk assessment is performed, are the actual hazards investigated in an adequate way? 
• are acute base set studies on algae, daphnids, and fish representative for continuous 
exposure  (Berard and Benninghoff, 2001; Daughton and Jones-Lepp, 2001; Huggett et al., 
2002; Ferrari et al., 2003)?  
• are the common lethality, growth and reproduction endpoints representative  (Hartmann et 
al., 1998; Chee-Sanford et al., 2001; Forbes and Calow, 2002b)? 
• Are the effect models (model species and test designs) vulnerable to medicines (Fong, 
1998; Thorpe et al., 2001; Länge and Dietrich, 2002; Brooks et al., 2003; Pro et al., 2003; 
Cleuvers, 2003)? 
Is the risk model actually covering the environment?  
• Given the hazard of groundwater and drinking water contamination, how should the risk be 
assessed? Are exposure triggers desirable, and how should exposure and effect be assessed 
(Webb, 2001a)? 
• The human pharmaceuticals guidance focuses on surface water through waste water 
discharge, which in turn can connect to groundwater (Tröger, 1997; Heberer et al., 1998; 
Seiler et al., 1999; Kuch and Ballschmiter, 2001). Protection of surface water protects 
groundwater in this way, but are the quality standards the same (Notenboom, 2001)? 
• The possibility of transfer of drug residues via sludge from sewage treatment plants to soil 
has been included in updates of the guidance in accordance with the TGD (ECB, 1996). In 
view of the total residue approach: are model calculations performed using the most 
relevant data? 
• Literature indicates that transport out of the site to surface water, groundwater or drinking 
water wells may occur (Holm et al., 1995; Ahel and Jelii, 2001), and that this general 
process can be modelled and assessed (Mills et al., 1999). Should the fate of drug residues 





2.4. Pharmaceuticals in drinking water: a comparison of human and 
environmental risk assessment 
 
Groundwater, and as a derivative, drinking water pollution, are two hazards that are 
addressed both from a public health and an environmental point of view. The available public 
literature on pharmaceuticals in the environment was reviewed in 1996 by the German 
Ministry of Environment and in 2001 by the Dutch Institute for Inland Water Management 
and Waste Water Treatment (RIZA)  (Römbke et al., 1996; Derksen et al., 2001; Jongbloed et 
al., 2001). The measured concentrations that were reported are summarised below (MC 
values in Table 2-1). In this section no attempt is made to be complete on all monitoring data 
in drinking water (Heberer, 2002; Sacher et al., 2003). Mostly maximum values are reported 
when ranges were available. It should be noted that information on negative samples, 
sampling strategy, and other compounds, is not used.  
Based on the results obtained for the analysis of surface and groundwater in other 
European countries (Germany, Switzerland, Denmark, and United Kingdom) and the 
consumption of drugs, 13 pharmaceuticals were selected for drinking water analyses in the 
Netherlands by RIVM. Most of the 13 pharmaceuticals are medium polar and polar 
substances; therefore, liquid chromatography was the separation method of choice. As 
regards detection, the use of MS/MS will allow us to combine screening and confirmation in 
one procedure. Details of the analytical method are described in Stolker et al. (2004). The set 
of compounds included sulphamethoxazol, paracetamol, metoprolol, carbamazepine, 
diclofenac, bezafibrate, erythromycin, fenofibrate, acetylsalicylic acid, clofibric acid, 
ibuprofen, bisoprolol and chloramphenicol. With the described method, all compounds could 
be determined in surface water, ground- and drinking water with limits of detection ranging 
from 1-10 ng/l. The repeatability standard deviation ranged from 2-12% at the concentration 
of 100 ng/l (n=5). The within laboratory reproducibility (%RSD) at the same concentration 
level of 100 ng/l ranged from 4-29% (n=10). These results are very satisfactory for this type 
of analysis.  
The identities of the compounds detected in real-life water samples were confirmed by 
using the EU draft guidelines for the identification of micro-contaminants, EU commission 
decision 2002/657/EC (EC, 2002a). Conform to these criteria all positive (screening) samples 
were re-injected and for the confirmation of the identity of the pharmaceutical compound two 
MS/MS ions were monitored and the ion ratios were checked against the reference ratio of 
standards or fortified samples.  
The LC-MS/MS procedure has been used for the monitoring of surface, drinking- and 
groundwater within the Netherlands. In the spring of 2002 samples were collected at different 
spots all over the Netherlands. Finally the total amount of 15 groundwater, 29 surface water 
and 22 drinking water samples were screened for the pharmaceuticals. Table 2-1. shows the 




In all samples of water (acetyl)salicylic acid was detected. With the described method it 
was not possible to distinguish between salicylic acid and acetylsalicylic acid. Due to the fact 
that salicylic acid was detected in the real ‘blank’ samples of pure demi-water to a maximum 
of 50 ng/l, only those water samples containing concentrations of salicylic acid exceeding 50 
ng/l were counted as real positive samples. In none of the samples fenofibrate, 
chloramphenicol, ibuprofen or paracetamol were detected.  
From the results presented in Table 2-1. it can be concluded that for only a few samples 
of drinking water positive results were obtained. One sample of drinking water was positive 
for sulfamethoxazole and one sample was found positive for diclofenac, two samples were 
positive for (acetyl)salicylic acid and two for clofibric acid. A second conclusion is that all 
samples of groundwater contained one, two or three pharmaceutical compounds. Most 
frequently (acetyl)salicylic acid, carbamazepine and clofibric acid were detected. A third 
conclusion is that all surface water samples (not shown in Table 2-1) contained 2 to 8 
different pharmaceutical compounds per sample (cf. Kolpin et al. (2002)). Two samples 
contained carbamazepine at the level of > 100 ng/l. Most frequently (acetyl)salicylic acid, 
carbamazepine, sulfamethoxazole and diclofenac were detected.  
Toxicological limits of the 13 medicines plus ethinylestradiol in drinking water were 
determined. The limits are based on 10% of the ADI (acceptable daily intake) or the MRL 
(maximum residue limit) for milk determined for veterinary medicines, an average consumer 
bodyweight of 60 kg and a drinking water intake of 2 litres a day. If the medicine is not used 
as a veterinary medicine, the public databases are used to determine whether an ADI is 
determined for other purposes. If no ADI or MRL are available, a provisional ADI is 
determined from the lowest pharmacological effective dose and a safety factor of 100.   
Table 2-1. Number of positive water samples in the Netherlands (2002) with LC-MS/MS analyses (Stolker et al., 
2004), and measured concentrations (MC) in drinking water in Europe (Jongbloed et al., 2001).  
 MC drinking water (n=22 ) 
ng/L 
groundwater (n=15)  
ng/L 
  <25 25-100 >100 <25 25-100 >100 
(Acetyl) salicylic acid* 290 - 2 - - 11 - 
Bezafibrate 27 - - - - - - 
Bisoprolol  - - - - - - 
Carbamazepine  1 - - 8 2 - 
Chloroamphenicol  - - - - - - 
Clofibric acid 270 - 2 - 2 3 - 
Dehydroerythromycine  - - - 1 - - 
Diclofenac 6 - - - 4 - - 
Fenofibrate 210 - - - - - - 
Ibuprofen 3 - - - - - - 
Metoprolol  - - - - - - 
Paracetamol  - - - - - - 
Sulphamethoxazole  2 - - 3 - - 





From this provisional ADI, a provisional drinking water limit is derived. Although it is 
known thatsome medicines interact at pharmacological effective doses, no information is 
available on the interaction at the level of the proposed drinking water limits. Therefore, no 
attempt was made to determine drinking water limits for combinations of medicines.  
Based on ecotoxicological data, predicted no-effect concentrations are derived by, or 
included as proposed in Webb (2001a) and Schowanek and Webb (2002). 
 
Paracetamol (CAS No: 103-90-2). Use: antipyretic, analgesic and anti-inflammatory. Human oral 
dose minimum 5 mg/kg bw in children up to 4 times a day (=1.2 g per day). Paracetamol is included 
in Annex II of Council Regulation No 2377/90. An Acceptable Daily Intake (ADI) of 3 mg/person 
was determined based on a pharmacological Lowest Observed Effect Level (LOEL) of 5 mg/kg 
bw/day for an antipyretic effect in human infants and a safety factor of 100 (EMEA/MRL/551/99). 
Calculation: 3 mg/person * 10% / 2 L/person. Drinking-water limit: 150 µg/L. The proposed 
environmental PNEC is 9.2 µg/L (Schowanek and Webb, 2002). 
Sulfamethoxazole (CAS No: 723-46-6) Use: antibiotic. Human oral dose minimum 2 gram per 
day. Sulfamethoxazole is also used as a veterinary medicine. Sulfamethoxazole is included in Annex I 
of Council Regulation No 2377/90 as part of the inclusion of the sulphonamides. No ADI was 
determined but a Maximal Residue Limit (MRL) of 100 µg parent drug/kg milk was proposed 
(EMEA/MRL/026/95). This MRL in milk is based on a consumption of 1.5 L per day. Calculation: 
100 µg/kg milk * 1.5 kg milk/person / 2 L water/person. Drinking-water limit: 75 µg/L. For 
pathogenic bacteria the MIC50 was reported to be 0.002 - >256 mg/L. Pseudomonas putida gave a 16h 
IC50 of 256 mg/L (Al-Ahmad et al., 1999). The PNEC would be 0.2 µg/L based on the most 
vulnerable taxa. 
Carbamazepine (CAS No: 298-46-4). Use: antiepileptic and psychotropic. Human oral dose: 
minimum 100 mg per day. A provisional ADI of 1 mg per person was derived from the lowest 
effective dose in humans. Calculation: 100 mg/person / 100 * 10% / 2 L/person. Provisional drinking-
water limit: 50 µg/L. Ferrari et al. (2003) established a NOEC of 25 µg/L for Cerodaphnia dubia, the 
lowest value for four species. The PNEC would be set at 2.5 µg/L. Using the program ECOSAR a 
PNEC of 6 µg/L was calculated (Jones et al., 2002).  
Metoprolol (CAS No: 54163-88-1; 37250-58-6). Use: cardio-selective betablocker. Human oral 
dose: minimum 100 mg per day. A provisional ADI of 1 mg per person was derived from the lowest 
effective dose in humans. Calculation: 100 mg/person / 100 * 10% / 2 L/person. Provisional drinking-
water limit: 50 µg/L. Environmental PNEC 7.3 µg/L (Cleuvers, 2003). 
Bisoprolol (CAS No: 66722-44-9). Use: cardio-selective betablocker. Human oral dose minimum 
2.5 mg per day (Fuchs, 1997). A provisional ADI of 25 µg per person was derived from the lowest 
effective dose in humans. Calculation: 2.5 mg/person / 100 * 10% / 2 L/person. Provisional drinking-
water limit: 1 µg/L. No PNEC can be derived, but some data on this group of beta-blockers are 
available.  
Invertebrates (C. dubia, D. magna and H. azteca) were exposed to atenolol, metoprolol, nadolol and 
propranolol and average invertebrate 48h LC50 ranged from 0.85-29.8 mg/L. Reproduction of H. 
azteca after a 27 days exposure was impacted at sublethal levels of propranolol with a NOEC of 0.001 
and a LOEC of 0.1 mg/L. C. dubia reproduction NOEC and LOEC were 0.125 and 0.250 mg/L 
(Huggett et al., 2002). A PNEC for propranolol of 1.87 µg/L was derived earlier in (Webb, 2001b), 
now a PNEC for all these beta-blockers might be established at 0.01 µg/L. 
Diclofenac (CAS No: 15307-86-5). Use: anti-inflammatory drug. Human oral dose: minimum 0.25 
mg/kg bw anti-pyretic effect in children (=15 mg per day) (Keinanen-Kiukaanniemi et al., 1980). A 
provisional ADI of 0.15 mg per person was derived from the lowest effective dose in humans. 




acute tests with Daphnia, Desmodesmus and Lemna, Lemna was the most sensitive species with an 
EC50 of 7.5 mg/L (Cleuvers, 2003). Ferrari et al. (2003) established a NOEC of 1 mg/L for 
Cerodaphnia dubia, the lowest value for four species. The PNEC would be set at 100 µg/L. However, 
in fish diclofenac concentrations of 1 µg/L significant differences in renal tissue compared to controls 
were observed, thus indicating potential adverse effects (Triebskorn et al., 2002). The PNEC is set at 
1 µg/L. 
Bezafibrate (CAS No: 41859-67-0). Use: lipid-regulating drug. Human oral dose minimum 67 mg 
per day (renal impairment). A provisional ADI of 0.67 mg per person was derived from the lowest 
effective dose in humans. Calculation: 67 mg/person / 100 * 10% / 2 L/person. Provisional drinking-
water limit: 35 µg/L.  
Fenofibrate (CAS No: 49562-28-9). Use: lipid-regulating drug. Human oral dose minimum 100 
mg per day. A provisional ADI of 1 mg per person was derived from the lowest effective dose in 
humans. Calculation: 100 mg/person / 100 * 10% / 2 L/person. Provisional drinking-water limit: 50 
µg/L. 
Clofibric acid (CAS No: 882-09-7; 637-07-0 (clofibrate)). Use: lipid-regulating drug. Human oral 
dose minimum 20 mg/kg bw (= 1.2 g per day). A recent summary of the IARC is available (IARC, 
1990). No NOELs were determined in this summary. The lowest LOEL was found in humans (Larsen 
et al., 1994). In this study, effects on serum cholesterol and triglycerides were found in patients with 
type III hyperlipoproteinemia treated with approximately 1 mg/kg bw/day for 8 weeks. Based on the 
effect level determined and a safety factor of 100, a provisional ADI of 0.6 mg/person can be 
calculated. Calculation: 60 mg/person / 100 * 10% / 2 L/person. Provisional drinking-water limit: 30 
µg/L. An ambient water quality criterion (AWQC) of 220 µg/L was derived for clofibrate, and of 
1930 for clofibric acid, by (Schulman et al., 2002). 
Ferrari et al. (2003) established a NOEC of 246 µg/L for Brachyonius calyciflorus, the lowest value 
for four species. The PNEC would be set at 25 µg/L. 
The environmental PNEC for clofibrate is calculated as NOEC/AF 10/50 = 0.2 µg/L (Schowanek 
and Webb, 2002) and might apply to the group of fibrate derivatives. In acute tests with Daphnia, 
Desmodesmus and Lemna, Lemna was the most sensitive species with an EC50 of 12.5 mg/L 
(Cleuvers, 2003), Ferrari et al. established a NOEC of 246 µg/L for Brachyonius calyciflorus, the 
lowest value for four species. The PNEC would be set at NOEC/AF 10/10 = 1 µg/L, due to the 
extended chronic dataset (Ferrari et al., 2003).  
Erythromycin (CAS No: 114-07-8) Use: antibiotic. Humane oral dose minimum 1 g per day. 
Erythromycin is included in Annex I of Council Regulation (EEC) No 2377/90. A microbiological 
ADI was determined by the CVMP of 300 µg/person. An MRL of 40 µg parent drug/kg milk was 
proposed (EMEA/MRL/720/99). The total allowed uptake of erythromycin from veterinary use is 
90% of the ADI. A limit for drinking water of 15 µg /L can be calculated based on 10% of the ADI 
and a water intake of 2 L per day. The total uptake based on these limits remains below the ADI 
because it is not assumable that someone drinks 1.5 L milk plus 2 L water per day. 
Calculation: 0.3 mg/person * 10% / 2 L/person. Drinking-water limit: 15 µg /L. PNEC >74 µg/L 
(Webb, 2001b).  
Acetylsalicylic acid (CAS No: 50-78-2). Use: anti-inflammatory drug. Human oral dose minimum 
20 mg per day. Acetylsalicylic acid is included in Annex II of Council Regulation (EEC) No 2377/90. 
An ADI of 0.5 mg/person was determined by the CVMP based on a LOEL for effects on bleeding 
time and thromboxane B2 production in humans of 10 mg per person and a safety factor of 20 
(EMEA/MRL/695/99). Calculation: 0.5 mg/person * 10% / 2 L/person. Drinking-water limit: 25 
µg/L. An ambient water quality criterion (AWQC) of 480 µg/L was derived for acetylsalicylic acid, 
and of 190 µg/L for salicylic acid, by (Schulman et al., 2002). The environmental PNEC would be 




Ibuprofen (CAS No: 15687-27-1). Use: anti-inflammatory drug. Human oral dose minimum 
children 5 mg/kg bw (= 0.3 g per day). A provisional ADI of 3 mg per person was derived from the 
lowest effective dose in humans. Calculation: 300 mg/person / 100 * 10% / 2 L/person. Provisional 
drinking-water limit: 150 µg/L. Based on a 48h EC50 for Daphnia magna of 9.06 mg/L the PNEC 
would be 9.1 µg/L (Webb, 2001a). 
Chloramphenicol (CAS No: 56-75-7). Use: antibiotic (limited human use). Human oral dose 
minimum 25 mg/kg bw in neonates (= 1.5 g per day). Chloramphenicol is no longer allowed as a 
veterinary medicine in animals producing foodstuff for humans in the European Union and has only 
very limited use in humans. The CVMP or the WHO determined no ADIs or MRLs. According to the 
IARC, this substance should be regarded as carcinogenic to humans. Chloramphenicol is positive in in 
vitro mutagenicity tests and positive in some in vivo mutagenicity tests. Adequate carcinogenicity 
studies are not available. A limited carcinogenicity study in mice shows an increase in lymphoma’s 
and livercell tumours. Many case reports have described an unusual succession of leukaemia 
following chloramphenicol-induced aplastic anaemia and bone marrow depression in humans. 
Additional evidence for the association between use of chloramphenicol and leukaemia has come 
from a single large case-control study in China, which demonstrated a relationship with duration of 
exposure (IARC, 1990). There is no clear dose effect relationship between exposure to 
chloramphenicol and the occurrence aplastic anaemia and it is considered that victims may have some 
genetic or biochemical predisposition. More recent epidemiological research indicates that an 
association between ocular chloramphenicol and aplastic anaemia cannot be excluded. The incidence 
among users was 0.36 cases per million weeks of treatment compared to 0.04 cases per million weeks 
in non-users. The adjusted odds ratio was 3.77 (95% confidence interval, 0.84-16.90) (Laporte et al., 
1998). In a second epidemiological study, no evidence of an increased risk of developing adult acute 
leukaemia after topical chloramphenicol use was found (Smith et al., 2000). Also, it is unclear what 
dose of chloramphenicol is systemically available after ocular use (Walker et al., 1998b). Therefore, 
no NOEL or LOEL can be determined from the human data. The mouse study can not be used 
because it is a limited study only and it is unclear whether aplastic anaemia can be induced in mice by 
chloramphenicol. Subchronic exposure of mice to chloramphenicol induced a reversible anaemia but 
not a chronic bone marrow aplasia (Turton et al., 2000). Therefore, no limit in drinking water for 
chloramphenicol can be determined from the toxicological data. Seen the carcinogenicity, the 
concentration of chloramphenicol should be as low as possible. Therefore it is proposed to use the 
limit of quantification as the drinking-water limit. Environmental PNEC 305 µg/L (Webb, 2001b). In 
a 24h-bioluminescence test with Vibrio fischeri an EC10 of 0.0187 mg/L was found (Backhaus and 
Grimme, 1999). Based on these chronic data for a vulnerable species a PNEC of 1.9 µg/L is 
established. 
Ethinylestradiol (CAS No: 57-63-6) Use: synthetic oestrogen. The minimum therapeutic dose is 
0.010 mg per day (Webb, 2001a). A provisional ADI of 0.1 µg per person is derived from the lowest 
effective dose in humans. Calculation: 10 µg/person / 100 * 10% / 2 L/person. Provisional drinking-
water limit: 5 ng/L. The PNEC is 0.1 ng/L (Schowanek and Webb, 2002). Concentrations of 
ethynilestradiol in drinking water ranged up to 22.5 ng/L (Rurainski et al., 1977; Kuch and 
Ballschmiter, 2001). 
 
Depending on the data set and the effect assessment methodology different standards 
have been derived, as shown in the examples of acetylsalicylic acid and clofibric acid. The 
selected effect limits are presented in Table 2-2. For some substances the human effect limit 
is more stringent than the environmental limit, and environmentally acceptable 
concentrations in groundwater would surpass human drinking water limits if this groundwater 




Table 2-2. Effect limits [µg/L] for selected pharmaceuticals in drinking water. The Margin of Safety (MOS) is based 




Human limit Environmental limit Measured 
concentration 
MOS  
(Acetyl)salicylic acid* 0.1 25 168 0.290 0.35 
Bisoprolol 0.1 1 0.01 - - 
Metoprolol 0.1 50 0.01 - - 
Carbamazepine 0.1 50 2.5 <0.025 >4 
Chloroamphenicol 0.1 0.001 (LOD) 1.9 - - 
Bezafibrate 0.1 35 1 - - 
Clofibric acid 0.1 30 1 0.270 0.37 
Fenofibrate 0.1 50 1 0.210 0.48 
Dehydroerythromycine 0.1 15 74 - - 
Diclofenac 0.1 7.5 1 0.006 17 
Ibuprofen 0.1 150 9.1 0.003 33 
Paracetamol 0.1 150 9.2 - - 
Sulphamethoxazole 0.1 75 0.2 <0.025 >4 
Ethinylestradiol 0.1 0.005 0.0001 0.0225 0.004 
MOS is calculated as the [lowest limit]/[measured concentration in drinking water] 
 
In 11 out of 14 substances the PNEC is more critical than the human drinking water 
limit, and it may from an environmental perspective not be acceptable to discharge this 
drinking water to surface water. The general numeric standard for pesticidal substances in the 
drinking water directive (0.1 µg/L) is not sufficiently protective for the environment for 3 out 
of 14 substances. 
Four of the reported substances have been found in drinking water above the lowest 
limit, one concentration (ethinylestradiol) is above both the human and the environmental 
limit, although there should be a large margin of safety between daily intake and therapeutic 
dosage (Webb et al., 2003). It should be noted that measured concentrations in groundwater 
are often higher than in drinking water (Derksen et al., 2001).  
A prediction of groundwater and drinking water exposure seems to have become very 




In regulatory frameworks, known modelling limitations, the applicable effect 
assessment approach, and acceptability standards should have been harmonised in the 
process. From the regulatory point of view three important aspects of risk modelling are:  
• the goal of the modelling versus the type of model; 
• the relation between the model and the use of the product (both in time and space); 




Several of the challenges identified in the first edition of this book have been addressed 
in the recent regulatory guidance documents (Montforts, 2001). However more research 
challenges lie within these three aspects of risk modelling. They are centred on the coherence 
of the risk model components, the connection between risk model and user, and the 
development of methodology for hazards yet to be addressed, and include the following 
points: 
• Harmonisation of protection goals. At this level policy makers and scientists should engage 
in a reconnaissance of regulatory goals (central marketing authorisation, national 
registration, protection goals, standards), assessment scales (e.g. landscape level vs. local), 
model approach (predictive or monitoring), and uncertainty and variability of data 
associated with the assessment.  
• Within the risk model for the environmental risk assessment, emission and distribution 
routes, compartments, substance properties (persistency, bioaccumulation) and effect 
endpoints (ecosystem structures, population, processes, species) should be linked.  
• The risk model of the environmental risk assessment process should produce predictions 
with reference to the quality levels that are pursued for the compartments. Exclusion of 
compartments (soil, surface water, groundwater, drinking water, and sediment) either 
because the risk is supposed to be covered through other submodels, or because models 
have yet to be developed, greatly impairs the risk characterisation, and thus the decision 
making. For different compartments different limits may apply. These limits should be 
harmonised. 
• Also, it should be possible to feed risk mitigation measures back into the risk model. The 
targeted use (and waste) of the product should be explored. Repetitive use, season-related 
use or concurrent use over large areas should be considered, next to the timing and scale of 
emission to the environment (i.e. spreading of manure) and the restrictions set by the 
product registration (e.g. no comparative assessments). The guidance documents provided 
set out general directions and more directions on data selection, specifically on model 
parameterisation, are welcomed. 
• The risk model should be able to handle other modelling approaches in a higher tier. How 
does one compare e.g. catchment level simulations to the first tier basic calculations (Di 
Guardo et al., 2001; Schowanek and Webb, 2002)? What kind of information is added by a 
mechanistic modelling of groundwater contamination at a depth of 1 metre, compared to an 
empirical model in which the porewater concentration is calculated using partitioning 
between the water and solid phase? The information to decide which of the two models 
represents the target groundwater better is not within the model, but with the definition of 
the protection goal. 
• A prediction of groundwater and drinking water exposure seems to have become very 
relevant both from an environmental and a public health point of view. Exposure via water, 
soil and landfill waste should be taken into account. Harmonisation of environmental and 




And finally, in case quality standards are not met, an indication of the actual impact or 
costs will be needed to come to a cost-benefit analysis. The registration process for medicines 
is the exponent of risk assessment (Di Fabio, 1994). Policy makers, scientist and other 
interested parties (ESC, 2001) should engage in a reconnaissance of expressing, scaling and 
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3. The exposure assessment for veterinary medicinal products 
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The EU has issued Directive 81/852/EEC (1981) in which is stated that with a request 
for registration of a veterinary medicinal product information is to be provided to enable an 
assessment of the safety for the environment. In 1997 the Committee for Veterinary 
Medicinal Products (CVMP) issued a note for guidance on the environmental risk assessment 
(EMEA, 1997)outlining procedures, trigger values and backgrounds to the proposed risk 
assessment methodology, in order to harmonise the assessment procedure in Europe. The 
proposed methodology is based on the hazard quotient approach, that is widely used in the 
environmental risk assessment frameworks of new and existing substances and of plant 
protection products and biocides (Anonymous, 1991a; ECB, 1996). 
This article will shortly discuss the structure of the environmental assessment, and 
will elaborate on the exposure assessment with exposure models adapted to the Dutch 
agricultural situation. 
Risk management 
The basis for the 81/852/EEC directive is the precautionary principle18. The 
assessment is part of a risk management process consisting of two distinct phases: a risk 
assessment phase and a risk management phase (Van Leeuwen, 1995). Here only risk 
assessment will be considered. The first step in risk assessment is the hazard identification, 
for which is referred to Directive 81/852/EEC. The second step is the exposure assessment. 
Exposure assessment can either be done by measuring exposure concentrations or by 
predicting them with models. The latter involves determining the emissions, pathways and 
rates of movement of a substance and its transformation in order to obtain concentrations to 
which environmental compartments may be exposed (yielding PEC-values: Predicted 
Environmental Concentrations). Underestimation of the exposure in a compartment is 
avoided by making worst-case assumptions. Worst-case assumptions can be modified to 
realistic worst-case assumptions once reliable information is available. 
Effect assessment or dose-response assessment is the estimation of the relationship 
between the level of exposure to a substance, and the incidence and severity of an effect. In 
                                                 
18 This suggests that the precautionary principle was already operative within the EU at that time; it was not. A 
precautionary approach as a concept in public health policy had been advocated as early as 1854. In Germany the 
‘Vorsorgeprinzip’ had been used in the Clean Air Act of 1974. On a trans-national level, the principle was first referred to 
in 1984 by the North Sea Ministerial Conference in the Bremen Declaration. At the EU level it finally made its first 
appearance in the Treaty of Maastricht in 1992. At the time of writing this paper, it was my intention to indicate that a 
scientific assessment of the risks connected to the use of a medicinal product before it is used, fits well into a 




ecological or environmental risk assessment (ERA) millions of species and processes may be 
exposed by a variety of routes. Laboratory-established No-Observed-Effect-Concentrations 
(NOEC) are used to derive Predicted No Effect Concentrations (PNECs) for different 
environmental compartments: water, sediment, and soil, by applying “assessment factors” 
usually in the range of 10-10,000, or by extrapolation based on a statistical analysis. In this 
way the uncertainty that the effect value used underestimates the effect on species in the field 
is reduced. 
The processes of risk assessment (how risky is the situation) and risk management 
(what shall we do about it) are influencing each other when it comes to deciding on 
endpoints, (un)acceptable effects, and uncertainty factors. Risk characterisation integrates the 
previous steps, for example in PEC/PNEC ratios, also called Risk Characterisation Ratios 
(RCR), as is often done in many international regulatory frameworks. We only know that the 
likelyhood of adverse effects increases when the RCR increases. Regulatory choices have to 
be made when deciding on the RCR that must lead to further assessment or risk mitigation 
measures. This choice will depend on the uncertainty in the models as well as on the political 
or economical implications of the mitigation measures. 
What does the ERA for veterinary medicinal products based on the CVMP Guidance 
document look like (EMEA, 1997)? The amending Directive 92/18/EEC describes the ERA 
process as composed of two phases. The first phase (Phase I) shall assess the potential of 
exposure of the environment and is thus limited to product identification and exposure 
assessment. Several exemptions for further testing are given, such as trigger values for PECs: 
100 µg/kg in slurry, 10 µg/kg in soil, 0.1 µg/l in groundwater, 10 µg/kg in dung; or trigger 
values for halflives: DT50slurry 30 days. These values are the result of the negotiations in the 
EMEA working group between all interested parties and have no scientific basis. Their 
primary function is to serve as management tools. When exemptions do not apply and trigger 
values are exceeded, one enters Phase II.  
Phase II includes effect assessment and risk characterisation and here the notifier is 
facing considerable testing efforts. The possibility that the ERA may end at the exposure 
assessment is an ‘escape route’ that is welcomed by the pharmaceutical industry, as this could 
make the difference between an economically profitable product and a dead end. To the 
regulatory authorities this escape route increases the demand for a thorough exposure 
assessment. Considering that at the side of the effect assessment the uncertainties are 
relatively well known, and the concept of using ‘assessment factors’ is more and more 
refined, one has to realise that the exposure assessment has a relatively high level of 
uncertainty. 
The risk assessment should cover the whole product, all its ingredients, and all 
relevant metabolites that are released into the environment. Identifying emission and 
distribution routes is an important stage in the process, as both the environment and the 
notifiers will be confronted with the consequences. A uniform and systematic analysis of 
possibilities guarantees a reliable assessment. Emission can take place at any step in the life 
cycle of the product. Dosage, route of application, type of target animals, excretion, route of 




- at application; 
- at removal of waste material containing the product (manure, fish water); 
- by excretion via faeces and urine; 
- by contagion (immunological products); 
The main categories of emission scenarios are: 
- removal of waste containing the product (containers, manure, fish water, medicated 
drinking water); 
- excretion via faeces and urine; 
- spillage at external application or direct exposure/discharge outdoors 
Based on product identity an exemption for further assessment is made for 
physiological substances such as vitamins, electrolytes, natural amino acids and herbs. Based 
on the use of the product and limited routes of emission, products for companion animals 
(excluding horses) are also exempted.  
A third reason for exemption is the application to a small number of animals as 
opposed to mass treatment. A typical example is the treatment of a wounded cow with 
antibiotics, as a result of an accident. Should more than one animal be involved, it becomes 
evident that there is no clear borderline with mass treatment. In case of doubt, it is suggested 
to perform an exposure calculation, as there are more trigger values along this process.  
One should be aware that some parameters used in exposure and distribution 
assessment are directly used in the risk characterisation process. The substance properties of 
sorption capacity (Koc) and transformation rate in soil and slurry (DT50) are used as triggers 
in the risk characterisation process because they are indicators of the outcomes of distribution 
routes and processes. This implies that attention should be paid to the reliability and 
usefulness of the studies investigating these parameters (Mensink et al., 1995). 
Livestock breeding and rearing is an important industry in the Netherlands (Table 1). 
Considering the above and the diversity of target animals listed in table 1, it is worthwhile to 
put a major effort into elaborating the exposure assessment. To illustrate the consequences 
some exposure models based on the Dutch agricultural practice are given (section 2). The 
results of these models are discussed in section 3. 
 
Table 1. An overview of animal husbandry in the Netherlands. 
Category number of animal places (x 1000) number of farms 
dairy cows 1,675 36,000 
cattle 4,550 54,400 
pigs 14,400 21,250 
horses and ponies 107 20,000 
sheep 1,625 21,000 
broilers 44,000 1200 
laying hens 39,500 2700 
turkeys 1,250 140 
fish 2500 tonnes 50 





3.2 Exposure assessment: agricultural practice, emission modelling, and 
trigger values 
 
A realistic worst-case exposure assessment can be performed if the daily agricultural 
practice is taken into account. The Dutch situation is characterised by a number of distinct 
features: bio-industry; manure surplus; restricted application time (March-September) of 
manure in certain regions; slurry injection (5 cm depth) or direct tillage (20 cm depth); large 
areas with grassland and cattle, and indoor fish cultivation. Three exposure scenarios are 
discussed: excretion by grazing cattle (section 2a); manuring of land (arable and grassland; 
section 2b)); and fish farm wastewater discharge (section 2c). In section 2d the use of the 
trigger values is discussed. 
 
2a. Exposure assessment: excretion by grazing cattle 
In the Netherlands beef cattle and heifers, suckler cows and dairy cows are grazed. A 
common treatment before animals are grazed is an anthelminthic treatment by injection, oral 
dosage, or intra-ruminal bolus. Residues of these substances are secreted into urine and 
faeces and are excreted onto the land or into the water. To determine the concentration in 
these compartments, one needs to know how much of the substance is excreted, and the rate 
of excretion. In case these distribution parameters are not available, the worst-case 
concentration in faeces can be calculated with the following model and defaults (table 2). 
Cattle defaecate 10-11 times per day (Marsh and Campling, 1970). This model suggests that 
the entire administered dose is excreted in one defaecation event. 
 












input   
Qproduct dosage of product used [kg.kgbw
-1.d-1] 
Cc concentration of chemical (c) in product [mgc.kg
-1] 
manimal (averaged) body weight [kgbw.animal
-1] 
Ttreatment duration of treatment [d] 
Fmax. excreted  dung highest fraction excreted in dung in one day [-] 
Pdunganimal dung production animal in field [kgwwt.animal
-1.d-1] 
Nexcretion number of dung excretion events per day [d-1] 
output   









Table 2. Default settings for the module for the calculation of the maximum concentration in dung. 
parameter symbol unit value 
duration of treatment Ttreatment [d] 1 
highest fraction excreted in dung in one day Fmax. excreted  dung [-] 1 
number of dung excretion events per day Nexcretion [d-1] 10.5 
 
Table 3. Body weight, therapeutic dosage, and dung production of selected target species. 







Qproduct ⋅ Cc [mg.kgbw
-1] 
dairy cows 600 37 0.2 
beef cattle  330 17 0.2 
horses 600 23 0.2 
 
 
In the assessment process the trigger is 10 µg/kgwwt, below which further assessment 
is not necessary. Information on the excretion pattern is therefore very useful. Ivermectin is 
used here as an example. Ivermectin (CAS 70288-86-7) is an anti-parasitic substance used as 
anthelmintic in animal husbandry. Ivermectin is hardly excreted in urine (<2%), and c. 90% 
of a dosage is excreted via faeces in the 7 to 14 days following administration, depending on  
the route of administration (Campbell, 1989; Halley et al., 1989). After oral application of 
labelled ivermectin to cattle, 60% of the label is excreted within two days, the remaining 
fraction is excreted in the following four days. On the second day after application 93-94% of 
the measured radioactivity was found to be ivermectin, whereas after 6 days only 44-52% of 
the measured radioactivity was found to be ivermectin (personal communication Dr. H. 
Rogiers, Merial NV/SA, Belgium, 1997). For reasons of convenience, the excretion of the 
labelled ivermectin is described in two steps, with a fast initial phase of two days releasing 
60% of the label, and a second phase releasing 39% in the following four days. It is further  
 
Table 4. The excretion of labelled ivermectin by cattle after oral dosage. 
days after 
application 

















directly    0.88 36 30 
1 1 0.37 0.97 0.359 1.39 1.16 
2 1 0.23 0.94 0.216 0.84 0.70 
3 2 0.23 0.84 0.193 0.75 0.63 
4 2 0.11 0.72 0.079 0.31 0.26 
5 2 0.04 0.61 0.025 0.10 0.08 
6 2 0.01 0.51 0.006 0.02 0.02 
7 2 0.008 0.43 0.004 0.02 0.01 







Table 5. Measured ivermectin concentrations in dung. 






as reported recalculated to 
[mg/kgwwt] 
source 
cattle 276 kg 0.2 (s.c.) 0.42 mg/kgwwt 
after 5 days 
0.42 Lumaret et al., 19931 
 
cattle c. 300 kg 0.5 (p.) 9.0 mg/kgdwt 
after 1 day 
1.35 
cattle c. 300 kg 0.2 (s.c.) 3.9 mg/kgdwt 
after 2 days 
0.58 
Sommer and Steffansen, 
19932 
 
cattle 278 kg 12 mg/d (i.r.) 0.66 mg/kgwwt 0.66 Strong et al., 1996
 3 
 
horse 0.2 (o.) 8.5 mg/kgdwt after 1 
day 
1.70 Herd, 1995 4 
 
i.r. = intra-ruminal; s.c. = subcutaneous; o. = oral; p. = pour-on; dwt = dry weight; wwt = wet weight; bw = body 
weight 
1 After 12 days no ivermectin detected. Limit of detection was 0.02 mg/kg. 
2 After 14 days no ivermectin detected (pour-on); or 0.3 mg/kg dwt (subcutaneous). Limit of detection was 0.05 
mg/kg. 
3 Determined with bioassay with the fly Neomyia cornicia. 
4 After four days no ivermectin detected. Limit of detection was 0.05 mg/kg. 
 
assumed that the decrease of unchanged ivermectin is also a two step process: from 100 to 
93.5% in two days and from 93.5 to 44% in the following four days. The calculation of 
exposure concentrations in dung requires a dosage, animal body weights and dung production 
data (table 3). With the assumption that the processes in every step follow first-order kinetics, 
the course of the excretion and concentration is given in table 4. 
One can see in table 4 that the calculated concentrations using excretion data 
(maximum 1.39 mg/kg) are over 25 times lower than calculated with the worst-case scenario 
(36 mg/kg). Table 5 shows measured concentrations ivermectin in dung reported in scientific 
literature. The concentrations based on wet weight in the fourth column are recalculated using 
a moisture content of 85% for cattle dung and 80% for horse dung. Unfortunately, the results 
with cattle were obtained from subcutaneous or pour-on treated animals, and show that the 
excretion period following these types of treatment is longer than is expected after oral 
treatment (ca. one week). The results from the intra-ruminal sustained-release bolus can be 
compared to the model calculations. If the model beef cattle of 330 kg was treated with this 
sustained-release bolus (Strong et al., 1996) the calculated concentration in dung would be 
0.62 mg/kg, which is equivalent to the 0.66 mg/kg measured. Assuming that the excretion 
pattern for cattle is representative for horses as well, the concentration in horse dung after 1 
day can be calculated to 1.9 mg/kg. This value is also very close to the observed 
concentration of 1.7 mg/kg. 
These data show that the worst-case calculations are overestimating the 
concentrations, and that an exposure assessment based on concentrations derived with 




2b Exposure assessment: manuring of land. 
Calculation models for the concentration in soil are presented by Spaepen et al. (1997) 
introducing the key to the concentration in soil: the phosphate and nitrogen immission 
standards for manure. The basic calculations (here based on phosphate immission) are given 
in formula set A. 
 
How do these calculations, based on yearly manure production figures and yearly 
number of cycles, relate to agricultural manuring practice? A limited inquiry showed that 
manure is hardly ever stored for over half a year, and that the manuring regime on grassland 
might be quite different from the regime on arable land planted with corn (Zea mais). In 
certain regions in the Netherlands farmers have to deal with restricted spreading times 
(spreading of slurry is only allowed between March and September). The following scenarios 
for arable land and grassland were developed, using the specific situation to improve the 
worst-case exposure calculations to realistic worst-case calculations (Montforts, 1997a). 
 
Manuring of land: PIECsoil calculations for arable land. 
The only time the farmer can manure the arable land is before the crop is growing. 
Taking into account the immission standards the farmer will spread the manure that has been 
stored during the winter (October-March: 152 days) in one event. The possible concentration 
of excreted residues in the slurry now depends on the number of treatments during this 
storage time and the time lapse between the excretion of the residues and the moment the 
slurry is spread. In a worst-case scenario all residues are excreted the day before the slurry is 
spread. The best case scenario will allow the residues to break down during the maximum 
available time. With the assumptions that every animal cycle is treated once, and all cycles 
are treated at the same life-stage (i.c. at their averaged body weight), the following formulas 
calculate the concentration in slurry taking degradation into account over the averaged 
storage time for the residues. 
 
























input   
Qproduct dosage product used [kg.kgbw
-1.d-1] 
Cc concentration chemical (c) in product [mgc.kg
-1] 
Ttreatment duration of treatment [d] 
manimal (averaged) body weight [kgbw.animal
-1] 
Fexcreted fraction excreted in faeces and urine [-] 
Ncyclusanimal number of cycli per year [animal.place
-1.yr-1] 
PP phosphate production animal in stable in one year [kgP2O5.place
-1.y-1] 
Tstorage average storage time slurry grassland/arable land 365 [d] 
Trest maximum duration of storage after last treatment [d] 
kdegslurry reaction constant transformation in manure [d
-1] 
QP2O5 phosphate immission standard [kgP2O5. ha
-1.yr-1] 
RHOsoil bulk density of soil [kg.m-3] 
DEPTHfield mixing depth with soil [m] 
CONVarea field conversion factor for the area of the agricultural field [m
2.ha-1] 
intermediate results   
Qexcreted amount  substance excreted [mgc.place
-1.yr-1] 
CP2O5 concentration in phosphate [mgc.kgP2O5
-1] 
output   
PIECsoil predicted initial environmental concentration in the soil [mgc.kgsoil
-1] 
 
The second term in the first formula of formula set B (with Qexcreted) calculates the 
initial concentration in the slurry (phosphate) after one treatment. The third term (with 1-
(Frsl)^Napplication) corrects for multiple treatments during the storage period, and the 
degradation during the time between these treatments. When there is only one treatment, this 
term is equal to 1. When the degradation rate is unknown, this term equals Napplication. The 
fourth term corrects for degradation in the slurry during the time left after the last treatment 
during the storage period. The maximum time left after the last treatment (Trest) is calculated 
with the third formula, and is averaged with the minimum time (zero days) by dividing with a 
factor two. When there is only one treatment, Trest equals Tstorage. 
To illustrate the difference with the basic formulas of Spaepen et al. (1997) some 
calculations are made (table 7) using the information shown in table 6 and the two sets of 
formulas: set A based on the year-based approach; set B based on the Dutch agricultural 
practice. For matters of convenience, the calculation of Trest is from the same formula for both 
sets.  
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input   
Qexcreted amount  substance excreted [mgc.place
-1.yr-1] 
PP2O5  phosphate production of animal in stable [kgP2O5.place
-1.d-1] 
DT50degslurry halflife time in slurry [d] 
Tcyclus, animal duration of cyclus [d] 
Tstorage average storage time slurry grassland/arable land [d] 
Napplication number of applications per storage period [-] 
kdegslurry reaction constant transformation in manure [d
-1] 
QP2O5 phosphate immission standard [kgP2O5. ha
-1.yr-1] 
RHOsoil bulk density of soil [kg.m-3] 
DEPTHfield mixing depth with soil [m] 
CONVarea field conversion factor for the area of the agricultural field [m
2.ha-1] 
intermediate results   
kdegslurry reaction constant transformation in manure [d
-1] 
Frsl fraction of the concentration remaining in slurry after time 
Tcyclus, animal 
[-] 
CP2O5 concentration in phosphate [mgc.kgP2O5
-1] 
Trest maximum duration of storage after last treatment [d] 
output   




The example is performed with data for oxytetracycline hydrochloride 
(oxytetracycline HCl) (CAS 2058-46-0), oxytetracycline (CAS 79-57-2) and 
chlortetracycline (CAS 57-62-5), used for sows and turkeys in rearing. 
Oxytetracycline HCl is dosed with 40 mg/kg bw for 5 days. It was found that wethers 
(castrate ram) excrete at least 21% of the oral dosage oxytetracycline and that young bulls 
excrete 17 - 75% of an oral dosage chlortetracycline as the parent compound (Roij and De 
Vries, 1980). The Fexcreted used here is 0.75. Chlortetracycline is found to degrade in cattle 
manure with a DT50 of approx. 1 week at 37°C, increasing to a DT50 >20 days when 
decreasing the temperature to 28°C. Using the Arrhenius-equation to recalculate the DT50 
from 37°C to 20°C the DT50 (20°C) amounts to 30 days. From the data presented by 
Soulides et al. (1962) an average DT50 in soil of 4 days (25°C) can be derived, and 
recalculated to a DT50 (20 °C) of 6 days19. To illustrate the relative weight of the DT50 in 
slurry and soil, calculations with DT50 of 100 or 15 days are also presented.  
The results in table 7 show that exposure concentrations differ by a factor thirty, 
depending on the substance properties. 
                                                 




Table 6. Agricultural parameters for arable land in the Netherlands. 
Symbol Parameter value unit 
manimal, sow (averaged) body weight sow 240 [kgbw.animal
-1] 
manimal, turkey (averaged) body weight turkey 2 [kgbw.animal
-1] 
PP2O5 sow phosphate production sow in stable sow 0.0556 [kgP2O5.place
-1.d-1] 
PP2O5 turkey phosphate production turkey in stable turkey 0.00071 [kgP2O5.place
-1.d-1] 
Tcyclus, sow duration of cyclus sow 365 [d] 
Tcyclus, turkey duration of cyclus turkey 49 [d] 
Tstorage, set A average storage time slurry arable land 365 [d] 
Tstorage, set B average storage time slurry arable land 152 [d] 
Napplication,A,sow applications per storage period to sow set A 1 [-] 
Napplication,A,turkey applications per storage period to turkey set A 7.4 [-] 
Napplication,B,sow applications per storage period to sow set B 1 [-] 
Napplication,B,turkey applications per storage period to turkey set B 4 [-] 
QP2O5 phosphate immission standard 110 [kgP2O5. ha
-1.yr-1] 
RHOsoil bulk density of soil 1500 [kg.m-3] 
DEPTHfield mixing depth with soil 0.2 [m] 
CONVarea field conversion factor for the area of the field 10,000 [m
2.ha-1] 
 
Table 7. Results of PIECsoil calculations (µg/kg dw) in arable land for two distribution scenarios (A and 
B), two animal species, and various DT50 values in slurry. 
animal sow turkey in rearing 0-6 weeks 
formula set A B A B 
no DT50 slurry 64 155 315 410 
DT50 slurry 100 days 18 92 275 260 
DT50 slurry 30 days 1 28 200 140 
 
Manuring of land: PIECsoil calculations for grassland. 
The farmer can manure the grassland during the whole season. The farmer will fill the 
immission standard in more events, in order not to harm the grass. The dosage of the product 
to the land depends on the number of treatments during the storage time and the time lapse 
between the excretion of the residues and the moment the slurry is spread. The concentration 
in the soil after the last batch is spread depends on the degradation rate in the soil. The Dutch 
model assumes that within the period March-September the phosphate immission standard is 
filled in four events: one at the start of the season, one at the very end, and two at equal 
distances inbetween. The slurry spread at the start of the season has been stored for 152 days, 
the other batches for 71 days. The formula set for sows is almost equal to set B, with one 
animal treatment per year only, but now only one of the batches contains contaminated 
manure. The formula set for turkeys is different, because the period between the moment of 
animal treatment and the moment of manure spreading changes with every cycle. In case of 
seven animal cycles per year, two treatments may take place during the winter storage period 
and five during the three summer storage periods. Every storage period results in a dosage that is 




Table 8. Agricultural parameters for grassland in the Netherlands. 
Symbol Parameter value unit 
manimal, sow (averaged) body weight sow 240 [kgbw.animal
-1] 
manimal, turkey (averaged) body weight turkey 1 [kgbw.animal
-1] 
PP2O5 sow phosphate production sow in stable 0.0556 [kgP2O5.place
-1.d-1] 
PP2O5 turkey phosphate production turkey in stable 0.00071 [kgP2O5.place
-1.d-1] 
Tcyclus, sow duration of cyclus 365 [d] 
Tcyclus, turkey duration of cyclus 49 [d] 
Tstorage, set A average storage time slurry grassland, set A 365 [d] 
QP2O5 phosphate immission standard 135 [kgP2O5. ha
-1.yr-1] 
RHOsoil bulk density of soil 1500 [kg.m-3] 
DEPTHfield mixing depth with soil 0.05 [m] 




The concentration in the soil directly after the last treatment is calculated while taking 
degradation in the soil before the last treatment into account. The most realistic period that 
degradation can take place in slurry and in soil cannot be determined with a rule of thumb. 
Given the number of cycles per year, and assuming that the time between the applications in 
the cycles is constant, one can search for the worst-case and best case combinations of slurry 
storage time and soil residence time. However, as these combinations largely depend on the 
(unknown and individual) substance properties, selected values are given for every livestock 
category of interest. 
 
The formula set for sows (C) is given by: 
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The formula set for turkeys (D) is given by: 
 
















































































To illustrate the difference with the basic formulas of Spaepen et al. (1997) the same 
calculations as for arable land (table 9) are performed using the information shown in table 8 
and the two sets of formulas: set A based on the year-based approach; set C & D based on the 
Dutch agricultural practice. 
The results show that exposure concentrations differ by a factor of fourty, depending 
on the model and the substance properties. The availability of a DT50soil can lower the 
PIECsoil  for grassland substantially.  
These calculations show the difference between the models for grassland an arable 
land. In table 10 the differences in the results of the grassland and arable land scenarios are 
shown. 
 
Table 9. Results of PIECsoil calculations (µg/kg dw) in grassland for two distribution scenarios (A and 
C/D), two animal species and various DT50 values in slurry and soil. 
animal sow 
 
turkey in rearing 0-6 
weeks 
formula set A C A D 
DT50 slurry DT50 soil     
none none 315 400 1550 1710 
100 50 90 315 1350 580 
100 15 90 315 1350 440 
30 15 4 180 980 290 





Table 10. Results of PIECsoil calculations (oxytetracycline, in µg/kg dw) for arable and grassland 
(distribution scenarios B and C/D), two animals, and various DT50 values (days) in slurry and soil. 
animal species sow turkey in rearing 0-6 weeks 
target land arable grass arable grass 
DT50 slurry DT50 soil     
none none 156 400 410 1710 
30 6 28 180 140 280 
 
 
Using experimental data on degradation in slurry and soil, PIECs are lowered by 
factors 2 - 6 compared to worst-case calculations. With the new models presented here PIEC 
in grassland will always be higher than in arable land, but given the differences in soil depth 
and phosphate immission standards, the incorporation of a DT50soil can lower the PIECsoil 
substantially. The new models give higher estimations for animals with long life cycles 
compared to the basic year-averaged model, whereas for animals with short life cycles 
(young turkeys, broilers) estimations can be lower, depending on the substance properties. 
These calculations show also that the choice of the trigger values (DT50slurry 30 days, PIECsoil 
10 µg/kg), as made by the EMEA, are not harmonised. For example: with a DT50 of <30 
days further assessment is not necessary, but PIECsoil may still be >10 µg/kg. 
 
2c: Exposure assessment: fish medicines. 
The scale of fish cultivation for commercial purposes is limited in the Netherlands 
(Kamstra and Van der Heul, 1995). In 1994 in total 26 and 10 companies were involved in 
cultivating eel and catfish, respectively. Most nurseries use water recirculation systems, in 
which the water is recycled after a water treatment by filtration. Catfish nurseries discharge 
on the municipal Sewage Treatment Plants (STP), but 40% of the eel nurseries discharge 
directly on surface water. The exposure scenarios presented here are based on a fish farm that 
breeds 50 tonnes of eel a year, the median production in The Netherlands. Two scenarios are 
distinguished, based on the incidence of administration of the product, and the type of 
wastewater treatment: 
- continuous medication; without recirculation/filtration, followed by a settlement tank; 
- occasional medication (≤4 times a year), without recirculation/filtration before discharge 
on the settlement tank. 
On a yearly basis the nursery discharges 250 m3 water per tonne of fish, resulting in a 
turnover rate of 35 m3.d-1. It is assumed the total water volume of the nursery is 70 m3. After 
the settlement tank the water fraction is either dicharged on surface water or into the STP. 
This STP module is not described here and the reader is referred to (Struijs et al., 1991; 







Table 11. Pick list for the default settings of the fraction of retention in sludge, treatment time and volume 
of wastewater from fish nurseries. 
type of treatment type of water treatment before STP Fret  [-] 
 
Vwaste water [l] DILUTIONfish [-] 
continuous filtration and settlement tank 0.75 35000 5 
occasional settlement tank 0.5 70000 3 
 
 
Due to the settlement tank the total amount of substance emitted is equally spread out 
over 25 days. The surface water concentration in case of continuous treatment is therefore 
constant.  
The fish farm and the STP discharge on a small waterway that dilutes the effluent by a 
factor 5 or 3, depending on the water volume discharged. The recirculation/filtration system 
and the settlement tank both have an estimated removal efficiency of 50% of the dose of 
organic substances from the water (table 11). 
The use of several medicinal products in fish nurseries is listed in table 12 (Kamstra 
and Van der Heul, 1995). 
 
Model for the calculation of the emission to surface water. 
 




















input   
Qproduct dosage product used [kg.l
-1] 
Cc concentration chemical in product [mgc.kg
-1] 
Vwaste water volume of waste water discharged [l] 
Fret fraction of retention in sludge [-] 
Temissionstp emission period for discharge to STP [d] 
intermediate results  
Qemitted amount of substance emitted [mgc.d
-1] 
Elocalwater emission to waste water during episode [mgc.d
-1] 
output   







Table 12. Summary of medicinal products used in fish nurseries and PIECsw calculated without STP. 
Substance max. conc. 





mebendazole 5 0.010 0.067 
oxytetracycline 75 0.15 1.005 
malachite green 0.3 0.0006 0.004 
flumequine 11 0.022 0.147 
 
It is interesting to see what the effect of the STP module would have on the 
concentrations in surface water (table 13). The Elocalwater is the input for the STP module.  A 
logKow is needed to calculate the partition between water and sludge. Using the structure-
activity calculation method of Mackay et al. (1980) a logKow of 0.02 is calculated for 
oxytetracycline, a value that is consistent with the weak adsorption found for this substance 
in soil (Soulides et al., 1962; Roij and De Vries, 1980). The effect of the degradability of a 
substance is also modelled in table 13. 
 
In this example sorption to sludge removed only 0.01% of the daily load. Differences 
in the results between the scenarios ‘no STP’and ‘STP without degradation’ are a result of 
different water volumes before (input from fish nursery) and after the model STP. Reliable 
data on sorption to sludge (or removal rates) can lower the PIECsw further. 
 
2d: Exposure assessment: trigger values. 
Decisions for further assessment are made by comparison of predicted exposure 
concentrations to trigger values. Some remarks can be made concerning these triggers given 
in the EMEA (1997) document. The exposure trigger level for further testing when the 
environment is exposed by dung from grazing animals is 10 µg/kgwwt. This trigger will have 
no practical consequences for the pharmaceutical industry. Even substances with relative low 
dosages (like ivermectine) will exceed this trigger 100 times. It is even more remarkable that 
ivermectin at concentrations of 0.5 µg/kgwwt still induces abberrations in wings of the dung 
fly Scatophaga stercoraria (Strong and James, 1992). In this case the trigger is not even 
protective enough.  
 
Table 13. Predicted concentrations in surface water of oxytetracycline with and without STP. 
oxytetracycline concentration 






with STP, no 
degradation 
PIECsw (mg/l) 




75 0.15 0.07 0.003 
occasional 
treatment 
75 1.00 0.49 0.017 




The duration of exposure is not taken into account in Phase I. It was found that larvae 
of the dung fly Neomyia cornicia did not develop in dung from cattle collected up to 32 days 
after injection with ivermectin (Wardhaugh and Rodriguez-Menendez, 1988), whereas after 
oral treatment all ivermectin residues are excreted after one week (see table 4). The Phase II 
assessment will eventually have to answer to the question whether field populations of insects 
will be reduced due to the use of the medicine. In view of this population-dynamic approach 
in Phase II (e.g. field testing), the Phase I assessment should at least take the expected 
distribution in space and time into account. 
The exposure trigger for the concentration in slurry (housed animals) is 100 µg/kgwwt, 
and for the concentration in soil 10 µg/kgdwt. Without going into calculations here, it is stated 
that these two triggers are independent of each other. As demonstrated in previous 
paragraphs, the triggers for the DT50 in manure and the PIEC in soil are irreconcilable. For 
instance, a DT50 does not take the amount of substance into account. A rapid degradation 
may still result in high concentrations. The value for the DT50 in manure (30 days) is not 
recognisably related to manure storage times, and further investigations into this storage 
practice, in relation to manuring regimes, and into manure degradation studies are desirable. 
Attention should be paid to conditions concerning pH, redox potential, moisture content and 
the temperature in manure storage facilities. 
Environmental exposures of fish medicines will always lead to a Phase II assessment 
as there are no trigger values. The lack of a trigger for surface water (and sediment) is not 
consistent with the fact that there are triggers for soil and dung. However, is there a 
reasonable trigger value for the aquatic ecosystem? Because various existing chemicals are 
known to cause harmful effects at low concentrations, the trigger value would equal zero, i.e. 
only no exposure of surface water is acceptable. For example, tributyltin compounds cause 
imposex in gastropods at 1 ng/l in the sea along major ship routes (Bryan et al., 1986) and the 
EC50 of ivermectin for daphnids is 25 ng/l (Halley et al., 1989). Besides this in many 
countries fish are cultivated in open water (e.g. salmonids) and medicines are administered 
directly to the water in therapeutic, thus effective concentrations. As a consequence, there can 
be no safe trigger value for exposure to fish medicines. 
One model not discussed here is the calculation of the concentration in groundwater. 
The trigger for a Phase II assessment is 0.1 µg/l. The EMEA document refers to a certain 
partition model that calculates the concentration in soil porewater (ECB, 1996). Degradation, 
climate data and hydrological information are not taken into account. The parameters that 
influence the result are therefore the concentration in soil and the sorption coefficient of the 
substance. Suppose the concentration in soil is just below the soil trigger of 10 µg/kgdwt, the 
sorption coefficient (Koc) has to be >5600 l/kg not to exceed the ground water trigger of 0.1 
µg/l. This high sorption coefficient does not apply for hydrophylic substances like most 
antibiotics. Therefore, unless the DT50 in slurry is <30 days, every antibiotic is bound to 








Given the fact that at the stage of the exposure assessment already decisions are made 
on the acceptability of the environmental risk of a product, regulatory authorities have to be 
careful in choosing exposure scenarios. A simple worst-case exposure approach might satisfy 
the safety demands with respect to the environment, but the implications with respect to the 
benefits of a product do not allow a too rigid cut-off procedure. The exposure and distribution 
models should lead to practical risk management. 
Four models were presented for three routes of emission and distribution of veterinary 
medicinal products that reflect realistic agricultural practice in the Netherlands. It was shown 
that simple general models, considering common agricultural practice and useful substance 
properties can change predicted exposure concentrations by a factor 2 - 40. It is not an 
imaginary situation that the registration of a product is hampered by the choice of a too 
restricted exposure model, or serious environmental risks are overlooked. It is obvious that 
arbitrarily chosen values concerning the percentage of the herd treated, and misinterpretations 
of phosphate immission standards or phosphate contents of slurry, will lead to further 
differences in outcomes of calculations. A clear presentation of parameter values for every 
country of the EU is needed.  
With the models presented here the PEC in grassland after manuring the land will 
always be higher than in arable land. It might therefore be worthwhile to limit the phase I 
calculation to grassland only. A reason to maintain this distinction is that EMEA has required 
studies on plants for arable land risk assessment (to protect crop production), and not for 
grassland risk assessment. There might also be reasons why slurry will be disposed on one 
type of land only.  
The results shown in tables 12 and 13 indicate that substantial concentrations of fish 
medicine (up to 1 mg/l) might be present in surface water bodies near discharge points of fish 
nurseries for a period of time after treatment (25 days). STP treatment should be able to 
reduce these concentrations; for example steroids were found to be eliminated for 58-91 % in 
sewage treatment (Stumpf et al., 1996). Depending on the degradation rate in the STP, the 
calculated concentration in surface water can differ up to 29 times. Even with these 
elimination factors, the environmental burden of fish water treatment will be considerable. 
Monitoring of surface water for antibiotics and anthelminthics used in fish nurseries is 
needed to validate this assessment module. 
Because of the diversity in trigger values, and the absence of any logic in their 
appearance in the decision scheme, they rather contribute to the uncertainty of the exposure 
assessment, than to a margin of safety. However, the current values were agreed upon in the 
European working group and are at the moment one of few broadly accepted management 
tools in the EU. Furthermore, the possibility to overrule the trigger value and continue the 
assessment is left open. 
The compartments that are exposed determine what effects should be assessed. Effect 
values are the product of harmonised and validated experimental procedures based on 




note for guidance has identified several endpoints (species and functions) and triggers that are 
well known from pesticide and new chemicals assessment. Effect parameters used are NOEC, 
LC50, EC50, MIC, %effect, and PNEC. The RCRs are compared to trigger values of 0.01, 
0.1, and 1. This means that decisions are based on no-effect situations (PNEC, NOEC) or on 
maximum effect situations (MIC: the minimum concentration that inhibits growth 
completely), and RCR are compared to numerous triggers, clearly incorporating assessment 
factors. A clear approach, using only PNEC values and one trigger value (1) is more 
appropriate. Amongst others, this approach leaves the opportunity to the notifier to provide 
data on more species in order to refine the PNEC.  
 
There can be great differences in agricultural practice and environmental conditions 
from one country to another, while at the same time on the European scale there is a need for 
harmonised exposure models and realistic trigger values. An interdisciplinary approach using 
knowledge of veterinary and agricultural practice, risk management, and environmental 
toxicology and chemistry, is needed to discriminate between relevant exposure scenarios and 
far-fetched worst-case calculations. These dilemmas call for an ongoing harmonisation 
process, preferably guided by a European technical guidance document on the environmental 
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4. Validation of the exposure assessment for veterinary medicinal 
products 
 





The marketing of veterinary medicinal products is actively regulated in the European 
Union by Directive 2001/82/EC, amended by Directive 2004/28/EC, in order to protect the 
environment, next to animal health, consumers, and professional users. An environmental 
risk assessment is to be performed at registration, and there is a clear policy and regulatory 
infrastructure to deal with this issue, as well as a number of regulatory guidance documents 
on the environmental risk assessment (EMEA, 1997; VICH, 2000; DG Enterprise, 2000; 
VICH, 2003).  
Given the nature of risk assessment for new applications, there is a need to model 
exposure concentrations and associated risks. Addiscot et al. (1995) stated that some form of 
critical evaluation procedure is essential both to maintain the integrity of modelling and to 
ensure that the use of models by regulators does not result in the propagation of misleading 
information. The validation of screening models contributes to a better understanding of the 
information generated in the risk assessment and thus to the quality of the decision making 
process (Addiscot and Wagenet, 1985; Addiscot et al., 1995; Dee, 1995). Validation is used 
here in the meaning of establishing whether the model is ‘well founded and applicable’.  
The first objective of this paper is to validate existing screening level exposure models 
for the risk assessment of veterinary medicines spread in manure, that have been presented 
previously in this journal by Montforts et al. (1999).  
A second objective is to develop scenarios for the risk assessment under different 
European conditions, incorporating information on realistic agricultural and veterinarian 
practice, land use, geomorphology, and climate. The objective of the scenarios is to make the 
models applicable for European registration procedures for veterinary medicines. 
A third objective is the verification of the 50% removal factor, the dilution factor and 
the emission pattern, assumed for the exposure assessment of the use of medicines in fish 
nurseries, by Montforts et al. (1999).  
 
 4.2 Screening model validation 
 
Screening level models do not intend to represent reality accurately, but to provide 
rapid predictions of the potential environmental fate of a compound (Tarazona et al., 2003). 
To validate this claim, the available screening models were compared to field data published 




Haller et al., 2002; Hamscher et al., 2002; Boxall et al., 2002; De Liguoro et al., 2003; Aga et 
al., 2003; Schlüsener et al., 2003).  
 
4.2.1 Empirical validation of the soil exposure models 
Soil exposure screening models for veterinary medicines have been proposed and 
discussed in literature (Spaepen et al., 1997; Boxall et al., 1997; Jorgensen et al., 1998; 
Montforts et al., 1999; WRc-NSF, 2001; Kelly et al., 2003). The deterministic and functional 
modelling of local exposure concentrations was also applied for other environmental 
contaminants such as heavy metals, pathogens and biocides (Breimer and Smilde, 1986; 
Montfoort et al., 1996; Walker and Stedinger, 1999; Van der Poel and Bakker, 2002). The 
modelling of regional distributions as applied for nutrients or pathogens in manure, was 
generally not used for registration of chemicals (Walker, 1997; Walker et al., 1998a; Walker 
and Stedinger, 1999; Vega et al., 2001; Menzi et al., 2002). The exception to the rule was the 
VetPec model used in the UK for veterinary medicines (WRc-NSF, 2001). 
The soil exposure models at the screening level describe the concentration of the 
excreted residue in the slurry, and the concentration of the residue in soil after application of 
the slurry. The elementary deterministic soil concentration model used for veterinary 
medicines is described by: 
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with the following explanation of symbols (Table 4-1). 
Empirical data on slurry concentrations and soil concentrations obtained in controlled 
studies are most useful for the empirical validation of this model. The data for the veterinary 
antibiotic sulfachloropyridazine (SCP) obtained in a field experiment in the United Kingdom 
are used to verify the soil concentration function (Boxall et al., 2002). This field experiment 
was performed with spiked manure spread over a sand soil and a clay soil, and all terms in 
the model were controlled. The sand soil was amended with slurry containing SCP at a 
concentration that would result in a nominal concentration in our standard models of 440 
µg/kg. Corrected for the actual soil bulk density of the sand soil the nominal soil 
concentration amounts to 393 µg/kg dw. The initial measured concentrations (averaged over 





Table 4-1 Explanation of symbols for the soil concentration model. 
input   
Qproduct dosage product used [kg.kgbw
-1.d-1] 
Cc concentration chemical (c) in product [mgc.kg
-1] 
Ttreatment duration of treatment [d] 
manimal (averaged) body weight [kgbw.animal
-1] 
Fexcreted fraction excreted in faeces and urine [-] 
Ncyclusanimal number of cycli per year [animal.place
-1.yr-1] 
Pslurry slurry production animal in stable in one year [kg.place
-1.y-1] 
Tstorage duration of storage  [d] 
kdegslurry reaction constant transformation in slurry [d
-1] 
Qslurry slurry immission standard [kg. ha-1.yr-1] 
soil bulk density of soil [kg.m
-3] 
DEPTHfield mixing depth with soil [m] 
CONVarea field conversion factor for the area of the agricultural field [m
2.ha-1] 
intermediate results  
Qexcreted amount  substance excreted [mgc.place
-1.yr-1] 
Cslurry concentration in slurry [mgc.kg
-1] 
output   




predictions. Thus the model performed satisfactorily as a screening tool. The clay soil was 
amended with slurry containing SCP at a concentration that would result in a concentration,  
corrected for the actual soil bulk density, of 500 µg/kg dw. The range of SCP concentrations 
(averaged over 20 cm depth) was between the limit of detection and 120 µg/kg.  
Assuming a normal distribution for these measurements, regression analysis indicated 
that 90 percent of the distribution of soil concentrations would be within a range of 8 - 145 
µg/kg dw soil. The modelled concentration of 500 µg/kg corresponds to the 0.11 percentile of 
the distribution. The probability of a concentration taking a value of 500 µg/kg or greater is 
only 0.11%, which makes it very unlikely that the theoretical concentration actually had been 
present anywhere in the field. Spatial heterogeneity may have accounted partly for these 
deviations (Vischetti et al., 1997). Thus the screening model did not predict the measured 
field concentrations in clay very well, or alternatively, about 90% of the SCP was lost 
between spiking of manure and analysis of clay soil samples.  
Another paper contained empirical data on both soil and slurry concentrations of a 
veterinary medicine. Soil concentrations of 15 µg sulfadimidine per kg soil were found in 
Eastern Westphalia (Germany) in January 2002, in soil where 7 months earlier pig slurry had 
been applied (Christian et al., 2003). Pig slurry from the same location as used on the soil, 
although sampled some four months after this soil amendment, contained sulfadimidine at a 
concentration of 1.1 mg/kg ww. Assuming incorporation to 30 cm in a soil with a dry bulk 
density of 1740 kg.m-3, the authors argued that the soil concentration was explained by the 
slurry concentration. However, since it concerns different batches of slurry, this 




The UK field study cited above was only concerned with the soil compartment, not 
with the slurry compartment. Using the data reported by Hamscher et al (2000; 2002) on 
tetracyclines (tetracyclin (TC), chlortetracyclin (CTC), oxytetracyclin (OTC)), a comparison 
was made between model calculations for one animal type (sows) and one dosage, and 
measurements in both slurry and soil. Two screening models were used: the Spaepen model 
(Spaepen et al., 1997) and the RIVM model (Montforts, 1999). In the model calculations, per 
place only one sow per year was supposed to be present, dosed with tetracyclines at 40 mg/kg 
bw for 5 days. The excretion factor was set to 1. DT50 for tetracyclines as a group may vary 
between 4 and 175 days, without correction for matrix, aeration or temperature (Jagnow, 
1977; Kühne et al., 2000). (Soulides et al., 1962; Vej-Hansen et al., 1978; Gavalchin and 
Katz, 1994; Ingerslev et al., 2001; Winckler and Grafe, 2001a; Lumaret and Errouissi, 2002). 
In the calculations the degradation was assumed negligible. With the Spaepen model, soil 
concentrations of 75 µg/kg dw were expected. See Figure 4-1. The model calculations 
presented by Spaepen et al. (1997) were underestimating both the mean initial and maximum 
concentrations for tetracyclines (TC, OTC, and CTC). In the RIVM model the upper limit for 
the predicted soil concentrations was 207 µg/kg dw. Measurements reported were below or 
just above the RIVM prediction. The RIVM model provided for the more protective results, 
thus performing better as a screening tool.  
The authors noted however that the measured soil concentrations were a factor 2-4 
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Figure 4-1 Graphical presentation of mean and maximum measurements of oxytetracycline (OTC) in soil 
in Germany (1999-2001). Straight line: initial PEC according to Montforts (1999) ; dotted line: initial 





considered that this difference indicated the presence of residues in the soil, additional release 
of bound residues between the sampling in the years 2000 and 2001, or higher application 
volumes than stated (Hamscher et al., 2002). Alternatively, due to incomplete mixing of the 
slurry matrix before the slurry sample is taken, strongly sorbed substances may have 
concentrated in the solid fraction in deeper layers. Measured concentrations in the liquid 
fraction may hence have lead to underestimation of the total substance load present. The 
RIVM model predicted a maximum concentration of 52 mg/L in slurry at a dosage of 40 
mg/kg for 5 days (fattening pigs), which resulted in the predicted 207 µg/kg in soil.  
Winckler and Grafe (2001c) found in German pig breeding facilities mean 
tetracycline concentrations of 11.6 mg/L and a maximum concentration of 66 mg/L in slurry. 
Compared to these data, the measured concentration in the ‘controlled’ slurry samples of only 
4 mg/L reported in (Hamscher et al., 2002) was indeed rather low.  
The soil sub-routine in the RIVM model tends to be conservative in predicted 
exposure levels, which satisfies the need to err on the safe side in the screening phase. In 
particular the prediction of the slurry concentration is challenged by uncertainties concerning 
dilution, mixing, and dissipation of residues. 
 
4.2.2 Functional validation for surface water 
Three screening level models were available for surface water. The EMEA and RIVM 
model contained a transport subroutine (soil-to-water transport rate) and a catchment 
subroutine (distribution and concentration in surface water) (EMEA, 1997; Montforts, 1999). 
The models were conceived around one algorithm (an export coefficient depending on 
sorption properties and a static water volume). The RIVM model assumes a dilution factor of 
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The EMEA model assumes a dilution factor of 3.3 and describes the partitioning 











Table 4-2 Explanation of symbols for the surface water exposure functions. 
input   
DILUTIONleaching dilution factor for leaching [-] 
PECsoil concentration in the soil [mgc.kgsoil
-1] 
soil fresh bulk density of soil [kg.m
-3] 
solid density of soil solids [kg.m
-3] 
Fairsoil fraction air in soil [m
3.m-3] 
Fwatersoil fraction water in soil [m
3.m-3] 
Fsolidsoil fraction solids in soil [m
3.m-3] 
Focsoil fraction organic carbon in soil (w/dw) [kg.kg
-1] 
Koc partition coefficient organic carbon - water [dm3.kg-1] 
intermediate results   
Ksoil-water partition coefficient solids and water in soil (v/v) [m
3.m-3] 
Kpsoil partition coefficient solids and water in soil (v/w) [dm
3.kg-1] 
PECporewater predicted concentration in pore water [mgc.l
-1] 
output   
PECswleaching  predicted concentration in surface water [mgc.l
-1] 
 
In this methodology, the concentration in surface water depends on the concentration 
in soil as a result of spreading of slurry. The degree of surface water contamination in these 
lower level exposure models is not related to the actual transport processes (erosion, run-off, 
and drainage), the ratio between treated soil and receiving surface water, nor to the distance 
to the surface water. The screening models consider that the soil to water transfer is linked 
exclusively to the soil pore water concentration, which is estimated from equilibrium 
processes based on the Koc or related parameters, followed by a dilution factor between soil 
porewater and surface water. The distance to the surface water is not modelled. 
The VetPec model is more complex, consisting of a run-off model and an aquifer 
model that accompany the soil concentration model (WRc-NSF, 2001). Distribution of 
chemicals between porewater and solids are calculated using fugacity equations. The aquifer 
and catchment sub-models are capacity models consisting of cells with a limited number of 
variations in parameter properties, parameterised on English aquifers and river water 
catchments. Every time step, substance degradation, inflow and outflow are calculated, after 
which a new equilibrium is obtained (MacKay et al., 1986). The surface water predictions by 
VetPec have been validated with a selection of data on the pesticide isoproturon. The 
hydrology in the models was however not validated. No validation on less mobile compounds 
has been performed. 
These models were subjected to an empirical validation using data from a field 
experiment with the veterinary antibiotic SCP performed in the United Kingdom (Boxall et 
al., 2002). In the sand soil, soil porewater concentrations of SCP had been measured, and in 




compartments was however not assessed. The validation of the fugacity models in VetPec 
was hampered by this approach, since the transfer rates were to be validated and not the 
equilibrium concentrations. This validation exercise generated highly variable and 
unsatisfying results, as shown in Table 4-3. These model approaches did not perform 
satisfactorily as a screening tool.  
Few data on surface water contamination by medicines and hormones via land are 
found in literature. A selection is briefly discussed below to add further considerations to the 
validity of screening level exposure models. 
Ivermectin has a very high sorption coefficient Kom of 4500-5500 L/kg, and is rather 
persistent in soil with degradation half-lives (determined at 22°C under laboratory conditions) 
of 93 to 240 days (mean 187 days, n=4) (Halley et al., 1989). Transport of ivermectin by 
drainage would be considered negligible, since this route is not assessed in the EMEA model 
at Kom >500 L/kg. In a study on run-off from cattle feedlots in the United States, only trace 
amounts (up to 2 ng/L) of ivermectin were indeed detected occasionally (Nessel et al., 1989).  
Oxytetracycline shows strong adsorption behaviour in soils with logKoc of 4 - 5 
(Rabølle and Spliid, 2000). In an Italian study, no oxytetracycline was detected in drainage 
ditches adjacent to treated fields (LOD 1 µg/L) (De Liguoro et al., 2003), which is consistent 
with the EMEA model trigger that surface water is not exposed if Koc is >500 L/kg (EMEA, 
1997). In an US investigation, 31% of the water samples proximal to swine farms and 67% of 
the samples proximal to poultry farms were found to contain antimicrobial compounds used 
in these farms: chlor-, oxy- and tetracycline, sarafloxacin, lincomycin, and sulfadimethoxine, 
generally at levels <4 µg/L (Campagnolo et al., 2002). In an UK field study, mass losses from 
soil into drainage water accounted for not more than 0.5% of the dose applied to the soil. 
Peak concentrations of oxytetracycline were 36 µg/L. For sulfachloropyridazine, the peak 
concentration was 613 µg/L (Kay et al., 2004). Of sarafloxacin and related fluoroquinolones 
the logKoc is reported to be 5 – 6 (AHI, 1997; Nowara et al., 1997). However, the 
concentrations of tetracyclines and sarafloxacin found occasionally (1-36 µg/L and 4 µg/L, 
respectively) do not support the above-mentioned EMEA model trigger. These scarce data 
cast further doubt on the applicability of the surface water exposure models for screening 
purposes.  
 
Table 4-3 A summary of model calculations for surface water and peak drain flows in the UK field 
experiment with SCP (Boxall et al., 2002). All results are in [µg/L]. nc = not calculated. 
Peak flow from 
drainpipe (clay) or soil 
pore water (sand) 
























Year 1 Year 2 
Sand  393 0.84 0.01 370 112 37 0 0 





Veterinary pharmaceuticals are released into the soil as part of an organic matter rich 
matrix, and it is well known that organic amendments including manure can increase but also 
decrease the adsorption of chemicals to soil (Iglesias-Jimenez et al., 1997; Morillo et al., 
2002). In addition, the direct transfers of the non-dissolved chemical fraction should be 
considered. The transfer of particle-bound fractions is particularly important for run-off, 
while colloidal associations should be considered for drainage since the fraction bound to 
small particles could also be relevant for preferential flow via macropores. For example the 
sorption of oestradiol-17β is associated with the surface area and/or the cation exchange 
capacity of the soil, with high correlation to particle size (clay) and organic matter. KF values 
were in the range of 86 – 6670 L/kg, with Kom values of 1800-72500 L/kg (median 2600 
L/kg) (Casey et al., 2003). In soil column leaching studies performed with oestradiol-17β Kom 
values ranging from 950 to 1700 L/kg were determined. The strong sorption did not appear to 
hinder degradation; degradation half-life values of 0.4-10 days were determined (Das et al., 
2004). Nevertheless, from experimental plots treated with horse stall bedding or poultry litter, 
20% and 30%, respectively, of the added amount of oestradiol-17β was transported in run-off 
directly following a simulated storm. In the poultry litter experiment, the total loss in a 
second simulated storm event seven days later was 69% of the first loss, which is in 
proportion with the load remaining after the first event (Nichols et al., 1997; Busheé et al., 
1998).  
 The screening level models tend to be conservative in predicting exposure levels, 
which satisfies the need to err on the safe side in the screening phase. However, the trigger 
value for surface water exposure clearly obscures the possibility of transport of strongly 
sorbing substances.  
 
4.2.3 Functional validation for groundwater 
With respect to groundwater, in Phase I of the EMEA Note for Guidance the 
concentration in the ground water is set equal to the concentration in the porewater (EMEA, 
1997). The EMEA scheme suggests that the PECsoil as calculated for the upper layer is the 
input term for the calculation. Conceptually, in this model the groundwater table reaches to 
the mixing depth defined by the soil concentration module, or it supposes complete vertical 
transposition of the residue to the depth of the groundwater table.  In this model partitioning 
depends on equilibrium sorption to solids, no saturation at binding places, and steady-state 
conditions. Movements, dilution, desorption, and transformation is not modelled. As 
explained in the previous section, in VetPec the distribution of chemicals between porewater 
and solids are calculated using fugacity functions.  
In Table 4-3 a comparison is made between the predictions and the porewater 
measurements of SCP in the UK field experiment (Boxall et al., 2002). Again, these model 
approaches did not perform satisfactorily as a screening tool. 
The accuracy of the partitioning model predictions depended strongly on the soil layer 
to which the measurements were standardised. If a 5 cm layer was chosen instead of the 




calculations have overestimated the actual porewater concentrations. The maximum 
drainflow concentration from the clay field in the first year (Table 4-3) corresponded 
reasonably with the EMEA porewater calculation. The field measurements are clearly the 
result of preferential flow of both solutes and manure-associated particles through soil cracks 
following a massive rain event. The second year the soil had been tiled and disked, thus 
cutting off the cracks that lead to the drainpipes, resulting in lower concentrations. 
 
4.3 Scenario parameters 
 
The exposure modelling can be split in three major subroutines: one for the animal 
husbandry phase, one for the slurry handling, and one for the environmental phase. The 
situation of interest that is to be modelled defines the model approach (mechanistic, 
deterministic) and the respective parameter values. A specific combination of parameter 
values is denoted a scenario. The following variables and scenario parameters need to be 
observed in the scario and have to be addressed, either as a parameter or as default: 
1) Emission 
a) disease incidence and remediation: occurrence of infections throughout the year(s) 
b) dose administered  
c) duration of treatment 
d) excretion of residues by animals 
2) Storage 
a) slurry production 
b) storage time 
c) storage conditions 
d) slurry removal: timing and amount 
e) slurry texture 
3) Substance behaviour in slurry 
a) degradation in slurry 
b) distribution in slurry layers or fractions (solid-liquid) 
4) Immission into soil 
a) dosage applied 
b) repetitions 
c) soil management 
5) Substance behaviour in soil and water 
a) degradation in soil 
b) distributions in soil (spatial heterogeneity) 








Given the quantity of variables, it is virtually impossible to control all variables and examine 
one parameter at the time in an experimental setting. Below key parameters are discussed. 
 
Emission. Disease incidence and dosage are static parameters, since in the risk assessment at 
registration the modelling is performed using a given prescribed dose to a target animal. 
Several target animals have more production cycles in one year, which may all need 
treatment. Depending on the relation between animal cycles and manure storage in the model, 
a certain number of cycles should be observed in the emission module. Excretion of residues 
is also an input-parameter in the model. Excretion patterns and cumulative excretion may 
differ depending on species, race, mode of application and dosage. Data reported in literature 
suggest that total cumulative excretion may range from 0.2 to 1, and the excretion time from 
1 and 100 days, depending on species, substance, dosage, and route of administration (Short 
et al., 1987; Halley et al., 1989; Lumaret et al., 1993; Herd, 1995; Ramazza et al., 1996; 
Strong et al., 1996; Winckler and Grafe, 2001c). Although the parent compound may be 
transformed into transformation products, the conjugates may be reverted in the slurry to 
active compounds (Henschel et al., 1997; Panter et al., 1999) and others may have some 
activity themselves (Schowanek and Webb, 2002). Excretion of metabolites may hence 
contribute to the effects of the parent compound.  
 
Storage. The input, storage and outflow of contaminated and uncontaminated slurry 
determine the loads that will reach the soil. Different animal types may contribute to the same 
slurry storage system and the treated animals do not exclusively determine final 
concentrations. Slurry production and quality is monitored more or less intensively in EU 
countries due to the restrictions in the use of fertilisers. The figures in the publications are not 
always comparable, as they may refer to some (adult) individuals or to the total husbandry 
system (including young) and are not always identical (due to differences in feed, race and 
housing conditions). Body weights at treatment are proposed based on adult weights for 
parent animals and the mean of slaughter weight and starting weight for production animals. 
Depending on the physical state of the manure, the manure is kept in bedding, piled, or stored 
in tanks or lagoons. Proportions of manure types and storage systems differ considerably 
between countries (Menzi, 2002). Depending on structure and handling, the manure can be 
aerobic or anaerobic and there will be a great variation in temperature, redox potential, pH, 
and storage time of the slurry.  Different manure types and storage systems will influence 
storage conditions and manure composition in different ways (Donham et al., 1988). 
Conditions like oxygen levels, manure age, microbial activity and temperature will determine 
the fate of organic contaminants to a large extent, but are highly diverse within and between 
storage systems (Hoeksma et al., 1987; Novem, 1991; Jenkins et al., 1997; Richard et al., 
1998; Pitts et al., 1998; Qiang, 1999; Arogo et al., 1999; Schiffer et al., 2001; Moreira, 2001). 
Depending on climate, season, storage systems and manure structure, temperatures can range 
from ambient (freezing) to 65°C (composting) (Kelley et al., 1994; Eghball, 1998). For 
underground slurry storage systems this range can be narrowed down, because average soil 




(piles, containers) temperatures can be quite higher and varying due to composting processes 
(until anaerobicity is reached).  
Manure models that describe manure loading, quality change, and fate of constituents 
(i.e. CO2, NH3) do exist, and could be adapted, but also have to be improved amongst others 
on insufficiently developed manure production submodels and the limitation to liquid manure 
facilities (Ni, 1999; Ni et al., 1999; Hilhorst and De Mol, 2002). The most realistic period in 
which storage can take place cannot be determined with a rule of thumb. Storage time is a 
function of manure output and substance and manure input. Since these functions largely 
depend on the (unknown and individual) substance prescriptions, disease patterns, and 
manure management, either a complete manure model with detailed inputs is needed, or a 
scenario for every livestock category of interest has to be defined. In the latter option, dosing, 
excretion and manure handling are made part of the scenario rather than of the model 
algorithms. Given the sheer endless variability described above, the slurry storage, 
production, and removal, should be defined in scenarios for screening level models. 
 
Soil immision patterns. Agricultural practices will play a very important role in determining 
the concentrations of veterinary drugs in the environment. Livestock manure is the second 
most important source of nutrient inputs to agricultural land (Pau Vall and Vidal, 2001). The 
pattern of agriculture and manure use can vary widely from one region to another. The 
nutrient content of manure varies from country to country and from one region to another 
within a country (Provolo and Riva, 2002). The relative contribution of the animal types to 
the manure-N input to soil per EU country is depicted in Figure 4-1. These data indicate that 
bovine and pig manure are the main slurry types used to fertilise land (if organic fertilisers 
are used). However, sheep and poultry manure are regionally and locally important. We 
propose to use the lower nitrogen production standards presented to the European Resource 
Management of the European Commission DG XI (Ketelaars and Van der Meer, 2000) 
(Table 4). Storage systems differ between countries and animal types. The frequency at 
which slurry is taken out of the storage facilities can have a different timing. For example, for 
cattle and pig slurry, seven respectively three moments are considered by (Tijmensen et al., 
2002). Another source reports average slurry storage times of 9 months (range 0 – 50 months; 
see table 5), but it is not specified to what animals the data apply (WRc-NSF, 2000). 
Spreading events are monitored at regional levels (ADAS, 1998; Berende, 1998; Van 
Staalduinen et al., 2001). In the Netherlands and in Belgium, over 95% of the agricultural 
(arable) land is manured one to three times per year. The manure produced by livestock will 
be applied to land, the amount applied being dependent on immission limits for nitrogen and 
phosphorus, fertiliser recommendations, soil type or crop tolerance for slurry. These limits 
which are designed to avoid the excessive input of nutrients in soils vary across member 
states. For example in Italy, at national level, the maximum amount of manure which can be 
applied to land that is not designated as a vulnerable area is the annual production from 4 






Table 4-4 Standardised nitrogen production standards (PN), rounds (Nanimal), and treatment body weights 
(manimal), for different livestock categories (Ketelaars and Van der Meer, 2000). 
Livestock PN 
[kg N/place/year] 
Nanimal manimal  
(number of young per year) 
Cattle    
Dairy cows 60  425 kg per adult, 25 kg per calf  
(0.6 calves per place per year) 
Other cows 44  425 kg per adult, 25 kg per calf  
(0.6 calves per place per year) 
Veal# 10 1.8 140 kg 
0-1 year 18  200 kg 
1-2 year 31  400 kg 
>2 year 35  450 kg 
Pigs    
Sows with piglets till 25 kg 32  240 kg per adult; 9 kg per piglet  
(20 piglets per place) 
Slaughter pigs 25-105 kg 7.5 3 65 kg 
Poultry    
Laying Hens 0.35  1.6 kg 
Broilers, 1.8 kg 0.23 9 1 kg 
Ducks, 3.3 kg 0.41 7 1.6 kg 
Turkeys, 13 kg 0.90 2.7 6.5 kg 
Sheep    
Ewes with lambs till 40 kg 13  75 kg per adult; 20 kg per lamb 
(1.6 lambs per place) 
Goat     
Females with kids till 7 kg 13  65 adult; 3.5 kg per kid  
(1.8 kids per place) 
Rabbit    
Females with kittens 3.9 6.75 
births 
2 kg per adult; 1 kg per kitten  
(50 kittens per place) 
Equines    
Horses 35  400 kg 
# veal data based on (Van Staalduinen et al., 2001) and (Montforts, 1999) 
 
the data in Table 4, the annual load may range up from 275 kg N/ha for turkeys to 550 kg 
N/ha for dairy cows. The exact amount that is allowed will depend on the way the production 
per hectare is quantified over the year, and the nitrogen content of the manure produced. 
The amount of slurry that is actually applied (in one time) will depend on many other 
practical factors. A different situation is found in the Netherlands, that designated its entire 
territory as a vulnerable area under the EU Nitrate Directive (91/676/EC). This directive 
applies to areas that are vulnerable to leaching of nitrate in all member states and the nitrogen 
immission standard of 170 kg N/ha can be considered as a realistic best case for these areas.  
Incorporation depths have been recorded in an inventory by WRc-NSF (WRc-NSF, 
2000) (see Table 4-5). Plough depths for slurry and solid manure were in the range of 0-28 





Table 4-5 Amounts of slurry stored and applied, time of application and length of storage (WRc-NSF, 
2000). 
 % applied quantity stored storage time application rate plough depth nitrogen content  
Slurry  gallon months kg/ha/y cm kg N/m3 
Average 100 1042571 9.1 21213 16.5 2.69 
Min 100 0 0 80 0 0.99 
max 100 5000000 50 100000 28 7 
Manure  tonne    tonne 
Average 98.4 2359 8.06 12637 16.5 2.11 
Min 25 0 0 3 0 2.11 
Max 100 110000 48 55000 28 2.11 
 
 
Environmental conditions. Climate and soils are important factors in the determination of 
chemical concentrations in the environment. In 1993, the European Commission and the 
European Crop Protection Association jointly established FOCUS (Forum for the Co-
ordination of pesticide fate models and their USe) which, as one of its tasks, established 
standard leaching and surface water exposure scenarios for pesticide registration in Europe. 
The simple fact that this methodology encompasses the same agricultural fields that are 
relevant for manure application, predestined these scenarios to be applicable to residues 
spread by manure as well.  
 
4.4 Scenario development for spreading of manure 
 
Since at the screening stage of the exposure assessment already decisions are made on 
the acceptability of the environmental risk, regulatory authorities have to be careful in 
choosing exposure scenarios (Montforts et al., 1999). The emission route from slurry to soil 
and water is unmistakably an important route, and a complex one. A critical component for 
the registration procedure is the identification of relevant scenarios. The actual use pattern of 
the product should be explored, because repetitive use, season-related use, or concurrent uses 
over large areas, in relation to the timing and scale of emission to the environment (i.e. 
spreading of manure), have a significant impact on the actual exposure. A general lack of 
information on distributions of parameter values within and between systems forces one to 
propose the use of a deterministic model with empirical parameters defined in a simple 
scenario of realistic and standardised conditions.  
The amount of slurry present in storage depends on the time of year; and depending 
on the number of cycles treated during this time, the concentration in the slurry is determined. 
A major difference between the two screening models that have been discussed is the time 
span in which clean manure is produced. The shorter this period, the higher the predicted 
manure concentrations will be. The amount of manure that is spread containing the residue of 
the treatment is delimited by the storage capacity of the system and the opportunities to take 
the slurry out. Most UK farms only have the capacity to store slurry for less than one month, 




incorporation depends on the method of application. In the field, no incorporation has been 
registered as general agricultural practice. If manure is incorporated, the mean incorporation 
depth is 16.5 cm. Maximum slurry loads ranged up to 550 kg N/ha/year and more. Realistic 
worst case conditions are hence proposed in a simple scenario assuming:  
- single treatment per animal place,  
- standard European nitrogen production values,  
- a manure production volume of 1 month (30 days) containing the full residue,  
- a nitrogen application rate of 600 kg N/ha/year in one time onto agricultural land, which 
is distributed over 5 cm soil with a bulk density of 1500 kg.m-3, 
- no dissipation during storage, and no after-treatment of slurry. 
If the exposure calculation in Phase I according to this scenario fails the trigger for 
further testing, safe use in all member states is possible.  
If not, then realistic best case conditions, characterising a possible safe use in 
vulnerable areas under the Nitrate Directive in the European Union, are proposed in a similar 
scenario, now assuming  
- active incorporation of slurry into 20 cm of soil,  
- at a nitrogen application rate of 170 kg N/ha/year in one time.  
If the trigger is exceeded, then a phase II assessment would be compulsory for all 
member states. Further assessments should be made at the member state level, since 
environmental concerns can be a reason to refuse (mutual recognition of) marketing 
authorisation20.  
The PECsoil can be used in conjunction with screening level models that predict mass 
transfer to groundwater and surface water. Both screening level and mechanistic models for 
distribution of residues from soil provided for pesticide registration by FOCUS are 
considered as suitable for veterinary drugs as for pesticides (FOCUS, 1995; Groen, 1997; 
FOCUS, 2000; FOCUS, 2001). The simple fact that this methodology encompasses the same 
agricultural fields that are relevant for manure application predestined these models and 
scenarios to be applicable to residues spread by manure as well. Application timers in the 
models should be set to relevant regional conditions for manure application. These may 
depend on spreading restrictions and where these do not apply, by worst case conditions (e.g. 
autumn vs. spring conditions).  
 
Interestingly, the predicted initial soil concentration using the proposed scenario in 
conjunction with Dutch default conditions, for a high volume compound like 
(oxy)tetracycline used in pigs or broilers, amounts to 200 µg/kg soil, with a possible 
maximum of 1000 µg/kg soil (Montforts, 2003). The average concentration of antibiotics in 
soil based on the total annual consumption of 402 tonnes and the total capacity of agricultural 
fields to utilise manure in the Netherlands, amounts to approximately 100 µg/kg soil (Van 
Staalduinen et al., 2001; MARAN, 2002). The difference between these results is within an 
                                                 




order of magnitude, which suggests that regional scale modelling of soil concentrations may 
provide suitable approaches for protective risk assessments. 
 
4.5 Fish cultivation 
 
The scale of fish cultivation, dominated by land based fish nurseries, for commercial 
purposes, is limited in the Netherlands. The production amounts to about 0.2% of the 
production of animal husbandry (Luiten, 2002). In 1994 in total 26 and 10 companies were 
involved in cultivating eel and catfish, respectively. Most nurseries use water recirculation 
systems, in which the water is recycled after a water treatment by filtration. Catfish nurseries 
discharge on the municipal Sewage Treatment Plants (STP), but 40% of the eel nurseries 
discharge directly on surface water. Tropical fish nurseries may also contribute to the 
emission to surface waters (Schrap et al., 2003) 
The surface water exposure scenarios discussed in Montforts et al. (1999) were based 
on a fish farm that breeds 50 tonnes of eel a year, the median production in The Netherlands. 
Two scenarios were distinguished, based on the incidence of administration of the product, 
and the type of wastewater treatment: 
- continuous medication; without recirculation/filtration, followed by a settlement tank; 
- occasional medication (≤4 times a year), without recirculation/filtration before discharge 
to the settlement tank. 
The total water volume of the nursery was set at 70 m3. After the settlement tank the 
water fraction is discharged to surface water. The settling tank is used in order to reduce the 
amount of precipitation in the waste water before discharge into surface water or waste water 
treatment systems, but it was also assumed to play a significant role in reducing 
concentrations of chemicals in the waste water. It was assumed that the settling tank had a 
removal efficiency of 50%. This 50% removal efficiency was taken from Wagemaker (1993) 
and is an estimated value based on the average difference between pesticide concentrations 
that were measured in the influent and effluent of settling tanks used at mushroom production 
plants, as reported in Van Beersum (1988). Due to the settlement tank the total amount of 
substance emitted was equally spread out over 25 days. In the exposure model the fish farm 
discharges on a small waterway that dilutes the effluent by a factor 5 or 3, depending on the 
water volume discharged. The surface water concentration was therefore constant for at least 
this emission period.  
 In addition to the Van Beersum (1988) data set, data on the concentration of 
pesticides in wash water from flower bulb processing facilities were analysed (Frijters, 2000). 
A critical evaluation of the available data was performed. The two sets of data analysed 
contained a total number of 251 observations: 
- Individual concentrations of 41 pesticides in the influent and effluent of settling tanks 
at three different mushroom processing companies at five different time points (Van 
Beersum, 1988) 
- Individual concentrations of 17 pesticides in the influent and effluent of settling tanks 




Figure 4-2: Distribution of removal percentages based on selected influent/effluent concentration, 


























The difference between influent and effluent concentration was expressed as a 
percentage of the influent concentration. The results are presented in Figure 4-2. The 
calculated ‘removal efficiencies’ based on 251 sample pairs varied from –571% to 100%. The 
available data show an averaged difference between the influent and effluent concentration of 
-2.35%. The median of the samples was at 17%. Thus, if an indication of the removal 
efficiency can be derived from these data, the settlement tanks removed a negligible amount 
of the total load.  
Perhaps more important is the applicability of the model for the situation of interest. 
The reduction to safe levels of the excess organic substances in effluent and the increase of 
the fraction of the water reused are the major purposes of wastewater treatment in indoor fish 
production systems. In nursery water treatment systems, a very high concentration of organic 
matter in wastewater, but no soil, can be expected (Kamstra and Van der Heul, 1998). A sub-
routine describing the effect of water treatment and sludge retention should be based on the 
systems of interest. 
The emission pattern of treated water is of importance. Some treatments require 
stopping the water flow for some time, followed by transfer of fish to clean water. Therefore 
a 100% immediate release should be expected for a worst case estimate. In the original 
model, emission of the residue was modelled over 25 days, but this retention factor lacks 
empirical or mechanistic underpinning.  
In the exposure model the fish farm discharges on a small waterway that dilutes the 




owing to the low flow, only poorly developed turbulence is likely to occur from time to time. 
Hence, in polder waters and the like, it is to be expected that noticeable lengths of these 
channels be gradually filled with poorly diluted effluent from waste water treatment plants or 
other point sources. In the Netherlands, about 60 domestic wastewater treatment plants (c. 
20%) have a dilution factor of 2 within 100 metres (De Greef and De Nijs, 1990). Whether or 
not the effluent flows of the fish nurseries are similar to those of the domestic treatment 
plants is unknown. Monitoring of effluent from a tropical fish nursery in the Netherlands, 
with presumably batch-like treatment, revealed concentrations of 11 – 41 µg/L for six 
therapeutics. The highest concentration found was 120 µg/L for oxytetracycline. Downstream 
of the effluent oxytetracycline was measured at a concentration of 57 µg/L (Schrap et al., 
2003). A dilution factor of two may be very well applicable to direct emission in low-flow 
ditches. Given the high sorption coefficient of oxytetracycline of logKoc 4 - 5 L/kg (Rabølle 
and Spliid, 2000), dissipation towards the sediment would be expected. For example at the 
emission point of a tank-based aquaculture system for trout in Northern Italy, a sediment 




The empirical validation of the soil concentration models with (oxy)tetracycline and 
sulphonamides conducted indicate that it is impossible to analyse the contribution of every 
single model parameter to the variability in the model predictions using random field 
samples. Not only variation in doses (a function of dosage and body weight) and excretion 
factors, dilution, degradation, slurry application rates, and soil variability, but also factors 
such as representative sampling in slurry and soil, and field residue history, complicate the 
validation of this part of the model in predicting maximum (nominal) values. It can be 
concluded that: 
- slurry or nutrient concentrations should be related to a realistic time frame in which the 
contaminated slurry is produced and diluted in order to optimise the worst case 
predictions; 
- the available field data do not allow for validation of the parameter selection in the 
models; 
- field concentrations may vary a factor 30 within one field. 
Surface water and groundwater models generated highly deviating predictions 
compared to the field results. What all models have in common is that soil porewater 
concentrations are exaggerated compared to the results of the sand soils, but not compared to 
the results of the clay soil. This provides reason to assume that surface water contamination is 
not controlled by sorption alone, and cut-off values on sorption properties are not warranted. 
Furthermore, the exposure model will always predict surface water exposure, which means 
that spreading manure containing residues of veterinary medicines always leads to pollution 
of surface water. This prediction always warrants a risk assessment, since all actions that may 





A scenario for a simplified soil exposure model has been made. The PECsoil can be 
used in conjunction with screening level models that predict mass transfer to groundwater 
and surface water. Both screening level and mechanistic models for distribution of residues 
from soil provided for pesticide registration by FOCUS are considered as suitable for 
veterinary drugs as for pesticides (FOCUS, 1995; Groen, 1997; FOCUS, 2000; FOCUS, 
2001). The simple fact that this methodology encompasses the same agricultural fields that 
are relevant for manure application predestined these models and scenarios to be applicable 
to residues spread by manure as well. Application timers in the models should be set to 
relevant regional conditions for manure application. These may depend on spreading 
restrictions and where these do not apply, by worst case conditions (e.g. autumn vs. spring 
conditions).  
Interestingly, the predicted initial soil concentration using the proposed scenario in 
conjunction with Dutch default conditions, for a high volume compound like 
(oxy)tetracycline used in pigs or broilers, amounts to 200 µg/kg soil, with a possible 
maximum of 1000 µg/kg soil (Montforts, 2003). The average concentration of antibiotics in 
soil based on the total annual consumption of 402 tonnes and the total capacity of agricultural 
fields to utilise manure in the Netherlands, amounts to approximately 100 µg/kg soil (Van 
Staalduinen et al., 2001; MARAN, 2002). The difference between these results is within an 
order of magnitude, which suggests that regional scale modelling of soil concentrations may 
provide suitable approaches for protective risk assessments. 
The development of regional and catchment area models for assessing pesticides and 
other agrochemicals, but also manure-borne pathogens, is receiving a significant attention 
(Walker and Stedinger, 1999; Arhonditsis et al., 2002; Deelstra et al., 2002; Bicudo and 
Goyal, 2003). In particular run-off and erosion in vulnerable areas of the Mediterranean 
region would be suitable processes for regional modelling. Additional alternatives are the use 
of total losses, which may be implemented through probabilistic models (Pablos et al., 1998). 
It should be, however, recognised that addressing these transfer routes requires regional 
models, which cannot be implemented as generalised screening tools. Recent studies 
demonstrate the influence of particle-bound fractions in regional transport modelling and the 
relevance of erosion in the overall transfer of organic matter from soil to watersheds. These 
findings suggest that the contribution of these mechanisms can be higher than expected, 
particularly for chemicals with a high binding potential (McLachlan et al., 2002; Polyakov 
and Lal, 2004). Smith et al. (2001) observed relevant contributions of surface run-off 
including particles losses for manure applications over 2.5-3.0 t/ha slurry solids in UK arable 
lands. But due to the higher run-off/erosion risk of the Mediterranean region a lower 
threshold should be considered for this area (Arhonditsis et al., 2002). Tentatively, screening 
assumptions can be done on the basis of simplistic models, correlating directly the 
concentration in the top soil layer with the expected concentration in the run-off. These 
models were initially developed for herbicides. They describe non-linear relationships, with 
an extraction coefficient representing removal of the pesticide from the top 1cm soil layer, 




extraction potential with ageing (Leonard et al., 1979; Southwick et al., 2003). The suitability 
of these models for pharmaceuticals should be studied. 
It is concluded that the original 50% removal efficiency of the settlement tank as used 
in Wagemaker (1993) and Montforts (1999) lacks empirical foundation since only part of the 
entire data set (the ‘positive’ efficiencies) had been used. There is no evidence that a settling 
tank contributes to removal of a substantial fraction of the total load of dissolved and particle-
associated pesticides from wastewater. Furthermore the nature of the settling process of fish 
nursery sludge may be very different from that of soil particles. The data available are 
unsuitable for a mechanistic analysis of retention processes, due to a lack of detail in the 
description of system dimensions, water volumes and flow rates, sludge characteristics, and 
total pesticide load. A sub-routine describing the effect of water treatment and sludge 
retention should be based on the systems of interest. Monitoring data from a location with 
direct emission of fish nursery wastewater indicated a dissipation (or dilution) factor of 2 
between effluent and downstream surface water concentrations. What dilution factor is most 
applicable to fish nurseries cannot be determined. Sediment contamination should be 
incorporated into the exposure model. 
This validation indicates that the surface water exposure model was not well founded, 
and is based on generalised data derived from situations that were not applicable. With the 
aim to eliminate no-risk situations from further assessment, a worst-case assumption would 
be that the therapeutic concentration would be the environmental exposure concentration. 
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Environmental protection legislation both in the USA and in Europe requires an 
environmental impact assessment for projects and activities, including the use of chemical 
substances (Zeeman, 1987; Van Leeuwen, 1995; Kolluru, 1996). 
The starting point of any risk assessment is the translation of the desired 
environmental quality in quantifiable goals. So far, protection goals have been associated 
with the structures and processes within the physical environment: water bodies, soil layers, 
systems, habitats, species and individuals (Van Leeuwen, 1995). It is the concept of risk that 
connects these protection goals with the possible presence and impact of substances.  
In the risk assessment, effect and exposure are treated as variables that are determined 
by product use and substances properties. The exposure is generally quantified in a model 
under realistic worst case conditions. The effects of a given substance are assessed using 
toxicity models (e.g. single species tests) in order to determine the exposure concentration 
that will not result in unacceptable effects. This concentration is derived from the lowest 
experimental (no-)effect value and a safety factor that depends on the underlying dataset, or 
from a statistical analysis of these underlying data. This statistical analysis assumes a normal 
distribution of toxicity data representing the ecosystem sensitivity to the given substance 
(Posthuma et al., 2002). More complex studies involving multiple species under 
environmentally relevant conditions are also relevant in determining an exposure level of no 
concern (De Jong et al., in press). The ratio between calculated exposure and the predicted 
acceptable effect level is the risk quotient (PEC/PNEC or RQ): the risk information the 
regulator can use to make a decision for that product. Guidance on exposure and effect 
assessment is given in Technical Guidance Documents (TGD) used in the European Union 
(EU) frameworks of new and existing substances, biocides, and medicines for human 
consumption (Forbes and Calow, 2002c; EC, 2003).  
In the EU, chemicals and products containing medicines, feed additives, pesticides, 
and biocides can only be notified or registered if risk-based standards laid down in the 
European legislation have been met, but at the same time non-risk standards are applied: 
triggers on production, emission, formation, occurrence, and hazard (Van Leeuwen, 1995; 
Bartell, 1996; Heyvaert, 1999b; SSC, 2002). Some examples are:  
• The standard for groundwater and drinking water for pesticides and biocides is 0.1 µg/L 
in the 91/414/EC and 98/8/EC directives. The exposure standard itself is however not 
based on risk, but on hazard considerations in combination with best available detection 
techniques at the time the standard was set. The trigger might be underprotective for some 
substances (Crommentuijn et al., 2000). The Scientific Committee on Plants (SCP) and 




European Commission DG Sanco stress the need for further risk evaluation at exposure 
concentrations below the 0.1 µg/L (SCP, 2000; CSTEE, 2002). 
• The assessment of the risk to sediment dwelling organisms under the 91/414/EC directive 
is triggered by the exposure of the sediment phase: >10% after 14 days in a 
water/sediment degradation test, in combination with the hazard to Daphnia magna 
(ECCO, 2002). 
• Persistence and bioaccumulation under the 91/414/EC and 98/8/EC directives have to 
meet hazard-based standards (DT50 <90 days, DT90 <1 year, BCF <100 L/kg), if not 
they trigger specific ecotoxicological testing.  
• In the 2001/79/EC directive on feed additives, an exposure concentration of 10 µg/kg soil 
is used as a threshold for further risk assessment. 
• In the guidance on risk assessment for veterinary medicines an exposure concentration of 
100 µg/kg soil is used as a threshold for risk assessment (VICH, 2000). 
• In the same guidance an effluent concentration of 1 µg/L for fish medicines is used as a 
threshold for risk assessment (assuming a dilution factor of 10 for surface water). 
The Scientific Steering Committee of the Health & Consumer Protection Directorate 
General (DG Sanco) of the European Commission (EC) endorsed the research on triggers for 
prioritisation (SSC, 2000).  
This paper discusses the scientific tools developed in ecotoxicology, environmental 
chemistry and risk assessment, employed to derive the trigger concentration in soil for the 
assessment of veterinary medicines. 
 
5.2 Case study: the soil concentration trigger value  
 
The EU directive 2001/82/EC on the registration of veterinary medicinal products 
calls for an environmental risk assessment (Anonymous, 2001b). An international 
harmonisation of the guidance and data requirements pertaining to the environmental risk 
assessment of veterinary medicinal products in the EU, USA and Japan was started in 1996 
by the International Co-operation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products (VICH). The resulting guidance document on 
the environmental impact assessment (Phase I: exposure assessment) is now operational in 
the product registration for veterinary medicinal products in Europe (VICH, 2000; EC, 
2001b; Koschorreck et al., 2002). The guidance document foresees no risk-based assessment 
for substances with a presumed negligible emission and exposure level. Science was called in 
to back up the numerical value of the soil exposure trigger, with an assessment of a dataset of 
several drug substances. Concepts and methods developed in ecotoxicology, environmental 
chemistry and risk assessment were introduced and applied to data which lead to the 
recommendation that the lowest toxicity value (100 µg/kg) in the available dataset should 
provide an acceptable measure of safety to protect the environment (AHI, 1997).  
The soil concentration trigger decides if a risk assessment is needed. It is an exposure 
trigger and is based on effect data. All data that were at the base of the value of this trigger 




exposure level for this substance, if several assumptions are made and if necessary conditions 
have been fulfilled. Below the effect data and assessments that were the basis for the soil 
exposure trigger value are subjected to a critical appraisal. Three sections relate to data 
selection and interpretation, two sections relate to the context of the trigger value within the 
risk assessment scheme: 
1. Are the data representative for the terrestrial ecosystem, 
2. Are the data complete or have other data been neglected or overlooked,  
3. Have the data been assessed correctly, 
4. Is the trigger value standardised to the conditions specified in the risk model, and 
5. Does the soil trigger have influence on other parts of the risk assessment scheme? 
 
5.3 Reflection of the terrestrial ecosystem 
 
The degree to which the data set represents the soil ecosystem is an important issue 
that may influence the outcome to a great extent. The relative importance of autotrophic and 
heterotrophic species, detrivores, producers, and predators should be reflected in the dataset. 
If population size is the protection goal, the endpoint should relate to population growth 
(2002b; Forbes and Calow, 2002c).  
However, the studies reported focus on endpoints that are not the most sensitive 
regarding population growth: chronic effects on micro-organisms, mostly tested in agar; sub- 
acute effects on Oligochaeta (Eisenia sp.) in artificial soil; and long-term effects on plants, 
tested in quartz sand. 
With respect to the microorganisms, the relation between the Minimum Inhibitory 
Concentration (MIC) in agar, and the desired level of protection in soil, is unclear. Firstly, the 
MIC is the lowest concentration that completely inhibits the growth and this value contains 
no information on the dose-response curve. Secondly, complete inhibition may occur at a 
very different concentration in soil than in agar. The bioavailability in agar plates during MIC 
studies can be much lower than in soils, since growth media contain a higher amount of 
organic compounds and complexing agents than most porewater (Van Dijck and van de 
Voorde, 1976; Lunestad and Goksøyr, 1990; Griebler, 2001). Thirdly, species were not 
identified in Table 1, so it is unclear if the lowest value relates to a bacterium isolated from 
soil-related bacterial communities, or to ascomycetes, moulds or algae, as explained in AHI 
(1997). Soil bacteria communities consist of a/o. gram-negative and gram-positive bacteria, 
with different sensitivities to contaminants (Rönnpagel et al., 1998). Fourthly, there are 
indications that the nitrifying organisms that can be cultured may not be representative of 
natural populations. Studies using 16S rDNA profiles have shown that Nitrosomonas 
europaea, which is readily isolated from most soils by classical methods, is not dominant 
before enrichment due to the high NH4+ concentration classically used to isolate nitrifying 
bacteria (Hiorns et al., 1995). This does not compromise the suitability of N. europaea as a 
model species, but does emphasise the gap between effect model results and impacts on 





Table 1. Tabulation of the Lowest Environmental Assessment Endpoints from Environmental Assessment 
Reports Submitted to the US FDA/CVM from 1973 to 1997 (AHI, 1997). Units were originally presented 
as ppb.  
Name of Drug 
 












Sarafloxacin 385 Antibacterial 1,000,000 30 1,300 130 




Tilmicosin 869 Antibacterial 918,000  100,000 1000 
Ceftiofur 546 Antibacterial  250  2.5 
Florfenicol 358 Antibacterial  400  4 
Pirlimycin 465 Antibacterial 1,000,000 130 400 13 
Lincomycin 461 Antibacterial 1,000,000 780  7.8 
Tiamulin 610 Antibacterial  500,000  5000 
Apramycin 785 Antibacterial 100,000 100 160,000 10 
Semduramicin 894 Anticoccidial  100,000 310 3.1 
Maduramicin 934 Anticoccidial  250 100 1 




 780 400 4 
Narasin 765 Anticoccidial 500 100 150 10 
Oxfendazole 315 Antiparasitic 971,000 9,000 900 90 
Fenbendazole 299 Antiparasitic 56,000 1,000,000 36,000 3600 
Ivermectin 861 Antiparasitic 12,000  560 5.6 
Doramectin 899 Antiparasitic 2,000 40,000 1,600 160 
Eprinomectin 913 Anthelmintic 295,000 1,000,000  2950 
Clorsulon 381 Antiparasitic  2,000  20 
Efrotomycin 1145 Perf.enhancer 1,000,000 20,000 400 40 
Morantel 370 Perf.enhancer  50,000  500 
Virginiamycin 535-823 Perf.enhancer  10,000  100 
Lasalocid 613 Perf.enhancer  200 2,000 2 
Monensin 693 Perf.enhancer 10,000  150 1.5 
Laidlomycin 792 Perf.enhancer  400 160 1.6 
Bacitracin 1421 Perf.enhancer  10,000  100 
Melengestrol 
acetate 
397 Perf.enhancer 1,800  2,000 18 
DrugA 1000* Anticoccidial 900,000 10,000 10,000 1000 
DrugB 1000* Antibacterial  1,000 130 1.3 
DrugC 1000* Perf.enhancer 8,110 64,000 7,500 750 
* estimate  
** based on assessment factors according to (ECB, 1996) and accepting the MIC as a relevant value. Values in 
bold were used for the derivation of the PNEC 
 
The toxicity testing on earthworms did not take reproduction into account. The 




earthworms (Gunn and Sadd, 1994). An EC50 (acute) of 15.8 mg/kg was accompanied by a 
NOEC at 2 mg/kg because 27% reduction in fecundity (note that the hatching of the cocoons 
was not investigated), found in the next lower dose, was statistically not significant. This 
result is not satisfying and with log-logistic regression analysis, the EC10 would be 0.5 mg/kg, 
30 times below the EC50 based on acute effects (Laskowski, 1995; Van der Hoeven et al., 
1997). The assessment based on acute data would be underprotective for fecundity, because 
the assessment factors (AF) on acute and reproduction endpoints differ only a factor of 10 
(EC, 2003). 
Plants are tested on germination and growth, which can be considered as relevant 
provided they were determined in soil. Phytotoxicity of antibiotics differs between species 
(Jjemba, 2002). However, it is unclear to what species of monocotyles and/or dicotyles were 
tested and whether leguminose species were included.  
Effects of antibiotics in soil on worms or on insects are not expected at the low-level 
toxic to bacteria. Effects on soil-dwelling Collembola and Enchytraeids, on the leaf-dwelling 
Orius spp. (a bug), and on larvae of the white-fringed beetle (Graphognathus spp.) were 
found in the range of 70-500 mg/kg substrate (soil or artificial food) probably due to 
interference with gut microflora (Bass and Barnes, 1969; Baguer et al., 2000; Arijs et al., 
2002; Jensen et al., 2003). Toxicity of anthelmintics and antiparasitics on these groups might 
be quite the opposite.  
In conclusion, the terrestrial ecosystem was not investigated in great detail, both with 
respect to the representation of test species and with respect to the selection of testing 
conditions and endpoints. 
 
5.4 Data selection 
 
The data set used for the trigger value consists of 64 test results on three 
taxonomic/trophic groups with 30 substances: three are anonymous (anticoccidial, 
antibacterial, and a performance enhancer), one hormone, 18 antibiotics/coccidiostats, three 
anthelmintics, three anthelmintics/antiparasitics, and one antiparasitic. For eight substances 
data are presented on three taxonomic/trophic groups; for seven substances one value is 
available. The general validity of such a small set of data may easily be refuted if new 
information is generated.  
Alternative data on drug substances available in public literature have not been 
included. A critical evaluation of the sensitivity of the selected effect models has not been 
attempted (Berland et al., 1969; Berland and Maestrini, 1969; Necas, 1971; Kumar and 
Kaushik, 1971; Van Dijck and van de Voorde, 1976; Jacob and Talpaysayi, 1977; Harras et 
al., 1985; Thiele-Bruhn, 2003; Vaclavik et al., 2004). 
Not all information that was available was presented, since only the lowest of the 
available endpoints were listed, and species names and test conditions were not identified. 






5.5 Assessment factors 
 
Three arguments were presented to justify the redundancy of assessment factors: the 
(low) bio-availability of substances in the presence of soil; the functional redundancy of 
microbes in soil; and the influence of degradation in soil. These arguments will be discussed 
to a greater extent below. 
   
Bioavailability in soil 
It was stated in the original assessment that due to sorption of the substances to soil 
matrix the availability will be reduced and thus the toxicity would be reduced compared to 
tests performed in quartz sand or agar. Binding of complex molecules to soil is depends on 
many factors, thus the partitioning of medicines cannot be generalised, although soil toxicity 
of several organic pollutants to earthworms has been correlated to porewater concentrations 
(Van Gestel and Ma, 1990; Tolls, 2001). An effect like mutagenesis is not necessarily 
diminished by sorption and, even though the contribution of this particular effect to 
reproduction and population growth rate is limited, it indicates that sorption and 
bioavailability are not mutual exclusive phenomena (Würgler and Kramers, 1992; Fretwurst 
and Ahlf, 1996). The argumentation on bioavailability provided is not used in a proper way to 
eliminate an assessment factor (AF). The AF intends to cover the uncertainty in the 
sensitivity of species, endpoints and exposure times, not the uncertainty in exposure 
concentrations. The latter uncertainty should be accounted for in the harmonisation between 
exposure calculations and effect assessment. The example of sarafloxacin in the original 
assessment is used here to demonstrate the effect of sorption. The EU-approach is followed 
as a model for calculation of concentrations in porewater (EC, 2003). The porewater 
concentration, representing the available fraction, depends on the concentration in the soil 















Default settings and input parameters for this model are explained in table 2. The reported 
logKoc of sarafloxacin amounts to 6 L/kg. This sorption coefficient is in agreement with 
findings for related fluoroquinolones (Nowara et al., 1997). Assuming that no sarafloxacin 
partitions into air (Fairsoil*Kair-water = 0), Ksoil-water equals 30000 and the relation between soil 
and porewater is described by: 
 




Table 2. Input and output parameters for the equilibrium partitioning model. 
Symbol Parameter  Unit  Default value 
Input    
PECsoil concentration of chemical [c] in the soil [mgc.kgsoil
-1]  
RHOsoil wet bulk density of soil [kg.m-3] 1700 
RHOsolid density of soil solids [kg.m-3] 2500 
Fairsoil fraction air in soil [m
3.m-3] 0.2 
Fwatersoil fraction water in soil [m
3.m-3] 0.2 
Fsolidsoil fraction solids in soil [m
3.m-3] 0.6 
Focsoil fraction organic carbon in soil (w/dw) [kg.kg
-1] 0.02 
Koc partition coefficient organic carbon – water [dm3.kg-1]  
VP vapour pressure [Pa]  
MOLW molar mass [g.mol-1]  
SOL water solubility [mg.l-1]  
TEMP temperature at air-water interface [K] 285 
R gas constant [Pa. M3.mol-1.K-1] 8.314 
Intermediate results   
Ksoil-water partition coefficient solids and water in soil (v/v) [m
3.m-3]  
Kpsoil partition coefficient solids and water in soil (v/w) [dm
3.kg-1]  
Kair-water partition coefficient air and water in soil [m
3.m-3]  
Output    




The reported MICagar was 30 µg/L. If the concentration in porewater equals 30 µg/L, 
MICsoil equals 530 mg/kg.  
In the original assessment no attention was paid to the differences in volume fractions 
of solids, air, water, or binding places in soil compared to agar. The reported MICagar was 30 
µg/L, the reported NOECsoil (with unknown organic carbon content) was 300 mg/kg, and the 
calculated MICsoil equals 530 mg/kg. Taking into account that a MIC is expected at higher 
concentrations than the NOEC, and that most soil bacteria are not freely dispersed but 
associated with particulate matter, just like the compound, the difference between the agar 
result and soil result is not inconsistent with the partitioning theory (Griebler, 2001). 
Also, mitigating effects due to functional redundancy may play an important role, 
since a calculated MIC based on an agar test for presumably one strain is compared to an 
empirical NOEC for a community process. This confuses the argument that the phenomenon 
of sorption actually reduced toxicity. Hence the result of MIC 30 µg/L in agar is not refuted 
by the test result with soil, and this MIC value remains the lowest representative endpoint in 
agar. 
One can also assume that compounds that are hydrophilic (weak adsorption), are 
concentrated in the porewater and may thus be able to exert toxic effects at lower soil 
concentrations. A discussion on the implications of this argument for highly water-soluble 





The ecological concept of functional redundancy was brought forward: the loss of a 
few vulnerable species will not affect system functionality, as brought forward in Van 
Straalen and Van Gestel (1993). This concept was used as an argument for omitting an 
assessment factor: A different reasoning is given elsewhere: though redundant species may 
not have to be protected, safety factors to extrapolate from tested species to more sensitive – 
yet not redundant – species are still required (Forbes and Calow, 2002a).  
For example in pesticide risk assessment effects on functional endpoints of bacterial 
communities are assessed on a soil community function level; a reduction of 25% after a time 
period of 100 days is considered acceptable in the EC Directive 91/414/EEC. However, this 
assessment is based on soil community tests, not on single strain growth tests. 
There are also arguments against this application of the concept of functional 
redundancy: 
• Not all microbes in soil are part of the same system: nitrifiers will not replace nitrogen 
fixers.  
• Once redundant species are gone, the system remains more vulnerable to future 
impacts.  
• Each species has its own function in the ecosystem and the replacement of microbial 
species by more resistant ones may have severe ecological consequences (Van Beelen 
and Doelman, 1997; Van Beelen and Fleuren-Kemilä, 1999).  
The original assessment contained predominantly single strain tests. It was argued that 
some species may be lost, but the assessment could not indicate how many species exactly 
would not be protected due to the fact that a safety factor was not applied. This emphasises 
the insuperability of assessing soil community functionality with endpoints for single strains, 
a problem that was also addressed in Van Straalen and Van Gestel (1993). 
 
Mitigation by degradation 
Degradation in soil is presented as a factor that will reduce the effects in soil. This 
may be true for some substances, but offers no reason to abandon assessment factors. Firstly, 
if the test substance degraded in the test system, it has been reflected in the endpoint value. 
Secondly, an effect that is caused by the initial concentration in the test system may very well 
become apparent in the field as well. Thirdly, one uncertainty in the exposure-effect 
relationship in the field is the time-to-effect. Dissipation in the test system may be slower 
than in the field, which may give rise to an overprotective assessment. However, this should 
be addressed, rather than obscured, in the effect assessment. 
Other uncertainties in the exposure-effect relationship in the field were not 
considered, such as the fact that degradation may also generate metabolites that need to be 
assessed separately for fate and effects. Also the other side of the medal, persistency, was not 
addressed. Substances may be very recalcitrant to degradation and give rise to long-term 





Conclusions on the safety factors 
It is common practice to use assessment factors on collections of endpoint values to 
derive predicted no effect concentrations (PNEC) (Crommentuijn et al., 2000; CSTEE, 2000; 
EC, 2003). The argumentation on the reduced availability due to sorption and degradation 
was substantiated only with examples that were representative for the argument. The exact 
exposure-effect relationships between agar and soil remain unsettled taking into account that 
most microbes in soil and sub-soil are associated with particles and are not dispersed in the 
porewater and that bio-availability in agar and nutrient broth may also be limited. The 
argumentation on the functional redundancy of microorganisms does not overcome the 
problems of assessing soil community functionality with endpoints for single strains.   
If we accept the MIC in agar as a NOEC, the proper use of assessment factors would 
result in a trigger of 1 µg/kg (see Table 1). This PNEC would serve only for the terrestrial 
system and for the substances within the dataset. 
 
 
5.6 The position in the risk assessment framework 
 
Does the context of the risk assessment framework call for further considerations of 
the applicability of the soil trigger value? Standardisation to the conditions specified for the 
risk model, differentiation between emission routes, and harmonisation between 
environmental compartments are considered here.  
 
Standardisation to risk model conditions 
The reference dataset yielded a threshold value derived from a specific effect study. 
The study conditions may very well be different from the generic conditions within the risk 
model or the specific conditions in the field. For example, in agricultural soils with moderate 
organic matter contents (0.7-4.1% o.c.) the substances will be more available than e.g. in 
artificial soil for earthworms testing, containing typically 10% organic matter, equivalent to 
approx. 6% o.c.) (FOCUS, 2001). Within the frameworks of pesticide registration and quality 
standard setting, toxicity results are corrected based on the organic carbon and clay content, 
provided the substance is hydrophobic (logKow >2) (Crommentuijn et al., 2000). Such 
standardisation cannot be performed with the data in Table 3, because the matrix properties 
are not given. 
 
Table 3. Properties and Environmental Quality Standards (EQS) of some substances used as pesticides 
and as veterinary medicines (Crommentuijn et al., 2000). 
Substance LogKoc Lowest soil 
NOEC in µg/kg 
Species EQS soil (normalised to 10% o.m. 
and 25% clay) in µg/kg 
Dichlorvos 1.83 75000 Lampito mauritii 0.0028* 
Cypermethrin 4.87 - - 0.39* 
Diazinon  2.64 350 Folsomia candida 6.2 




Differentiation between routes of emission 
In the original assessment it was acknowledged that the dataset, containing plants, 
earthworms and microbes, does neither represent all mode of actions nor all species. It was 
therefore recommended that “ecto- and/or endoparasiticides used in pasture should advance 
directly to Phase II to address specific areas of concern, e.g. dung fauna” (VICH, 2000). 
Nevertheless, parasiticides, hormones, and other compounds that were not well represented in 
the dataset (Table 1), that are administered to stabled animals (not on pasture), will be 
subjected to the trigger.  
 
Harmonisation between compartments 
It is important to note that the soil trigger decides on the further assessment of the risk 
to soil, surface water, and also groundwater. The environmental compartments soil, water, 
air, and sediment are connected and substances may be transported between compartments. 
The trigger value in soil should protect water and sediment as well. The equilibrium-
partitioning method has been applied to harmonise environmental quality standards 
(Crommentuijn et al., 2000; EC, 2003). The examples in table 2 illustrate that a safe level in 
soil does not necessarily protect surface water or groundwater. A trigger should –like quality 
standards– be harmonised between compartments.  
Several veterinary substances are used as pesticides as well, for which in European 
legislation standards have been set to water, groundwater and drinking water contamination 
(Anonymous, 1976; Anonymous, 1979; Anonymous, 1998b; Anonymous, 2000). The 
Netherlands Health Council advised the Ministers to treat medicines in a way comparable to 
‘pesticides and biocides’ because they are pharmacologically active, are spread continuously, 
and little is known on their effects (Health Council, 2001). This scientific opinion sides 
veterinary medicines with ‘pesticides’ and ‘biocides’ in the environmental legislation. A soil 
trigger that is not harmonised might result in violation of these water quality standards. 
 
5.7 Conclusions on the scientific evaluation of the dataset 
 
The conclusion of this section is that the potential of the scientific tools to assess the 
data has not been exhausted and the argumentation to discard assessment factors did not 
come up to the mark. The selection of species and test endpoints for establishing a trigger 
value was not optimal. A further correction of the reference data before the assessment, 
together with a harmonisation between terrestrial and aquatic compartments, based on 
agreements on boundary conditions within the risk model, was required. 
 
5.8 Extending data selections and interpretations 
 
Several tools from ecotoxicology, environmental chemistry and risk assessment can 




additional hazard identification, and harmonisation between compartments. These tools are 
examined below. 
Data selection 
New data provide information to lower the trigger without changing the original 
assessment approach. Twenty substances were tested on effect against Vibrio fischeri. EC90 
values, indicative of the MIC ranged from 30 µg/l to 388 mg/L. EC10 values, indicative of 
the NOEC, ranged from 4 µg/l to 90 mg/l (Backhaus and Grimme, 1999). In another research, 
eleven substances were tested on growth inhibition of sludge bacteria, both in a batch system 
and in a pour-plate system, where individual cells are exposed. EC50 values ranged from 100 
µg/l to >100 mg/L in the batch test, but from 28 µg/l to 449 mg/l in the pour-plate method. A 
test on growth inhibition of Nitrosomonas europaea yielded EC50 values ranging from 16 
µg/l to >100 mg/l; using the pour plate method the EC50 values for four selected compounds 
ranged from 2 to 460 µg/l (Halling-Sørensen, 2001). These data provide the following 
‘critical values’: for a single strain (V. fischeri) the EC90 was 30 µg/l, the corresponding 
EC10 was 4 µg/l (ofloxacin). The lowest EC50 was 2 µg/l (chlortetracycline on N. europaea 
pour plate method). For a community process the lowest EC50 value was 28 µg/l 
(chlortetracycline pour plate method). These last two results were obtained from a pour-plate 
method with low microbial density. Low seeding densities are regarded to yield sensitive 
indicators of in situ effects. For the protection of the gastro-intestinal microflora, the Joint 
Expert Committee on Food Additives (JECFA) selects not just the lowest MIC, but selects 
MIC values from all relevant sensitive species, and corrects test endpoint values for the 
higher microbial density in the gut (AHI, 1997). For the soil system, the desired level of 
protection in soil should guide the selection of species and assessment factors and it is not 
straightforward to downsize effects in order to correct for hypothetical different microbial 
densities in soil. Potentially, the trigger can be based on the results of 100, 30, 28, 16, 4, or 2 
µg/l, depending on the preference for a given community process, a particular single species, 
a certain inoculum density, or specific endpoint. 
Partitioning calculations 
The concept of partitioning has been addressed above for effects on microbes 
mediated through agar or soil. For a substance with low partitioning to organic matter, the 
MICsoil will actually be much lower than for a hydrophobic substance. Thus, what would be 
the result if the endpoint in agar for the hydrophobic compound was also to protect the soil 
for a potential hydrophilic substance? This is demonstrated here with the example of a 
hydrophilic substance (metronidazole) and the lowest MIC-value of 30 µg/L established for 
sarafloxacin (molar mass 385 g/mol) in table 1. Both the partitioning in the soil system, 
aiming at effective concentrations in the water phase, and the influence of differences in 
molar mass are accounted for in this example. 
Based on molar equivalents, this lowest MIC in agar amounts to 30/385 = 0.078 
µmol/L. The substance metronidazole has a molar mass (M) of 171 g/mol and a sorption 




be 11 µg/kg soil dw, based on effective concentrations in the porewater calculated with the 
formulas in Appendix 1. This value is very different from the predicted and validated value 
(530 and 300 mg/kg soil) for sarafloxacin, and is below the trigger.  
This partitioning approach can also be applied to a small hypothetical molecule with 
Koc equal to 0 L/kg. For this completely dissolved substance the trigger would be 0.01 
mmol/kg. Would this worst-case hydrophilic behaviour apply to a small molecule with M = 
100 g/mol, the trigger equals 1 µg/kg; in case of the highest molar mass in Table 1 of 1457 
g/mol, the result is 15 µg/kg. For a hypothetical substance, with a mode of action covered in 
the reference data set, and a strong preference for the water phase, the predicted MIC depends 
on the molar mass and will typically range between 1 and 15 µg/kg.  
If we accept the value of 2 µg/l as determined by Halling-Sørensen (2001) as the 
reference for the trigger, the result would be approximately an order of magnitude lower. 
Statistical analysis 
A collection of data can statistically be assessed to generate information on the 
distribution of no effect levels. This distribution reveals the potentially affected fraction of 
species at a given exposure concentration. One could assume that the data of interest are 
representative of a (log-)normal distribution. If all endpoints for all species had been listed, 
the distribution could be fitted on the data resulting in a threshold value at a chosen level (e.g. 
5th percentile) with a chosen confidence level (e.g. 95%) (Aldenberg and Jaworska, 2000). 
This technique is widely applied in standard setting and risk assessment (Van Beelen and 
Doelman, 1997; Posthuma et al., 2002). This Species Sensitivity Distribution (SSD) approach 
will be examined with the assumption that all substances that are present in the dataset have a 
similar distribution of effects. However, the dataset in Table 1 presumably does not show all 
available test results, which makes it impossible to assess the sensitivity distributions. For 
this purpose the data in Table 4 on soil microbes in agar are presented (Van Dijck and van de 
Voorde, 1976). In the table the Predicted MIC values (PMIC, using the lowest MIC and an 
AF = 10) and the Hazardous Concentrations (median level) at which 95% of the species are 
protected (HC5), are presented. The difference in numerical values between the PMIC and 
HC5 depends on the data set and is as high as a factor of 1-160. For this dataset, while the 
lowest value is 100 µg/L, a concentration of 10 µg/L would be the value that protects at least 
95% of all species for the most potent compound, gentamycin.  
The application of this statistical method for the sensitivity distribution of species to a 
single compound can be extended. It is applied here to the population of substances, under 
the assumption that the selection of substances is a representative sample of all possible 
substances. For matters of convenience the MIC values were not corrected for molar mass. 
The HC5 of each substance in Table 4 is taken as the representative effect endpoint per 
substance. The analysis of the collection of HC5 values results in a HC5 of 2 µg/L (Table 5). 
Continuing the line of reasoning in the original assessment from this point forward, the 





Table 4. Sensitivity of environmental micro-organisms to antimicrobial agents (Van Dijck & van de 
Voorde, 1976). All results >1000 mg/L are transformed to logMIC = 4 and all results <1 mg/L are 
transferred to logMIC = –1. PMIC and HC5 are not log-transformed. 
Antimicrobial agent logMIC (mg/L) for straina PMIC HC5su 
 mb md hy citr.1 citr.2 flav kl th cy rh hyph r.sp nitr mg/L mg/L 
tetracycline 0 2 0.7 2 1 2 2 2 1 2 1 -1 3 0.01 0.40 
polymyxin B . . . . . . . 4 2 4 2 1 4 1 3.2 
chloramphenicol -0.3 0.3 0.7 0.7 1 1 2 2 1 3 1 . 4 0.05 0.22 
streptomycin 1.7 2 1.7 2 3 3 . 4 2 2 3 -1 3 0.01 1.3 
neomycin 0 0 0 0 . -1 . 3 2 2 1 1 4 0.01 0.03 
gentamycin -1 -1 -1 -1 . -1 . 3 2 2 1 1 3 0.01 0.01 
kanamaycin 1 1 1 1 . 1 . 3 3 3 3 1 3 1 1.4 
benzylpenicillin 4 4 4 4 4 3 4 3 2 3 2 2 1 1 21 
ampicillin 3 3 1 4 . 1 . -1 2 4 2 1 2 0.01 0.31 
cloxacillin 4 4 4 4 . 4 . . . . . . . 1000 . 
oxacillin . . . . . . . 2 3 4 1 1 3 1 1.6 
cephalothin 3 2 2 2 . 3 . 2 2 4 1 3 3 1 11 
tylosin 2 2 3 4 . 2 . 3 1 2 2 1 4 1 4.2 
oleandomycin 2 2 2 2 4 . 4 3 1 3 4 2 4 1 9.2 
spiramycin 2 2 2 3 . 2 . 3 1 4 2 2 3 1 9.8 
virginiamycin 1.3 2 2 2 4 4 4 1 1 3 2 2 3 1 3.7 
flavomycin 1 1 3 3 . 1 . -1 4 -1 2 . 3 0.01 0.05 
novobiocin 1.3 2 2 2 4 . 3 -1 -1 3 2 2 4 0.01 0.17 
bacitracin 2 2 3 3 . 1 . 4 2 3 2 1 4 1 5.0 
nystatin 4 4 4 4 . 3 . 3 3 4 4 4 4 100 1356 
sulfathiazol 4 4 4 4 . 3 . -1 2 2 3 2 3 0.01 1.6 
furoxone 4 4 2 2 1 1 1 2 1 3 2 2 3 1 2.3 
HC5species 0.21 0.54 0.51 0.93 1.56 0.24 5.7 0.17 1.0 7.3 3.24 0.29 90   
a Abbreviations: mb = Mycoplana bullata ATCC4278; md = M. dimorpha ATCC4279; hy = Hydrogenomonas 
sp.; Citr = Citrobacter sp 1 and 2; flav = Flavobacterium sp.; kl = Klebsiella sp.; th = Thiobacillus thiooxydans 
504 DSM; cy = Cythophaga johnsonae 425 DSM; rh = Rhodopseudomonas sp.; hyph = Hyphomicrobium sp.; 
r.sp = R. sphaeroides 158 DSM; nitr. = Nitrobacter sp. HC5su = HC5 for substance; HC5species = HC5 for 
species. 
 
Table 5. HC5 values calculated using individual HC5 values for all substances except nystatin, oxacillin, 






lowest PMIC  0.01  
lowest HC5 for substances 0.01 0.0001 
HC5 of all lowest values per substance 0.02 0.002 
HC5  of all HC5substances 0.02 0.004 
PMIC = predicted minimum inhibitory concentration 





Applying this approach to the endpoints for all substances in Table 1 using ETX1.021, the 
following distributions and thresholds after normalisation on molar mass are revealed. 
Figures 1 and 2 show the median HC5, but not the lower confidence intervals. Based on the 
data on plant species for all substances (Figure 1) the HC5 is 0.04 µmol/kg dw in soil with a 
lower 95-percentile confidence interval of 0.008 µmol/kg dw in soil. Based on the MIC data 
these HC5 values are 0.08 and 0.03 µmol/L in agar (Figure 2).  
 
Figure 1. Substance/species sensitivity distribution for plants. The arrow indicates the HC5 
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These HC5 values can be transformed to triggers based on the example of the 
hypothetical small hydrophilic substance (M = 100). This yields a trigger of 4 µg/kg for 
plants in soil, with a lower confidence interval of 0.8 µg/kg in soil, and a trigger of 1 (lower 
confidence 0.4) µg/kg for microbes in soil. The distributions can be used to assess the 
fraction of the different taxonomic groups that is not protected at a given exposure. At 100 
µg/kg there is a 45% likelihood that the substance will affect plant species and an 80% 
likelihood that bacterial species are affected.  
 Incorporation of the new data presented above may lower the result of this analysis. 
Due to the different endpoints (MIC, EC90, EC50, EC10) this is not attempted here. 
                                                 




Figure 2. Substance/species sensitivity distribution for micro-organisms (MIC). The arrow indicates the 










-2.0 -1.0 0.0 1.0 


















The hazard of resistance development 
The effects of antibiotics can range from simple parameters like a decrease in 
biomass, respiration rate or denitrification rate, to more complex parameters like community 
shifts and the survival of new genetical information (Landi et al., 1993; Badalucco et al., 
1994; Da Gloria Britto De Oliveira et al., 1995). Effects of some antibiotics on nitrification 
and decomposition in soil have been reviewed and the few studies available indicate effects at 
very high concentrations only (Jensen, 2001; Thiele-Bruhn et al., 2003). It was put forward 
that the substances will be an energy-source to other species rather than a pollutant, although 
this may be at a sub-therapeutic, thus a resistance-inducing concentration. Perhaps other 
assessment strategies could provide more relevant information.  
Shifts in community tolerance caused by soil pollution have been shown to have 
impacts on e.g. extinction of sensitive species, competitive abilities, and metabolic diversities 
(Van Beelen and Doelman, 1997; Siciliano and Roy, 1999; Mcbain et al., 2002; Russel, 2002; 
Séveno et al., 2002). The survival of adapted bacteria in absence of the compound that the 
bacteria have adapted to, is usually said to be limited, but the acquired functionality (e.g. 
resistance genes) remains present at low levels (Cooke, 1983; Stappen et al., 1989; Zuidema 
and Klein, 1993; Séveno et al., 2002; Park et al., 2003). The costs for resistance can even be 
compensated for (Björkman et al., 2000). In some cases related compounds can uphold the 
resistance level against another compound (Aarestrup et al., 2001). Horizontal transmission 




be transferred from manure to soil and groundwater, where low levels of antibiotics may be 
present (Hoffmann et al., 1998; Chee-Sanford et al., 2001; Halling-Sørensen et al., 2002; 
Sengeløv et al., 2003). Resistance development occurs already at the Minimum Effect 
Concentration (MEC) at which growth is reduced, that is tenfold below the Minimum 
Inhibitory Concentration (MIC), the endpoint used to derive the soil concentration trigger 
discussed in Chapter 5 (O'Reilly and Smith, 1999). Thus, even at concentrations below the 
Phase I trigger, resistance genes may be favoured, which can be transferred from manure to 
soil and groundwater (Halling-Sørensen et al., 2002; Sengeløv et al., 2003). The management 
of resistance development in water and sediment face comparable challenges (Grabow et al., 
1976; Cooke, 1983; Linton et al., 1988; Rodgers, 2001; O'Reilly and Smith, 2001).  
Should resistance development be identified as a hazard? According to the European 
Commission this hazard is addressed in the current guidance, even though it obviously is not 
(EC, 2001b). What kind of hazard are we dealing with? Is it a hazard for the ecosystem 
integrity or also a hazard for public health in general? How can we express the degree of 
damage? Currently both molecular and ecological methods are investigated. Pollution-
induced community tolerance has been found suitable to detect community shifts at low 
concentration levels (Ares, 1999; Schmitt et al., 2004). If there is a genetic basis for these 
shifts is to be explored. It has been suggested to include not only the rate of appearance of the 
initial resistance mutations but also the possible counter-selection against the resistant 
variants as well as the rate of virulence-restoring compensatory mutations, which allows 
resistance to be maintained (Björkman et al., 2000). How can this information be used in 
decision making, knowing that it also applies to antimicrobial products used as pesticide and 
biocide (Björkman et al., 1998; Siciliano and Roy, 1999; Mcbain et al., 2002; Russel, 2002; 
Séveno et al., 2002; Midtvedt, 2004; Kümmerer, 2004a; Kümmerer, 2004b)? Resistance 
development occurs already at the Minimum Effect Concentration (MEC) at which growth is 
reduced, that is tenfold below the Minimum Inhibitory Concentration (MIC), the endpoint 
used to derive the trigger under discussion. This indicates that at the MIC level a selection 
pressure for resistance development is present. Since these effects may indeed occur at sub-
therapeutic levels, a safety factor of 10 for this aspect would have been warranted.  
 
Harmonisation between environmental compartments  
The HC5 for the most sensitive trophic level of bacteria in soil based on the original 
data was calculated at 1 µg/kg. Harmonisation between compartments is however required. 
As the soil threshold is based on a substance that is completely in the porewater, the aquatic 
compartment would be protected as well by this trigger. However, the porewater 
concentration at 0.1 µg/kg is 8 µg/L, which is above the trigger value set by VICH for 
effluent water (1 µg/L). Harmonisation of the soil trigger to the water trigger would lead to a 
porewater concentration of 1 µg/L, and hence to soil concentrations of 0.0125 µg/kg for the 
completely dissolved substance. The relevance of the aquatic data set for this purpose should 




Representativiness for other substances 
Although the information status of the trigger suggested above is higher than that of 
the operative trigger, they both are derived from an empirical exercise with a given set of 
substances and endpoints. The question is whether this set of compounds and endpoints is 
representative for the new compounds to be evaluated. There is no easy answer to this. One 
has to take into consideration what part of the population of substances was tested, what 
endpoints were tested, what endpoints will be tested if a full effect assessment is to be 
performed, and how the information was aggregated to derive the threshold.  
The compounds in the reference set were identified as a group because of two 
properties: they were applied as veterinary medicines and data were available. If the 
endpoints in the reference set are the same as those to be established in a full effect 
assessment, the threshold is certainly valid for the compounds that were in the reference set, 
but not naturally for other compounds. The fact that a substance was applied as a veterinary 
medicine is a property that contains no information on the likelihood that another compound 
will have comparable ecotoxicological properties. More information and more discriminating 
properties are needed to allow for a case based reasoning that extends from substances with 
identified common characteristics to substances that yet have to be developed. For instance, 
threshold levels for flavouring substances were based on numerous substances and endpoints, 
and correlated to structural classes (Munroe et al., 1996; Munroe et al., 1999). Statistical 
methods developed to derive substitute confidence intervals around tiny data sets can also be 
applied easily, but only have meaning, if the substitute data are representative (Aldenberg and 
Luttik, 2002). Case-based prediction of ecotoxicological effects of pesticides relies heavily 
on structural class of the compound under investigation (Van den Brink et al., 2002). This is 
fundamental to the derivation and application of (Quantitative) Structure-Activity 
Relationships ((Q)SARs) that might be very useful for the environmental risk assessment for 
medicinal products. Acceptability criteria relating to the accuracy of the predictions do have 
to be set, as accuracy of predictions of e.g. ECOSAR is only 67% (Breton and Boxall, 2003; 




Risk management of veterinary pharmaceutical products is one of the tasks of EU 
governance. The authorisation procedure for (veterinary) medicinal products is recognised to 
be the outstanding example of risk based decision making, because efficacy and side effects 
of the product, also in comparison to other products, are to be considered (Di Fabio, 1994). It 
has been considered that the registration process, and the risk models used, should reduce the 
costs to society in terms of environmental and economic damage, and the assessment process 
itself should neither hamper product development nor timely action (Cranor, 1997). The 
introduction of an exposure trigger can be a powerful tool in realising these objectives. A 
scientific analysis of data can strengthen the choice of the numerical value. A number of 




The dataset was not very comprehensive in number of substances and types of 
endpoints. Existing information available in literature was not considered. New information 
on effects of veterinary medicines on microbial species have become available, and provide 
reason to lower the trigger value even without changing the assessment approach.  
More information and more discriminating properties are needed to allow for a case 
based reasoning that extends from substances with identified common characteristics to 
substances that yet have to be developed. Next to the selection of the data, the selection of 
ecotoxicological tools determines the outcome of the scientific assessment of the same 
dataset. Most importantly, the argumentation on the use of assessment factors did not comply 
with the EU-guidance given in the frameworks of new and existing substances and pesticides 
and biocides (EC, 2003). It was demonstrated that further considerations of the given 
arguments for a soil threshold concentration provide for strong arguments to set a threshold at 
1 µg/kg. Complementary reasoning gives rise to set the trigger at 0.0125 µg/kg. This degree 
of variability in outcomes is troublesome, yet justifiable with a transparent consideration of 
starting points and assumptions, selection criteria, arguments and related uncertainties. 
In comparison to the information contained in the sensitivity distributions, the soil 
exposure trigger value of 100 µg/kg may be underprotective for 80% of soil microbial 
species. Another implication of the use of this trigger value is that, if Environmental Quality 
Standards will be derived for substances using the TGD, these may be below the operative 
trigger value. For some parasiticides that may enter the environment through the manure of 
stabled animals this may be the case, as shown in table 2.  
Also, the exposure trigger based on the soil compartment determines if a further 
assessment of the surface and groundwater compartments is performed, but it is not 






6. European medicines and feed additives regulation are not in 
compliance with environmental legislation and policy 
 
First published in Toxicology Letters 131 (2002) 125-136  
Revised for D. Dietrich, S.F. Webb, and Th. Petry (editors) Hot Spot Pollutants: pharmaceuticals in 
the environment. Elsevier Inc, San Diego, 2004.  




For the product categories of medicines, veterinary medicines and feed additives, the 
environmental risk assessment (ERA) procedure at registration is currently under 
development. The purpose of this paper is twofold: firstly, it investigates what limitations 
environmental legislation sets to the use of medicinal products and how an environmental 
assessment within the registration process can be of help in achieving environmental quality 
standards; secondly, it investigates whether the registration process and the assessment meet 
these expectations. As a case study, special attention is given to veterinary medicines. For a 
general overview of the knowledge, problems, and research concerning sources, fate and 
effects of medicines in the environment we refer to (Kümmerer, 2001). 
 
6.2 EU Environmental legislation and the relation with product 
registration 
 
The European Commission (EC) has issued several directives on the protection of the 
environment. The EC, national authorities and multi-lateral commissions (e.g. International 
Commission for the protection of the Rhine) are the competent authorities that ought to 
enforce a program in order to reduce existing pollution and set specific quality and emission 
standards in binding law, according to the (Anonymous, 1976), (Anonymous, 1979), 
(Anonymous, 2000) and (Anonymous, 1998a) directives on water, groundwater and drinking 
water, respectively (Wösten et al., 2001; Van Rijswick, 2001). Specific substances of concern 
have been identified and listed (List I and II). There is no European legislation on soil 
quality; however, because sediment and river banks are considered part of the water system 
and soil contains groundwater, quality of sediment and soil can also be considered an 
objective of environmental policy.  
Within the Framework Directive on Water (2000/60/EEC) all acts of discharging or 
spreading of waste-material, polluting and deleterious substances that might lead to 
contamination of surface water and groundwater are forbidden, unless the competent 
authority has granted authorisation (a permit). The permit specifies the receiving water body, 
the discharged substance(s), and the measures to be taken to prevent further pollution, for the 
legal person (e.g. a farmer) on a case by case basis. The use of a product (e.g. pesticide, 





have to be authorised by the competent authority (Ministry of Public Works, water-bodies, 
river-bodies, provinces, municipalities). These authorities are facing a huge administrative 
burden that would be relieved if all individual permits could be replaced by one single 
authorisation. Although registration of a product cannot be regarded as a permit nor as such a 
legal authorisation, registration can be a useful ‘start-of-pipe’ measure, because it reduces the 
need for regulating emission: general conditions and restrictions have already been identified 
and certain substances or uses will not be allowed. The competent authority can now focus on 
site-specific circumstances. 
It is possible that environmental directives on the quality of water already contain 
qualitative standards for substances used in medicines and feed additives, even though the 
products groups ‘medicines’ and ‘feed additives’ are not named in the environmental 
directives. The use of the terms ‘pesticide’ and ‘biocide’ in these directives do not refer to the 
product categories, but to the nature of the substances reaching environmental compartments 
after production, use or disposal of products. If an active substance in a medicine or feed 
additive should be denoted ‘pesticidal’ or ‘biocidal’ because of its properties, the standards in 
these directives do apply.  
Are medicines to be categorised as ‘pesticidal’? The Dutch government published in 
1989 a document on quality criteria for substances in soil and groundwater (TK, 1989). It was 
considered necessary to specialise the criteria for pesticides and biocides, “that constitute a 
special group of environmental hazardous substances: they are developed to repel organisms, 
modify the growth and development of organisms, or kill organisms, and are by definition 
biologically active. Also by their use they discern themselves, because these substances –
especially the agricultural applications- are brought into the environment directly and cannot 
be regained”. These criteria (repel, modify, kill, biologically active, (direct) introduction, not 
regain) apply to many medicinal products as well. Also the Netherlands Health Council 
advised the Ministers to treat medicines in a way comparable to pesticides and biocides 
because they are pharmacologically active, are spread continuously, and little is known on 
their effects (Health Council, 2001). 
The quality of drinking water is protected under the Directive 98/83/EC. This 
directive aims at protecting public health by setting quality objectives to drinking water.  
Within the Netherlands’ environmental policy it has been the rule since 1989 that with 
respect to xenobiotics also groundwater should comply with the standards for drinking water, 
as it often concerns soluble compounds that cannot, or insufficiently, be removed using 
common purification techniques (TK, 1989). This point of view is reflected in the directives 
on pesticides and biocides (Anonymous, 1991a) and (Anonymous, 1998b) where the 
allowable concentration in groundwater (irrespective of a use as drinking water) is 0.1 µg/L.  
Based on this reasoning, competent authorities have to set water quality standards to 
medicinal substances and feed additives that can be assigned to the List I and II of the water 
directives. Also, they have to develop action plans to control the pollution; medicines are 
acknowledged as a specific group of substances in the Netherlands’ 4th Water Action 
Program (NW4, 1998). Furthermore, to all substances that qualify as pesticidal, a qualitative 





groundwater (0.1 µg/L). And last but not least, the ERA should assess the risk to both surface 
water and groundwater for every use in order to fulfil its role as a tool in the environmental 
protection. 
The registration process should thus meet the following demands in order to be an 
effective tool for environmental policy: 
- An ERA is performed at every registration or renewal in order to take new data or 
methodologies into account; 
- Decision criteria are in compliance with the environmental directives; 
- Principles and practical procedures for the assessment at registration are operational; 
- The methodology for the setting of environmental quality criteria should be harmonised 
with the ERA methodology for products. 
 
6.3 Product registration and the relation with EU environmental policy 
and laws 
 
The EC unfolded its vision on chemicals in Europe in the White Paper (EC, 2001c). 
The European Union chemicals policy must ensure a high level of protection of human health 
and the environment as enshrined in the Treaty both for the present generation and future 
generations while also ensuring the efficient functioning of the internal market and the 
competitiveness of the chemical industry. Fundamental to achieving these objectives is the 
Precautionary Principle. Whenever reliable scientific evidence is available that a substance 
may have an adverse impact on human health and the environment but there is still scientific 
uncertainty about the precise nature or the magnitude of the potential damage, decision-
making must be based on precaution in order to prevent damage to human health and the 
environment. Another important objective is to encourage the substitution of dangerous by 
less dangerous substances where suitable alternatives are available. The White paper puts 
particular focus on substances which are carcinogenic, mutagenic or toxic to reproduction, 
and on substances which are PBT (persistent, bio-accumulative and toxic) or which otherwise 
give rise to high concern.  
The EC White paper on existing substances is to be regarded as the underlying 
principle for the regulation of substances. To underline the importance, we point out that the 
European Council already incorporated the principles of the White paper in their reaction to 
the evaluation of the pesticide directive 91/414: “The Council calls on the Committee to 
develop a new pesticides policy in line with the relevant aspects of the forthcoming EU 
Chemicals Policy based on the principles endorsed by the Council Conclusion in June 2001 
… In principle, these (PBT) substances should be avoided in plant protection products” (EC, 
2001a). 
Although the regulation of existing substances does not apply to products that are 
regulated in other frameworks, the same principles should (eventually) be applied in these 
frameworks. An ERA should be performed in order to determine the likelihood of effects in 
the environment. This implies that at product registration environmental data should be 





of use some substances are not wanted. In order to accomplish this in an effective manner, it 
should be clear: 
- What the protection goals (criteria) of the assessment should be; 
- What is acceptable (standards or levels) and what is not; 
- How the assessment should be performed (methodology). 
A regulatory problem arises when a product registration procedure is harmonised at a 
European level by the Communautarian authority, while the authorities at the national level 
are responsible for maintaining the desired environmental quality. This may lead to a less 
effective implementation of the ERA as a tool for environmental policy. The product 
registration process also determines the availability of a product on the common market; 
therefore the registration process should meet the following additional demands: 
In order to perform an ERA at registration for the common market, common 
(harmonised) environmental protection goals are required. European environmental 
legislation provides a common basis for environmental goals for all products. 
The ERA should be developed under the supervision of competent authorities (with 
respect to environmental quality), for example through national interdepartmental steering 
groups that prepare the national points of view. 
Implementation of the ERA procedure is an act that will have legal consequences for 
stakeholders (producers, users, and third parties). Formalisation of the contents and the 
procedure should be transparent and open to input by regulators, scientists, industry and other 
interested parties; a view shared by the EC (EC, 2001b). 
 
6.4 Product directives on medicines and the environmental assessment 
 
Medicines and feed additives can reach the environment at production, at use, after 
use (excretion) and as waste material. Only emission at production is outside the scope of the 
registration and is not dealt with here. Given the elaborate risk assessment schemes and 
methodologies formalised in a regulation on existing substances (Anonymous, 1993b), and 
directives for new substances (Anonymous, 1993a), plant protection products (91/414/EEC) 
and biocides (98/8/EC), where both the organisation (competent authorities, technical 
meetings and working groups) and the deliverables (uniform principles, dossier requirements, 
guidance for decision making and listing, guidance on risk assessment, guidance on models, 
guidance on preparing a monograph) are comparable and have been tested in practice, one 
would expect a similar system for medicines.  
The Directive on human medicines (Anonymous, 1965) recognises that an application 
for the marketing authorisation for a medicinal product for human use must be accompanied, 
if applicable, by reasons for any precautionary and safety measure to be taken for the storage 
of the medicinal product, its administration to patients and for the disposal of waste products, 
together with an indication of any potential risks represented by the medicinal product for the 
environment.  
The directive on veterinary medicines (Anonymous, 2001b), that replaces the 81/851 





product information is to be provided to enable an assessment of the safety for the 
environment. Both administration and excretion of the products, and the disposal of unused 
material or waste, should be assessed. The assessor is free to determine what information 
should be delivered.  
The directive on feed additives (Anonymous, 2001a) considers that the existing 
regulations on feedstuffs should be supplemented by the establishment of criteria for the 
assessment of the risk of the additive having an adverse effect on the environment. In contrast 
to the medicines, the decision-making criteria for feedstuff are fastened down in law, but 
hardly any methodology is provided.  
The directives of the three product groups all require an environmental assessment at 
registration. The quality of the assessment depends not only on the information in the 
directives. The directives may have been elaborated upon in national law and guidance 
documents, and the availability of operational procedures, assessment tools, and expertise at 
the evaluating and decision-making authorities are of importance. A further investigation into 
the process, the actors, and the deliverables is made. The veterinary medicinal products are 
explored in most detail as a case study. 
As discussed above, in relation to environmental policy making the registration 
process with respect to the environmental assessment should have the following five features: 
1. Formalisation of the contents and the procedure should be transparent and open to 
input by regulators, scientists, industry and other interested parties; 
2. European environmental legislation provides a common basis for environmental 
goals; 
3. Standards and harmonised methodology are (made) available; 
4. An ERA is performed at every (re-)registration; 
5. Principles and practical procedures are operational. 
Therefore not only the details of the scheme and the methodology are of importance, 
but also the organisation (who), implementation (what) and operationalisation (how) of the 
risk assessment procedure are to be considered. 
 
6.5 The development of the ERA for Veterinary Medicinal Products 
(VMPs) in Europe 
 
Figure 1 depicts the organisation of the registration process of VMPs, in which 
administrative, scientific and regulatory responsibilities are separated. The Directorate-
General (DG) Enterprise is responsible for the European legislation on the registration of 
VMPs. The registration process is mandated to the European Agency for the Evaluation of 
Medicinal Products (EMEA)22. Within EMEA, the scientific committees advise on the 
requests for Marketing Authorisation with respect to quality, efficacy and safety of the 
products. These committees are the Committee for Veterinary Medicinal Products (CVMP) 
for veterinary medicines and the Committee for Proprietary Medicinal Products (CPMP) for 
                                                 





human medicines. The Standing Committee on VMPs, as part of the DG Enterprise, decides 
on the proposal of the CVMP and turns it into binding law. DG Enterprise has also the 
Veterinary Pharmaceutical Committee (VPhC) at its disposal, which was installed by 
Directive 75/320, for advice on interpretation of the directives, compulsory consultation 
when changing directives, and other issues. Member states are involved in the registration 
process through their representations in the SC VMP and VPhC. Member states also appoint 
two independent experts to the CVMP. 
The EMEA was mandated by DG Enterprise to elaborate on the old 81/851 and 
81/852 directives (Blasius and Cranz, 1998). This has resulted in guidance documents for 
performing the environmental risk assessment of veterinary medicines (EMEA, 1996; 
EMEA, 1997), but this was not the end of the process. After the final draft of the EMEA 
(1997) guidance, an international harmonisation between the EU, USA and Japan was started 
by the International Co-operation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products (VICH)23 to which both DG Enterprise and the 
EMEA are committed (DG Enterprise, 2000). The guidance document on Phase I was 
completed and finalised (15 June 2000) for implementation by July 2001 in the European 
Union and United States (VICH, 2000) and replaces the EMEA 1997 guidance on Phase I. 
This guidance document is at this moment leading for the registration procedure. To 
understand the contents of this guidance, one has to understand the organisation that created 
it. The VICH Steering Committee (VICH SC) authorised formation of a working group to 
develop harmonised guidelines for conducting environmental impact assessments (EIA) for 
veterinary medicinal products. The mandate of this VICH Ecotoxicity/Environmental Impact 
Assessment Working Group (VICH Ecotox WG), as set forth by the VICH SC, is as follows: 











Figure 1 The relations between the EC, EMEA, CVMP, VICH, and SCVMP. Dotted lines: information 
and advice. Straight lines: proposals and decisions on Marketing Authorisation for products. 
                                                 





environmental impact assessment of veterinary medicinal products. It is suggested to follow a 
tiered approach based on the principle of risk analysis. Categories of products to be covered 
by the different tiers of the guideline should be specified. Existing or draft guidelines in the 
US, the EU and Japan should be taken into account.” The VICH working group consists of 
three representatives of industry and three of the regulatory authorities, one of each continent. 
The VICH Ecotox WG elected to develop harmonised guidance in two phases (Phase I and 
Phase II).  Phase I identifies VMPs that require a more extensive investigation of their 
potential to have environmental effects on non-target organisms. The VICH SC recommended 
to the WG that Phase II should include a list of studies needed for VMPs that enter Phase II and 
that decision-making or interpretative criteria should be included in Phase II.  The working 
group was advised not to incorporate risk management options into Phase II.  
In other words, the working group had to deliver harmonised guidance using limited 
resources (six experts) defending primarily industrial and governmental interests, secondarily 
environmental and regulatory interests. The interests of the three industrial representations 
are very close: maximum result (registration) and at minimum costs (in terms of both dossier 
requirements and consumer image). The interests of the three governmental representations 
were however more different: apart from opening the markets and removing trade barriers, 
the existing registration procedures should not be compromised too much, the availability of 
products should not be hampered, and the environment in the three ‘continents’ (with 
different legislative criteria) should be protected. The product of such a setting is likely to be 
clear on intentions, but not on details and procedures. 
The draft guidance documents published by the VICH are circulated for consultation 
to members of industry, the CVMP, and the DG Enterprise. These interested parties have the 
opportunity to provide their comments to their respective representatives. The EMEA 
working party member has to deal with (conflicting) comments from experts from all 
member states (represented in the CVMP), and from various experts from (governmental) 
science laboratories. Not until October 2001 (i.e. after the Phase was approved) a working 
group on ecotoxicology was established under the CVMP to advice on matters related to 
preparation of guidelines on environmental risk assessment, in particular providing comments 
on the VICH phase II guidelines, which are in preparation; to provide advice on issues not 
covered by existing guidelines such as developing agreed exposure calculation models; and to 
provide further advice at the request of the CVMP, on other issues related to environmental 
risk assessment of VMPs, in particular for facilitating a harmonised implementation of 
guidelines. After adoption by the Steering Group of the VICH the guidance is published by 
the EMEA and distributed to the member states, i.e. the national agencies for the 
authorisation of VMPs. Although the EC is informed on the progress of the work and 
contents of the guidance, it is not involved in regulatory approval of the guidance. Therefore 
the guidance has no legal status, even though it is an elaboration of the directive and it 







9. Are aquatic species
reared in a confined facility?
11. Is the environmental
introduction concentration
(EICaquatic) of the VMP
released from aquaculture
facilities < 1 µg/L?
17. Is the predicted
environmental concentration
of the VMP  in soil (PEC soil)
< 100 µg/Kg?
No
10. Is the VMP an ecto-
and/or endoparasiticide?
No













AQUATIC TERRESTRIAL7. Is the VMP used to treat
aquatic or terrestrial species?
8. Is entry into the aquatic
environment prevented by disposal
of the aquatic waste matrix?
14. Is entry to the terrestrial
environment prevented through disposal




5. Will the VMP  be used to
treat a small number of
animals in a flock or herd?
6. Is the VMP extensively




2. Is the VMP a natural substance,
the use of which will not alter the
concentration or distribution of the
substance in the environment?
3. Will the VMP be used only in
non-food animals?
4. Is the VMP intended for use in a
minor species that is reared and
treated similarly to a major species
for which an EIA already exists?
Figure 2.  Phase I Decision Tree
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The policy making process on the ERA for VMPs has the following characteristics: 
- Consensual approach between industry and registration agencies24; 
- No participation of other interested parties; 
- Little or no involvement of policy makers from DG Enterprise or DG Sanco, a concern 
expressed by the European Parliament (EC, 2001b); 
- The guidance and interpretative criteria have no legal status; 
- Until recently no scientific opinion was formed that represented the CVMP point of view; 
- There was no formal exchange between the VICH and EMEA working groups and 
steering groups or technical meetings for biocides or pesticides, even though these 
product groups share active substances and emission routes to the environment.  
Thus the first two of five features for a proper assessment (see page 99) are not 
present. The formalisation of the contents and the procedure is neither transparent nor open to 
input by scientists and other interested parties such as competent authorities (with respect to 
environmental quality); the formalisation has no legal status, and European legislation cannot 
provide common protection goals.  
 
6.6 Contents of the ERA for veterinary medicines 
 
Let us now look at the contents of the guidances. As discussed above, a proper 
assessment at this point should involve environmental goals based on European 
environmental legislation, and should contain standards and harmonised risk assessment 
methodology. The ERA for medicines and feed additives consists of two phases. In Phase I, 
products are assessed on their intrinsic hazard and their level of exposure (see Figure 2 on 
veterinary medicines).  
If the product fails to meet the triggers or exemptions, Phase II testing is needed. This 
step is not rigid, as some VMPs that might otherwise stop in Phase I may require additional 
environmental information to address particular concerns associated with their activity and 
use (VICH, 2000).  
Question number 8 highlights a crucial component of the decision scheme underlying 
the decisions also made in questions number 3, 5, 7, and 12: what are the emission routes at 
and after administration, and can one be certain that the emission is absent or insignificant? 
The burden of proof is at the applicant, and the decision is to the assessor. In the guidance 
emission is limited to four routes: no emission, emission to surface water, emission to soil 
and direct emission into the environment (pasture animals). Emission to water and 
groundwater via soil and direct emission at application are not considered. Emission in the 
waste-stage of the product is not included in the guidance, although it should be part of the 
safety assessment as required by Directive 2001/82, and notably, there is no EU policy on the 
quality of soil (which is assessed), but there is legislation on the quality of groundwater 
(which is not assessed). 
                                                 





A total residue approach on the active substance is adopted, relieving the applicant 
from performing degradation route studies (animal, manure, soil, and water). Although this is 
a worst-case approach concerning the effect exerted by the parent compound, the fate of 
different metabolic fractions is not considered. 
The exposure level that is considered irrelevant is quantified both for water and soil 
for antibiotics. For certain compounds (non-parasiticides) trigger values for exposure are 
introduced: 1 µg/L in water and 100 µg/kg in soil. These triggers are substantiated with an 
assessment of a dataset of toxicity values of several antibiotics, assuming: 
- The data set (substances) is representative for all substances with the same 
pharmacological mode of action; 
- The data set (endpoints) is representative for the aquatic respectively the terrestrial 
environment;  
- Safety factors on the lowest experimental effect value are redundant due to:  
- the availability of substances in the presence of soil (due to sorption); 
- the functional redundancy of microbes in soil; 
- the mitigating influence of degradation. 
The approach as such, i.e. determining the level of toxicity that will have a very small 
likelihood of being present in a product, and thus the level of exposure that can be considered 
an acceptable risk considering all products, is in fact equivalent to the practice in the 
exposure assessment, where the ‘insignificant’ emission routes are not considered in view of 
all other emission routes. However, the assessment to determine a safe level is found to be of 
poor quality from an ecotoxicological point of view (De Knecht and Montforts, 2001). The 
soil trigger for feed additives is, on the contrary, 10 µg/kg in the 2001/79 Directive.  
The VICH has not yet agreed upon a Phase II guidance. The European registration 
process has to rely on the available guidance on Phase II as published by (EMEA, 1997), that 
consists of the hazard quotient approach, where predicted exposure and effect are combined. 
Breaching of risk ratio triggers (e.g. PEC/EC50) leads to refinement of the assessment and 
inclusion of field studies. The guidance is however ambiguous on the decision schemes: what 
compartments have to be assessed: surface water and groundwater are not assessed directly in 
Phase I: do they have to be assessed in Phase II? What data are compulsory, what exposure 
models and effect models must be used, and how should field studies be designed or 
interpreted? And how should persistency and accumulation be expressed in exposure 
modelling and effect assessment? Methodological problems resulting from the lack of 
guidance have been discussed in (Montforts et al., 1999; Halling-Sørensen et al., 2001; 
Montforts, 2001). 
The available guidance is ambiguous on the ERA:   
- no clear data requirements; 
- testing protocols are lacking; 
- decision making criteria are not clearly defined; 
- there are no clear standards expressing acceptability; 
- the methodology has not been elaborated to a satisfactory extent; 





- the ERA does not cover all Communautarian environmental legislations (i.e. 
groundwater). 
The content of the VICH Phase I and the EMEA Phase II guidance do not bear the 
required characteristics of a proper assessment: it does not contain all Communautarian 
environmental quality criteria, clear acceptability standards, or harmonised methodology. 
 
6.7 Implementation of the ERA 
 
Let us now look at the implementation of the guidances. As discussed above, a proper 
assessment at this point should be performed at every registration to be effective. Because 
science is developing as well, also at every renewal the ERA should be reconsidered. The 
authority should apply environmental expertise at assessment and at decision-making, have 
methodology and criteria to its disposal, know how to weigh different interests, have 
expertise in the realism of risk mitigation measures, and should be able to deal with gaps in 
knowledge. Let us see if these requirements are met. 
In Article 13 of directive 2001/82 exemptions are made to the dossier requirements 
and the extent of the safety assessment, as a result of which all member states, except the 
Netherlands and the UK, do not assess existing substances on environmental safety (De 
Knecht et al., 2001). If this interpretation is juridical correct, the registration process cannot 
function as a tool in environmental policy and is not in accordance with the White Paper 
intentions. 
In order to prepare and make sound decisions on the safety of a product, 
ecotoxicological expertise is required at preparation and at decision making. Neither the 
members of the Netherlands Committee and Working Group on the Authorisation of VMPs, 
nor of the CVMP reflect the fact that ecotoxicology is a safety aspect on its own right. In 
several member states the ERA is not performed by qualified environmental chemists or 
ecotoxicologists, but by staff with a veterinary background (De Knecht et al., 2001), although 
dossier evaluation is a sensitive step in the registration process (Mensink et al., 1995), 
(Boesten, 2000), (Tiktak, 2000), (Pontolillo and Eganhouse, 2001). 
The authorities do not have, as discussed above, clear methodology and criteria to 
their disposal. The authorities have little experience with risk mitigation measures and the 
available guidance does not, as advised by the VICH, deal with this matter. Risk mitigation 
measures at registration usually target the emission of the product to the environment. 
Measures that target the necessity or redundancy of the product are not expressed in the risk 
assessment and are also outside the scope of the registration (which considers the use (and 
should also consider the disposal) of the product.). Product labelling intended to reduce risk 
can only influence the use and disposal of the (prepared) product and the treated animal, but 
not the use and disposal of the contaminated manure and slurry. Two examples are found in 
the literature (Greiner and Rönnefahrt, 2001). The first example is on the restriction on 
spreading of manure from animals treated with the product. A label to keep treated animals 
stabled is enforceable, but a label to spread the contaminated slurry not within some distance 





cannot foresee the eventual spreading of the manure. The inspector can check the quality of 
the slurry, but not whether the medicinal product had been applied according to the label or 
not. The second example is the registration of a product containing alkylphenols. It is EU 
policy to abandon the use of these compounds (Footitt et al., 1999), but this cannot be 
considered a risk mitigation measure at registration. Not only does the product in casu 
contain this substance, but also the use in medicines is exempted from the general risk 
reduction strategy and the safety of the products with these compounds should be assessed at 
registration. 
The authorities and have not made explicit how to weigh different interests nor how to 
deal with gaps in knowledge. The guidance on human medicines states “since for medicinal 
products the benefit for humans has relative precedence over any environmental risks, the 
environmental risk management procedures adopted for industrial chemicals and pesticides 
(i.e. prohibiting or restricting their use if an unacceptable risk to the environment is evident) 
is neither possible nor desirable in this case. Precautionary measures through product 
labelling are therefore the recommended risk management procedures for medicinal products, 
when concerns for the environment are present.” This guidance indicates that environmental 
risk is at most a reason to suggest risk mitigation measures and undermines the legitimacy of 
the ERA: why impose a burden on the producers that will not discriminate the products? The 
guidances for veterinary medicines and feed additives do contain decision-making or 
interpretative criteria, which only lead to requests for further assessment. No information is 
provided on weighing of risks versus benefits, on provisional approval given an expected 
(low) level of risk. As there are not strict dossier requirements, it is not clear how lack of 
information should be included in the decision making.  
The ERA at registration does not bear the last features for a proper assessment. 
Assessments are not made for all products, and the decision-making principles and practical 
procedures are not operational. It is therefore unlikely that any result of an ERA can be taken 
into consideration. 
 
6.8 Discussion and conclusions 
 
It has been argued that environmental protection in itself is not an issue to be dealt 
with at EU level. There are considerable problems that cross borders (e.g. groundwater 
depletion) or arise on a specific location due to actions of several states, but the level of 
quality desired on each location and the specific member states involved in each case are not 
uniform. Environmental legislation should thus be a case for member states only, or multi-
lateral negotiation (Golub, 1996). To illustrate this line of reasoning: the EC has issued 
directives on water and groundwater (trans-national relations), but not on soil. The 
framework directive on water (2000/60/EC) is a fine example of the awareness of the EC of 
both the subsidiarity principle (regulate at the lowest appropriate level) and the complexity of 
the existing regulations on water quality. The framework directive formulates common 
objectives, leaving a great deal of decision making to the member states, and provides for a 





areas, such as environment, nature, spatial planning, agriculture and product policy. It is 
argued here that the subsidiarity issue on environmental regulations is not only defined by 
scale of the revelation of the effects, but also by the mechanics that lead to the effects, 
including the working of the common market for products. This is why environmental 
legislation serves a purpose in European registration procedures for products. 
A regulatory problem arises when a product registration procedure is harmonised at a 
European level by the central registration authority, while the authorities at the national level 
are responsible for maintaining the desired environmental quality. This may lead to a less 
effective implementation of the ERA as a tool for environmental policy. This problem can be 
tackled in two ways: 
- the ERA should be based on common principles based on EU regulations and policy that 
steer the national authorities; 
- the ERA should be developed under the supervision of competent authorities, for example 
through national interdepartmental steering groups that prepare the national points of 
view. 
Both options are not reflected in the forging of the ERA for medicines and feed 
additives. The formalisation of the contents and the procedure is neither transparent nor open 
to input by scientists and other interested parties; the formalisation has no legal status, and 
European legislation cannot provide common protection goals in a global setting. The VICH 
Phase I and the EMEA Phase II guidance do not contain all Communautarian environmental 
quality criteria, nor clear acceptability standards, nor harmonised methodology. The scientific 
validity of the registration procedure is compromised (cf. (Heyvaert, 1999a)). Assessments 
are not made for all products, and the decision-making principles and practical procedures are 
not operational. It is therefore unlikely that any result of an ERA can be taken into 
consideration at registration, which undermines the legitimacy of the process.  
What is the ultimate effect of these developments? Assessors at the registration 
agencies do not know if and how to perform or conclude an ERA. Applicants do not know 
what effort the authorisation process will place upon them, which makes it difficult to take 
management decisions on the development of new products, or the renewal of old products. It 
is not the ERA as such, but the lack of clarity in procedure and requirements that may 
ultimately compromise product availability. Products that pose a threat to environmental 
quality at or after use or disposal may now be registered, forcing the authorities responsible 
for water and land quality to regulate and enforce product use and slurry use on a case by 
case basis.  
The major efforts recently made by the regulators and scientists within EMEA and 
VICH need to be founded on clear policy decisions and embedded in a uniform and 
transparent decision-making procedure. It should take little effort to postulate 
Communautarian decision-making criteria together with their levels of acceptability. These 
will provide a solid basis for the implementation of the existing risk assessment 
methodologies, and subsequently help to clarify the (compulsory) data requirements and 





data requirements, and mitigation measures) will then provide a reference for deciding on the 
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7.1.  Introduction 
 
European and national regulators are involved in managing environmental risks of 
veterinary pharmaceuticals from two perspectives. One is the registration of pharmaceutical 
products (Blasius and Cranz, 1998), and the other is the management of good environmental 
quality (Montforts and De Knecht, 2002). The framework of the registration procedure for 
veterinary medicines consists amongst others of the European Community legislation, 
Member State legislation, case law, as well as global (trade) agreements. In this paper we 
investigate what possibilities and obligations are created for applicants and authorities within 
this framework to assess the environmental impact of the use of a veterinary medicinal 
product, to take the results of the risk assessment into account in decision-making, and to 
bind users and third parties to precautions in the labelling and packaging. The objective of 
this article is then to investigate methodological and legal restraints that render the 
precautions in the labelling and packaging ineffective as risk mitigation measures within the 
European Union. For further reading on the legal context in the US the reader is kindly 
referred to Daughton and Jones-Lepp (2001), Haskell et al. (2003a; 2003b), and Nidel, 
(2003).  
 
7.2.  The obligation to take environmental risk into account at registration of 
veterinary medicinal products 
 
The codified EU Directive 2001/82/EC lays down rules for, amongst others, placing 
products on the market, labelling and package leaflet. Placing on the market evolves around 
the permit to market the product, the so-called marketing authorisation (MA), the procedures 
for granting the marketing authorisation, and procedures for mutual recognition of marketing 
authorisations within the EU. The Directive addresses both regulatory authorities and 
applicants, but not the consumers of the marketed products. The recently adopted Directive 
2004/28/EC amends the 2001/82/EC Directive. In this new Directive, any risk of undesirable 
effects on the environment is included in the definition of risks relating to the use of the 
product (worded in Article 1(19)). Article 12(3)j. requires the applicant ‘to provide tests 





shall be studied and consideration shall be given on a case-by-case basis to specific 
provisions seeking to limit it.’   
The risk assessment is to be examined by the registration authority. This examination 
is performed by a scientific committee, since the European Court of Justice (ECJ) ruled in 
case C212-91 (Angelopharm) that "the Scientific Committee is the only party involved in the 
policy-making process that is competent to make those scientific and technical assessments 
on which the legal validity of the measures depends" (Heyvaert, 1999a). At the European 
level Regulation (EC) 726/2004 (re)installed the Committee for Veterinary Medicinal 
Products (CVMP) to provide these risk-based opinions in the centralised procedures (Blasius 
and Cranz, 1998). The CVMP is also involved in decentralised procedures, where a 
marketing authorisation obtained in one Member State is taken for mutual recognition to 
other member states. When disputes between member states about public health or 
environment remain unsolved, the case is also referred to the CVMP, which will provide for a 
binding opinion on the matter.  
The framework of the registration procedure for veterinary medicines thus generates a 
scientific opinion on the environmental risk. There are two possible options for the authority 
in response to an identified environmental risk. The first option is to eliminate the risk by 
denying marketing authorisation. This option is based in the articles 30 and 33 to the 
Directive. In the Directive 2004/28/EC, amending the 2001/82/EC, Article 30 states that 
marketing authorisation is denied if the risk-benefit balance of the product is, under the 
authorised conditions of use, unfavourable. A risk/benefit balance is defined as ‘an evaluation 
of the positive therapeutic effects of the veterinary medicinal product in relation to the risks’. 
In Article 33, it is stipulated that a mutual recognition of a marketing authorisation can be 
denied if there are concerns for a potential serious risk to human or animal health or for the 
environment.  
The second option is to mitigate the predicted risk to an acceptable level by 
addressing the user of the veterinary medicine through the information that accompanies the 
product (Koschorreck et al., 2002). This option has the intention of establishing a code of 
conduct that is reaching further than the Good Agricultural Practice taken as a starting point 
in the risk assessment. This option is held in high esteem, since it is explicitly worded in 
Article 12.3.j of the 2004/28/EC Directive and the recital. This option is further investigated 
in this article, by examining the requirements set in the Directive towards the risk assessment 
methodology and the obligations towards the user of the medicinal product. 
 
7.3.  The structure of the environmental risk assessment 
 
The EU Directive and the Notes for Guidance provide for a methodology for 
assessing environmental risk following the use of the product under representative conditions. 





‘the assessment shall normally be conducted in two phases. In phase I, the investigator shall 
assess the potential extent of exposure to the environment of the product, its active substances or 
relevant metabolites, taking into account: 
• the treated animal species, and the proposed pattern of use (for example, mass-medication or 
individual animal medication), 
• the method of administration, in particular the likely extent to which the product will enter 
directly into environmental compartments, 
• the possible excretion of the product, its active substances or relevant metabolites into the 
environment by treated animals; persistence in such excreta, 
• the disposal of unused or waste product. 
In phase II, taking into account the extent of exposure of the product to the environment, 
the investigator shall then consider whether further specific investigation of the effects of the 
product on particular ecosystems is necessary. The available information about the 
physical/chemical, pharmacological and/or toxicological properties of the compound which has 
been obtained during the conduct of the other tests and trials required by this Directive have to be 
taken into account. As appropriate, further investigation may be required of: 
• fate and behaviour in soil, 
• fate and behaviour in water and air, 
• effects on aquatic organisms, 
• effects on other non-target organisms.’ 
Thus the Directive has specified the scope and boundary conditions for the 
environmental risk assessment to be performed. Article 33(2) of the recent Directive 
2004/28/EC coerces the Commission to adopt guidelines defining a potential serious risk for 
human or animal health or for the environment. This is essential to make the risk/benefit-
based decisions (Di Fabio, 1994). The European Medicines Agency (EMEA)25 and the 
CVMP have published guidance on the environmental risk assessment, that was implemented 
in 1997 in the European registration process (EMEA, 1997). A revised guidance document on 
Phase I has been implemented by July 1st 2001 (VICH, 2000). For Phase II the 1997 guidance 
is still leading, but a new Phase II guidance is under preparation that is expected to come into 
force in 2005 (VICH, 2003). The guidance documents consider the use stage of the products. 
The waste stage of the products is however not guided by these guidance documents, and 
neither will it be considered here.  
The Notes for Guidance identify acceptable risks of applications: generally when the 
level of exposure is below a predicted no-effect concentration. If the predicted exposure level 
were to be greater than the predicted no-effect level, the assessment proceeds to a next tier 
where the Note for Guidance requires more data and more advanced methods to refine the 
risk assessment. Regarding the exposure assessment, the identified and consolidated emission 
routes are direct emission to the environment, emission through dung of grazing animals, 
emission of contaminated water, and emission through spreading of slurry from treated 
animals. The assessment is performed taking codes of conduct according to Good 
Agricultural Practice into account. Good Agricultural Practices to the use of manure on land 
                                                 





may differ between members states and are amongst others set by the Nitrate Directive for 
vulnerable areas, advisory standards for crop fertilisation, and tolerance of crop for excessive 
manuring (Montforts and Tarazona, 2003). This allows for the use of generalised data on 
animals, manure production, storage, handling and spreading, under worst case conditions. A 
second important assumption is that spreading of manure is a given fact, and that the 
contamination by the veterinary medicinal products does not restrict the spreading of the 
slurry.  
The EU Directive and the Notes for Guidance provide thus for a methodology for 
assessing environmental risk following the use of the product under representative conditions. 
The most important conclusion is that risks arising from direct exposure, at treatment, or from 
exposure to treated animals, and indirect exposure, by the spreading of contaminated 
materials such as dung and manure, are within the scope of the registration assessment. 
Further details on the risk model and the available methodology will be addressed below, 
where relevant. We will now investigate what the possibilities are for risk reduction by 
provision of instructions to the user of the veterinary medicine.  
 
7.4.  Risk mitigation by labelling and packaging 
 
Together with the marketing authorisation, several documents and particulars with 
relevant information are issued at registration. These entail a summary of product 
characteristics (SPC) and an assessment report, as stipulated in Article 14 and 25, the 
containers and outer packages (Article 58), and a package leaflet (PL, Article 61). All of 
these particulars should contain ‘precautions (as a special class of prescriptions) for disposal 
of unused medicinal products or waste material from medicinal products, if any’. The SPC 
should also contain explanations of these precautions together with an indication of any 
potential risk to the environment. All these precautions shall conform to the particulars and 
documents pursuant to Article 12 of Directive 2001/82/EC. Precautions should therefore 
demonstrably reduce the environmental risk. We will now consider these documents and 
particulars in greater detail. It will be investigated what the subject of the measures can be, 
who the addressee is (the object of the precaution), and what the disposition of the 
precautions is (precept, prohibition, or recommendation). 
 
A precaution is not a mandatory enactment under the Directive 2004/28/EC. The 
Directive does neither elaborate on obligations to consumers to obey the documents and 
particulars nor on supervision and sanctions. Precautions are hence not legally binding 
through the Directive. Although it can be expected that the precautions will have their 
intended effects in a certain number of instances, the reasonable worst case situation remains 
the one where the precautions are not followed. In that sense, the precautions are merely 
recommendations. Paradoxically, all precautions should therefore be considered as 





legislation concerning the veterinary practice should turn these prescriptions into legal 
injunctions. The situation in the Netherlands is presented here as an example.  
In the Netherlands, rules on precautions have been laid down in the Veterinary 
Medicines Act (Diergeneesmiddelenwet) (Anonymous, 1985). It is established in Articles 7 
and 40 that it is forbidden to act against the prescriptions in the documents and particulars 
issued at registration. This prohibition applies to the users of the veterinary medicine, 
provided that the prescriptions are stated in the Package Leaflet, the container, or the outer 
packaging. Information in the SPC alone is however not legally binding, but may assist the 
veterinarian in selecting the appropriate treatment. Ignoring the prescriptions issued at 
registration is a penal offence, supervised and sanctioned, under the Economic Offences Act 
(Wet op de economische delicten) (Anonymous, 1950).  The Veterinary Medicines Act also 
controls the availability of veterinary medicines. There are three classes of veterinary 
medicines: freely available products, products under prescription that can be administered by 
the keeper of the animals, and products that can only be administered by the veterinarian.  
The subject of instructions (the ‘what’ question) in the labelling may be the product 
(e.g. dosage and posology), the treated animals, or animal products such as eggs and milk 
(e.g. withdrawal times). Likewise, the excreta of treated animals can be addressed by special 
instructions, since these are under control of the keeper of the treated animals. The addressee 
of these precautions (the ‘who’ question) may be the veterinarian or the keeper of the treated 
animals. Other persons or subjects are not the users of the products and cannot be addressed.  
 
It is also very important that the precaution addresses the right addressee with 
reasonable demands. Unreasonable demands will not only be ineffective, but may also delay 
the registration procedure. An illustration of unreasonable demands can be found in the 
precautions concerning the application of biocidal products for the impregnation of wood. 
The precautions of concern addressed the person that impregnates the wood with instructions 
on the selection of the product for certain types of wood. The precaution distinguished 
between the different final destinations of the wood: use in contact with soil and water, or 
not. A Netherlands Court, the Board for the Appeal of Private Enterprise (CBB) ruled that 
restrictions on the use of wood preservation products should only have bearings on 
destinations (of the treated wood) that were to be determined reasonably clear and objective 
at the time of use of the product (CBB, 2000). Restrictions bearing on the anticipated use of 
the wood in contact with soil or water were considered not to meet this requirement. It was 
taken into account, that the person applying the product for impregnation was not the person 
who determined the destination of the treated wood. When deciding on using the product on a 
given batch of wood, the destination of the wood would not be reasonably clear for him to 
make the right decision. The precaution that distinguished between contact with water and 
soil or not, was unreasonable and the authorisation was nullified. 
If precautions refer to the handling of treated animals or manure that has been 
contaminated with residues of the medicinal product, such precautions only should have legal 
force if the user of the product also controls these animals or this manure. Such precautions 





the destination of the animal or the manure. Without legal force, the precaution cannot be 
considered to mitigate the risk. There are two situations where this applies. 
Firstly, regarding the products that are to be administered by the veterinarian only, the 
precautions cannot instruct him or her on the destination of the treated animals or the manure, 
since the farmer controls these. Second, for products that are administered by the keeper of 
the animals, the precautions do have binding force. However, once the animals or manure 
have been sold to a third party, the precautions are no longer binding. For these open ends a 
solution must be developed. 
 
All precautions should be based on factual information provided in the dossier and 
generated in the risk assessment. To what extent the effect of the precaution is demonstrable 
by the risk assessment methodology will be explored in the next section. 
 
7.5.  The demonstration of the effect of risk mitigating precautions 
 
In European Member States, several medicinal products have been registered after 
decentralised procedures, with special precautions contained in the SPC, Package Leaflet, 
container and outer packaging. All these precautions shall conform to the particulars and 
documents pursuant to Article 12 of Directive 2001/82/EC. Precautions should therefore 
demonstrably, i.e. quantifiably, reduce the environmental risk. This means that the impact of 
the precaution should be expressed in the risk assessment, in conformity with the dossier and 
the risk assessment methodology. The methodology available typically targets realistic worst 
case conditions of use that cover all possible situations in the field. Special precautions 
should apply without exemption to the worst case conditions.  
Below some examples of special precautions for the environment are discussed with 
respect to the methodological demonstration of the efficacy of the precautions26.  
 
Many products containing parasiticides for pasture animals carry a precaution that 
dictates that treated animals should not enter surface water at or after treatment. Apparently, 
the aquatic environment is at risk when treated animals have access to surface water, since 
residues of parasiticides are excreted with dung for days after treatment (Lumaret and 
Errouissi, 2002). According to the Notes for Guidance, the risk for surface water is based on 
an exposure model where 1% of the dosage (per hectare) is excreted in a ditch (100 m3) 
adjacent to the field. The resulting exposure concentration is compared to the toxicity of the 
crustacean Daphnia magna, taking an assessment factor of 100 into consideration. A risk 
quotient >1 indicates risk and calls for refinement of the assessment or risk mitigation 
measures. A few examples of products with this precaution are presented here.  
The package leaflet of Eprinex Pour On (containing eprinomectin) carries the 





Without access to surface water, the treated animals will not expose the aquatic environment 
to excreted residues. The precaution on Eprinex Pour On eliminates demonstrably the risk to 
the environment since treated animals are not allowed to have access to surface water 
anymore. The precaution is technically sound. However, there is apparently no time period 
after which the risk of Eprinex Pour On would have become acceptable. It could be discussed 
whether this precaution is proportional since treated animals will have no longer access to 
fields with adjacent surface water. 
 
The package leaflets of both Equimax oral gel for Horses (containing ivermectin and 
praziquantel) and of Noromectin 1.87% oral paste for Horses (containing ivermectin) carry 
the precaution: ‘treated animals should not have direct access to surface water and ditches 
during treatment’. Apparently, the treatment poses a risk to the aquatic environment, not the 
excretion of residues after treatment, which would be expected. Based on the Notes for 
Guidance the predicted concentration ivermectin in surface water would be 25 ng/l after the 
treatment of ponies (0.2 mg/kg bodyweight, 250 kg bodyweight, 5 animals per hectare). 
Halley et al. (1989) reported an EC50 of 25 ng/l for ivermectin in Daphnia magna. Applying 
the assessment factor of 100 results in a toxicological threshold of 0.25 ng/L. The risk 
quotient of 100 is above the threshold of 1. This precaution does not eliminate the risk of 
surface water contamination due to entry of residues excreted by the horses after treatment, 
which most likely was the intention.  
The package leaflet of Triclaben 10% (containing triclabendazole) carries the 
precaution ‘Cattle should not have access to surface waters within 7 days after treatment.’ 
The package leaflet of Clik 5% Pour-on (containing dicyclanil) carries the precaution ‘The 
treated sheep should be kept away from water courses for at least one hour after treatment.’ 
Apparently, the risk to the aquatic environment is acceptable after 7 days, respectively 1 hour 
after treatment. These precautions provide clear instructions and the potential effect of these 
precautions can be demonstrated with the risk assessment methodology, since information on 
the excretion pattern of the active substance should be available (Montforts et al., 1999; 
Taylor, 1999).  
Apart from the technical aspect, other legal aspects will determine the conformity 
with the EU Directive, as discussed above. Third parties will not be bound by the precautions 
stated above; inferring that treated animals will pose a risk to the environment after they have 
been sold to third parties within the stipulated time periods. The proportionality of the 
precautions should also be observed.  
 
The product Sebacil Pour On (containing phoxim) is applied to pigs. The package 
leaflet contains the precaution: ‘When spreading manure from treated animals on agricultural 
lands a safety distance of 10 m to adjacent surface waters must be kept to avoid exposure of 
the aquatic environment.’ Apparently, the risk to surface water after manuring of land was 
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not acceptable. In the methodology provided by the Notes for Guidance in Phase I, the 
concentration in surface water depends on the concentration in soil as a result of spreading of 
slurry. The model assumes a dilution factor of 3.3 on the porewater concentration and 









where PECsoil is concentration in the soil in [mg.kgsoil-1], Focsoil is the fraction organic 
carbon in soil in [kg.kg-1], Koc is the partition coefficient organic carbon – water in [l.kg-1], 
and PECporewater is the predicted concentration in porewater in [mg.l-1]. The degree of 
surface water contamination in this exposure model is neither related to the actual transport 
processes (erosion, run-off, and drainage), i.e., the ratio between treated soil and receiving 
surface water, nor to the distance to the surface water. The water contamination depends on 
the equilibrium concentration between soil solids and soil porewater, and a dilution factor 
between soil porewater and surface water. The distance to the surface water is not modelled. 
The precaution must therefore have been based on an exposure assessment that handled this 
parameter of distance-to-edge, taken from a different source of exposure modelling. The 
German package leaflet contains the precaution: ‘Whenever slurry of animals treated with 
Sebacil Pour-on is applied on agricultural fields, because of the hazard of run-off, a minimum 
distance of 10 m to surface waters should be observed.’ The hazard of run-off is indicated 
here. The German EXPOSIT model is known to contain a function that calculates a reduction 
in run-off when a vegetative buffer strip is observed between the treated soil and the surface 
water. A 10 meter vegetative buffer strip would reduce surface water contamination with 
67% due to run-off (Winkler, 2001). Evidently, next to the process of run-off, drainage is a 
process to be considered (Kay et al., 2004), and the recommended no-spreading zone does 
not influence the contribution by drainage to the same extent. Moreover, in all operative 
drainage models, used in pesticide registration, the drainage model contains only a single soil 
column. The effect of a no-spreading zone, which would be a second soil column in the 
exposure model, is not demonstrable in drainage calculations with the currently available 
models in the frameworks of registration of veterinary medicines or plant protection products 
(VICH, 2000; FOCUS, 2001; WRc-NSF, 2001; Winkler, 2001).  
Since the Notes for Guidance do not define the relative contribution of the process of 
run-off to the final water concentration, the influence on the final exposure concentration 
could not be quantified. The methodology should be improved on these aspects in order to 
make these precautions demonstrably effective. Apart from the technical aspect, other legal 
aspects will determine the conformity with the EU Directive, as discussed above. Third 
parties will not be bound by the precautions stated above; inferring that the manure from 






Another example concerns the effect of the precaution on Nuflor Drinking Water 
Concentrate for Swine (containing florfenicol): ‘Manure from treated pigs should be stored 
for 3 months prior to spreading and incorporating into land’. Apparently, the concentration of 
the residue in the manure was too high. The precaution addresses the manure storage in the 
exposure model, which is in potential important in limiting exposure of the environment 
(Pierini et al., 2004). The precaution may generate a necessary certain amount of dilution of 
the residue with clean manure during these 3 months. However, the Notes for Guidance refer 
for an example of the calculation of the soil exposure concentration to the paper by Spaepen 
et al. (1997). In this paper, the shortest dilution period is about 5 months for slaughtering 
pigs, making it less conceivable that the intended risk mitigating effect is dilution. It is more 
likely that the effect of degradation on the concentration of the residue was assessed in the 
dossier. The assessment of fate and distribution of veterinary medicines in manure during 
storage is complicated, due to the lack of technical guidance both for conducting degradation 
studies and for interpretation of the results and subsequent exposure modelling. The 
performance and evaluation of laboratory studies on the degradation in manure have been 
investigated (Bouwman and Reus, 1994), but have not yet resulted in internationally accepted 
test guidelines (Van Vlaardingen et al., 2001). Also there is currently no scenario that lays 
down representative worst case conditions for the modelling of degradation during manure 
storage (Montforts and Tarazona, 2003). Proportions of manure types and storage systems 
differ considerably between countries and will influence storage conditions and manure 
composition in different ways (Donham et al., 1988; Menzi, 2002). Conditions like oxygen 
levels, manure age, microbial activity and temperature will determine the fate of organic 
contaminants to a large extent, but are highly diverse within and between storage systems 
(Hoeksma et al., 1987; Novem, 1991; Arogo et al., 1999). Manure models that model manure 
loading, quality change, and fate of constituents do exist for nutrients, but are not operational 
for organic contaminants (Ni, 1999; Ni et al., 1999; Hilhorst and De Mol, 2002). Therefore, 
the waiting period would probably contribute to risk mitigation, assuming at least some 
degradation of the relevant residue, but the exact effect under relevant worst-case conditions 
cannot be quantified using available methodology. The methodology should be improved on 
these aspects in order to make these precautions demonstrably effective.   
Again, apart from the technical aspect, other legal aspects will determine the 
conformity with the EU Directive, as discussed above. Third parties will not be bound by the 
precautions stated above; inferring that the manure from treated animals will pose a risk to 
the environment after it has been sold to third parties.  
 
7.6.  Discussion, conclusions and recommendations 
 
In this paper we investigated what possibilities and obligations are created by the EU 
Directive 2001/82/EC, to bind authorities, applicants, and users, to instructions and 
prohibitions in the labelling to the product. The regulatory framework obligated applicants 





be performed by a scientific committee. The CVMP Notes for Guidance provide for a 
methodology for establishing environmental risk following the use of the product under 
representative conditions. Risks arising from indirect exposure, by the spreading of 
contaminated materials such as dung and manure, are within the scope of the registration 
assessment.  
Doubts on the acceptability of environmental risks may constitute a reason for the 
applicant to change product characteristics or target species, and for the authority to deny 
marketing authorisation. The present article focuses on the alternative option to mitigate the 
risk to an acceptable level by special precautions in the information that accompanies the 
product.  
The retrieved precautions address the fate of treated animals or the contaminated 
excreta, seeking to rule out or diminish the exposure of the environment. The grazing of 
treated animals in fields adjacent to surface water, the storage of manure, and the distribution 
of manure on land adjacent to surface water, are the components of the exposure 
methodology that are altered by the precautions, which subsequently ought to demonstrate 
the necessary reduction in risk. The intended addressee is therefore the keeper of the animals 
and the manure. Should the intended addressee not be addressed and bound by the precaution, 
or the risk reduction not be demonstrable, it has to be accepted that the risk will not be 
mitigated. 
Several constraints have been identified that make risk mitigation measures 
technically or legally ineffective, hence unsuitable for labelling and packaging (see Table 1 
for an overview). 
First, through the Directive precautions are not legally binding to veterinarians and 
farmers (the consumers). In that sense, no precaution can be considered an effective risk 
reduction measure. National legislation concerning the veterinary practice must turn these 
recommendations into legal injunctions, in order to make the precautions work. The way 
precautions are worded, in relation to the national legislation determines the national legal 
status, and thus their efficacy as risk reduction measure. It is imperative that the legality of 
the precautions and the possible subjects and addressees of the precautions are defined in 
national regulation, and that this is harmonised between Member States. One way would be 
to incorporate in the Directive that consumers are bound to the precautions. Member States 
will have to transpose this into national legislation. By means of a Regulation this 
prescription would have direct effect on the consumers in all Member States. 
Second, precautions can be used to control the fate of the treated animal and the 
manure containing excreted residues, provided the legal person addressed is the keeper of the 
treated animals. If the product is to be administered by the veterinarian, environmental 
precautions regarding the treated animals or manure are thus not binding. The legislation at 
hand also does not transfer precautions regarding the treated animals and the manure to third 
parties. The solution to these shortcomings is to include this transfer of responsibilities to 
second and third parties, either in the precautions themselves or in the legislation, and to 
prohibit both trade and use of the animals and manure in the precautions during the time that 





Table 7-1 Overview of selected precautions included in the package leaflet of veterinary medicines with a 
view to mitigate environmental risk. 
Product Precaution Problem  Solution 
Eprinex Pour On  treated animals should not have direct 
access to surface water and ditches 
addressee, 
proportion 
Include transfer of liability to 
other parties, define waiting 
period 
Equimax oral gel for 
Horses ; Noromectin 
1.87% oral paste for 
Horses  
treated animals should not have direct 




Include transfer of liability to 
other parties, define waiting 
period 
Triclaben 10% Cattle should not have access to 
surface waters within 7 days after 
treatment 
addressee Include transfer of liability to 
other parties 
Clik 5% Pour-on The treated sheep should be kept away 
from water courses for at least one hour 
after treatment 
addressee Include transfer of liability to 
other parties 
Sebacil Pour-on At application of slurry of treated 
animals on agricultural fields a minimum 
distance of 10 m to bordering surface 
waters is to be observed 
addressee, 
efficacy 
Include transfer of liability to 





for Swine  
Manure from treated pigs should be 
stored for 3 months prior to spreading 
and incorporating into land 
addressee,  
efficacy  
Include transfer of liability to 





Third, precautions are only acceptable under the Directive if their potential effect can 
be demonstrated using the risk assessment methodology. Thus, the precautions forbidding 
release of treated animals or manure containing residues into the environment are technically 
effective, since the effect can be demonstrated in the methodology. The impact of temporary 
storage of manure containing residues cannot be quantified because of a lack of standardised 
model conditions. Likewise, the precise effect of the precautions prohibiting the spreading of 
manure within a certain distance to the surface water can as yet not be quantified with 
available exposure assessment methodology. The flexibility of the risk assessment 
methodology to deal with temporal and spatial differentiation in the exposure and effect 
assessment should be improved accordingly. 
Fourth, whether the precautions on confinement of the animals or the manure (for a 
time period or infinitely) leaves the farmer with reasonable alternatives is an issue of 
proportionality. Precautions that are impossible to incorporate in Good Agricultural Practice 
should be avoided. 
 
Discharges of slurry and chemical substances are in the EU also regulated by 
community legislation such as the Nitrate Directive and the Directives on water pollution 
76/464/EEC, on groundwater protection 80/86/EEC, and in the near future the Water 
Framework Directive (2000/60/EC). This type of legislation operates from the starting point 
that all actions that may lead to pollution are forbidden unless a permit is granted by the 
national competent authority. This legislation addresses different authorities than the 





application or purification techniques) as well as the maximum permissible concentration of 
the substance in the environment. The Marketing Authorisation is not a permit in this sense, 
but could provide for a firm scientific basis for the decision making by competent authorities. 
Ineffective precautions coerce the competent authorities to regulate the emission of residues. 
Also for products where the risk/benefit balance was favourable despite an environmental 
risk, the use or subsequent emission of residues necessitates regulatory consent. For example, 
for the use of Slice (containing emamectin) in the UK it will be necessary to obtain consents 
from the local environmental authorities (Anonymous, 2003). No-spreading zones are already 
Good Agricultural Practice in some Member States, for example in the UK (DEFRA, 2002). 
Alternative solutions to the use of precautions in the product information may thus be found 
in establishing precautions in permits, or in codes of Good Agricultural Practices, issued in 
these frameworks (Van Rijswick, 2001; Van Rijswick, 2003). Inevitably, the scientific and 
juridical underpinning of the precautions in these frameworks should be as meticulous as in 
the framework of registration, and will also require a flexible risk assessment methodology to 
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The objective of this thesis has been the validation of the environmental risk 
assessment methodology for the marketing authorisation of veterinary medicines27.  
 
The fate and behaviour of pharmaceuticals in the environment has been studied 
incidentally since the second half of the 20th century. In some instances, this was not with the 
intention of identifying ecological damage, but rather to find substances that combated 
(pathogenic or harmful) bacteria and had no side-effects on the particular organisms of their 
interest, such as fish for commercial breeding, algae for taxonomic studies, or soil fungi for 
research on soil nutrient cycling (Wellborn, 1969; Berland and Maestrini, 1969; Ingham and 
Coleman, 1984). The possible effect of residues on the quality of the environment was a 
concern that had been recognised since shortly after medicines were actually found in the 
environment towards the end of the 1960s. About a decade later, these concerns about 
pollution and effects had reached the regulatory agenda and were addressed in the 
81/852/EEC Directive on marketing authorisation for veterinary medicines. 
Effect studies with a variety of veterinary medicines on non-target organisms have 
been published in both environmental and agricultural literature. Exposure assessments of 
veterinary medicines by the spreading of manure were developed in the 1980’s comparable to 
those applied to heavy metals, nutrients, pathogens, and biocides. Notably from 1994 
onwards, when the EU Committee for Veterinary Medicinal Products (CVMP) initiated the 
drafting of a guidance document for the risk assessment of veterinary medicines, an 
increasing number of reviews on use, emission, fate, occurrence, effect, and risk of 
pharmaceuticals has been published in public literature. Several authors have provided 
suggestions on a risk assessment methodology for the Marketing Authorisation of veterinary 
medicines, thus increasing the body of information useful for this research into risk 
assessment.  
 
The validation exercise performed here addresses the quality of the science applied, 
which should target the high level of protection of the environment that the EU Treaty 
intends to reach (EC, 2002c). Performing a validation contributes to a better understanding of 
the information generated in the risk assessment. The representation of the environment in the 
risk model and the consequences of the choices regarding variables and relationships in the 
natural system were addressed in light of existing legislation and policy on environmental 
quality. Where possible, empirical validation of individual exposure models was performed, 
demonstrating the accuracy of the model for a specified use. The following research topics on 
model validation and on the interaction between science and regulation have been addressed 
in this thesis. 
 
                                                 





1. Harmonisation of protection goals and risk assessment methodology 
- What relevant environmental protection goals can be considered? 
- Does the integral risk model address the protection goals? 
2. The conceptual and empirical validation of models and precautionary labelling 
- Are screening level exposure models for surface water in aquaculture, for dung, and for 
soil and water in intensive animal husbandry well founded and applicable? 
- Is the soil trigger value based on effect data functional and validated? 
- Can the efficacy of mitigation measures be demonstrated by the methodology used to 
predict the risk? 
3. The use of science in the registration framework 
- Is science applied transparently and impartially in the development of risk assessment 
methodology and in the decision making for product registration?  
The findings are discussed below. 
 
8.1. Harmonisation of protection goals and risk assessment methodology  
 
In order to protect the environment, next to animal health, consumers, and 
professional users, the marketing of veterinary medicinal products is actively regulated in the 
European Union. In order to market veterinary medicines, one needs a Marketing 
Authorisation. This Marketing Authorisation is issued together with all information that can 
and should be made available when selling the product, after a scientific assessment of the 
products properties concerning quality, efficacy, and safety. An environmental risk 
assessment is to be performed as part of this assessment, and there is a clear policy and 
regulatory infrastructure to deal with this issue. This infrastructure consists of regulatory, 
administrative, and scientific bodies, at supranational, international, and national levels, and 
includes legislation, jurisprudence, trade agreements, and a number of regulatory guidance 
documents on the environmental risk assessment (EMEA, 1997; VICH, 2000; DG Enterprise, 
2000; Anonymous, 2001b).  
The guidance documents are of particular interest, since scientists forge these 
documents in order to guide other scientists in risk assessment. The first guidance document, 
or Note for Guidance, was prepared and released by the CVMP in 1997 and provided a 
comprehensive risk assessment methodology that followed the Directive in its prescription 
that the assessment had to be performed in two phases. A new guidance document on Phase I 
was prepared by the International Co-operation on Harmonisation of Technical Requirements 
for Registration of Veterinary Medicinal Products (VICH)28 and was implemented by July 1st 
2001. This guidance replaced the CVMP 1997 guidance on Phase I, the phase in which 
predominantly only the exposure of the environment to the veterinary medicines is assessed, 
but not the risks. The major changes concerned the soil concentration that should trigger a 
complete risk assessment. Not only was the trigger value increased tenfold, also groundwater 
                                                 





was no longer assessed in Phase I as an independent protection goal. This change drew the 
attention of both the scientific press and of the European Parliament29. 
As indicated in the introduction, environmental risk assessment is a scientific 
discipline that investigates the possible damage that certain activities, such as the use of 
veterinary medicines, may have on the environment. Often the risk is assessed in hierarchic 
levels, from screening level to advanced levels, where the estimations in higher levels 
overrule those in lower levels. At all levels, the same protection goals are observed, but the 
approach in the lower levels tends to be more conservative, less complicated, and with a low 
information need. When a risk in a lower level is deemed acceptable, no further assessment is 
required. 
The tiered approach in the risk assessment scheme of the registration procedure of 
veterinary medicinal products is depicted in Table 8-1. The registration procedure is divided 
in two phases, Phase I and II. Phase I has the objective to identify the level of exposure that 
determines if there is enough concern to proceed to Phase II. The objective of Phase II is to 
identify the risk and possible risk mitigation measures. From the table, it follows that the 
practice of applying exposure concentrations as triggers for risk assessment is viewed, by the 
Scientific Steering Committee of DG Sanco, as unscientific. In my opinion, the use of 
threshold values, or concentration triggers based on effect data, is still part of the scientific 
domain of risk assessment. This research is predominantly concerned with Phase I. 
 
My contradictory view on the scientific status of the use of thresholds is based on my 
perception of the scientific realm of risk assessment. The collection of protection goals, 
exposure models, and effect models, together with the conventions to apply the models and to 
harmonise their results, is by itself a model. It is a risk model to assess the risk of the use of 
veterinary medicines. The risk model includes all risk assessment methodology and all   
 





Stage in scientific 
risk assessment 
scheme 
Objective of stage Methods employed Requirements or 
applicability  
Phase I  Identify exposure  Action limits  No test requirements 
Phase II tier A Screening   Rapid prediction of 
(absence of)  risk 
Risk assessment Base data set on fate and 
toxicology  
Primary   Standard approach 
to ensure consistent 
decision making 
Extended data set on 
emission, fate and effect 
Phase II tier B 
Secondary  Substance and site-
specific refinement 
Risk assessment  
Case-by-case; depending 
on approach 
                                                 
29 Currently (April 2004), the draft guidance on Phase II, the phase in which the risk assessment is carried out, is still under 





activities employed in the risk assessment procedure at registration. The objective of the risk 
model is to provide comprehensive information on all risks related to the use of the veterinary 
medicines in order to optimise the risk-based decision (Di Fabio, 1994; Cranor, 1997). The 
aim of the tiered approach within the risk model of the registration process is to eliminate the 
no-risk situations from further regulatory actions. 
In risk assessment, both exposure and effects are modelled; the models are 
abstractions of reality and the outcomes are projections of what may happen. It depends on 
the level of protection what modelling scale is most suitable. Different scales of assessment 
aggregate information differently. Regional scale modelling may overlook local hot spots, 
and local modelling, in turn, may overlook spatial and temporal differences. The level of 
uncertainty and variability in the data associated with the assessment differs between the 
alternative scales of exposure and effect assessment. The choice of the scale hence influences 
both the modelling and the effect assessment approach. 
The objective of every individual exposure model is to predict sufficiently accurate 
exposure concentrations. Exposure models describe transport, partitioning, and degradation 
processes, and enable us to model the fate of a veterinary medicine and to predict 
concentrations in soil or water because of its use. Effect models attempt to reproduce effects 
in model organisms or model systems as a result of exposure to a veterinary medicine, and 
enable us to make an estimation of adverse effects in the environment. All model results need 
to be translated to the situation of interest, taking variability and uncertainty in the model 
predictions into account. The combination of harmonised exposure and effect data results in 
estimates of risks, for example expressed as risk quotients, or margins of safety, for the 
situation under examination. The collection of all risk parameters (i.e. all results for all 
compartments, all routes of exposure, all species of concern) is the basis for the classification 
of the risk associated with the specific use of the veterinary medicine. In general, the 
classification in deterministic risk assessment is binary: there is a risk or not.  
 
In the risk model, all relevant environmental protection goals are to be addressed. This 
statement sounds straightforward. The risk model should address all environmental 
compartments that are possibly exposed by the use of the veterinary medicine, at the high 
level of protection of the environment pursued by the European Union (Art. 174 of the EU 
Treaty (EC, 2002c)). The stage of hazard assessment is an important founding level for the 
protection goals and the geared risk model (Chapter 2).  
The risk model is to be developed to address qualitative hazards (i.e. damage to 
environmental assets) and, where applicable, quantified standards. The fact that neither the 
Treaty nor the veterinary medicines Directive define the concept of environment suggests that 
there is no ambiguity expected. It appears that this stage has been insufficiently explored in 
the drafting of the VICH Note for Guidance, since not all possibly relevant protection goals 
are targeted in Phase I. In Phase I, only soil is assessed for veterinary medicines applied to 
stabled animals. Surface water and groundwater are only assessed in Phase II. The picture 





of regulatory goals, assessment scales, model approaches, and the uncertainty and variability 
of data associated with the assessment.  
The organisational setting of the process in which the guidance was forged has 
contributed to this situation, as addressed in Chapter 6. Both the CVMP and the VICH 
guidance documents were drafted in an international working group of acknowledged 
environmental scientists, with experience in the environmental risk assessment for other 
chemicals, such as pesticides. In the drafting of the VICH Guidance, the experts involved, six 
in total, represented industry (three) and ‘regional’ governments (one for each region: EU, 
USA, and Japan). The experts had to operate with limited resources, instructions and 
responses, to design a methodology that suited different environmental interests. The EU 
expert had indeed considered the EU Directives on environmental quality in the drafting 
process. The expert had noted that the reference made in this legislation to ‘pesticides’ (in 
Directives 76/464/EEC and 80/778/EEC) and to ‘biocides’ (in Directive 80/68/EEC) was to 
affect ‘some veterinary medicines, but not all’30, further considering ‘that in specific cases 
there would be restrictions/provisions applying to products containing these substances’30, 
without a clarification of who would be responsible for these provisions. In light of this 
interpretation, the protection goals of surface water, groundwater, and drinking water quality 
should have been integrated in the risk assessment methodology. Only when this would have 
been accomplished, then for given applications it would be possible to assess whether the use 
of the veterinary medicine was to be within the reach of any environmental legislation. The 
purport of the European ‘regional’ environmental legislation was however not considered as a 
conditio sine qua non. Consequently, surface water, groundwater, and drinking water quality 
were not taken into account in the risk model as a protection goal in Phase I. 
A regulatory problem arises when a product registration procedure, through 
harmonisation at a trans-national level, neglects environmental quality objectives for which 
preservation authorities at the national level are responsible. It is clear and without dispute, 
that the legislation on registration of veterinary medicines is not an environmental legislation 
(based on Article 174 of the Treaty); and it is certainly not subsidiary to environmental 
legislation. However, there should be harmonisation of protection goals, standards and 
methodology between the relevant laws; else this may lead to a less effective implementation 
of the environmental risk assessment as a tool for environmental policy31. Not observing 
groundwater as an environmental criterion is not merely a technical flaw like having 
difficulty in establishing an acceptable effect32, as suggested by Long and Crane (2003), but a 
grave conceptual flaw in the risk model. 
For the implementation of the methodology in the European Union, a further 
elaboration of the technical guidance is therefore needed, since European environmental 
legislation forces national authorities to issue permits or letters of consent for the use of 
veterinary medicines and the emission of its residues. For example, the UK government has 
                                                 
30 Personal communication with the CVMP representative in VICH on Phase I, C. Long, June 2001. 
31 The implementation of the Framework Directive Water 2000/60/EC, with respect to the standard setting for pesticides, 
provides a recent example of this struggle.  





been subject to infringement proceedings from the European Commission over a complaint 
regarding groundwater pollution from organophosphate sheep dip, a veterinary medicine use 
(Maynard, 1997). This decision reflects the Commission’s concern that groundwater 
resources should be fully protected in accordance with Council Directive 80/68/EEC. Even, 
so to speak, if the soil concentration is below 100 µg/kg. 
Several (groups of) substances have been listed in this European environmental 
legislation as ‘priority substances’ or ‘substances of concern’. These groups of substances are 
for example ‘pesticides’, ‘biocides’, ‘chlorinated hydrocarbons’ or ‘heavy metals’. The 
decision of including a veterinary medicine in any of the special categories of, for example, 
‘pesticides’ or ‘biocides’ should be based on the state of scientific knowledge33. The 
Netherlands Health Council advised the Ministers to treat (veterinary) medicines in a way 
comparable to ‘pesticides and biocides’ because they are pharmacologically active, are spread 
continuously, and little is known on their effects (Health Council, 2001). This scientific 
opinion puts medicines on a par with ‘pesticides’ and ‘biocides’ in the environmental 
legislation34. Therefore, not only should the quality of various water compartments be one of 
the endpoints in the Phase I assessment, but also the quantitative standard for pesticides in 
drinking water (and in the Netherlands also for groundwater) of 0.1 microgram/L should 
apply. 
 
8.2. The conceptual and empirical validation of models  
 
I have performed the conceptual and empirical validation of exposure models in a 
number of publications. In the first instance, I presented and discussed in Chapter 3 four 
models for three routes of emission and distribution of veterinary medicinal products 
(aquaculture, grazing animals, and stabled animals) that reflect realistic agricultural practice 
in the Netherlands. Thereafter, an empirical validation of the slurry-soil-water models was 
attempted. For the different routes of emission, the findings are summarised below. 
Exposure assessment begins with the use and the emission routes. All relevant 
emission routes are covered in the methodology: by slurry, by dung, direct emission at 
application, and by wastewater, directly or after treatment, and by sludge. Distribution 
models follow on all these emission models35. The models that describe emission, distribution 
                                                 
33 The European Court of Justice decided in the Van Bennekom case, which addressed the question whether vitamins should 
be classified as medicinal products, that this classification must be decided on a case-by-case basis, "having regard for the 
pharmacological properties of each vitamin to the extent to which they have been established in the present state of 
scientific knowledge" C 227/82 [1983] ECR 3883. The core of this ruling is –in my opinion–, that the required 
classification of substances should be based on their properties that were established by scientific knowledge. 
34 The European Court of Justice regards pesticides and biocides as - per se - dangerous substances (Heyvaert, 1999a). The 
scientific opinion that medicines should be treated like pesticides transfers this qualification to medicines as well. 
35 Aerial emissions are not considered in the current guidance documents. Based on data from Zahn et al. (2001), air-borne 
emission of tylosin from medicated feed out of the barn was calculated to be 35% of the dosage (Powers, 2003). For 
veterinary medicines administered by water rather than feed, or directly in or on the animal, this percentage is likely to be 
much less. Differentiating this pathway will not change the worst-case exposure models for other pathways and is not 






and exposure are made up of model parameters and algorithms. The model parameters have 
dimensions and values, determined by the model structure and the environmental conditions 
that the model should cover. The different parameter values are hence not selected at random, 
but are selected from confined ranges. The combination of agronomic and environmental 
conditions that realistically represents an area in which a substance is to be applied, is named 
a scenario. Models can be run for different scenarios of interest, and provide exposure data 
for different situations of interest. 
  
Aquaculture. An exposure model for surface water through emission of waste water 
from in-house fish nurseries had been proposed for the registration procedure in the 
Netherlands (Montforts, 1999), and has been taken as a case study for this research (Chapter 
3). The results of the exposure modelling for fish medicines indicated that concentrations of 
fish medicine up to 1 mg/L might be present in surface water bodies near discharge points of 
fish nurseries (without passage through a sewage treatment) for a substantial period of time 
after treatment (25 days). However, depending on the degradation rate in a sewage treatment 
plant to which the nursery conceivably discharges, the calculated concentration in surface 
water could be 30 times lower.  
Apart from the possible connection to a sewage treatment plant, the functionality of 
the conceived settling tank in the water circulation system was validated (Chapter 4). The 
removal efficiency of settling tanks was verified using pesticide data in wash water from 
predominantly mushroom industries. Since the available data gave no proof for a settling tank 
contributing to the removal of pesticides from waste water, it was recommended for risk 
assessment purposes to consider an efficiency of 0%. The pesticide data available were 
unsuitable for a mechanistic analysis of the retention process, due to a lack of detail in the 
description of system dimensions, water volumes and flow rates, sludge characteristics and 
total pesticide load. Furthermore, the nature of the settling process of fish nursery sludge may 
be very different from that of soil or compost particles. A model sub-routine describing the 
effect of water treatment and sludge retention should be based on the system of interest.  
In order to empirically validate this model I had suggested monitoring of surface 
water for antibiotics and anthelmintics used in fish nurseries. Monitoring data from the 
effluent from a tropical fish nursery in the Netherlands supported the possibility that under 
low flow conditions of the receiving surface water the dilution of effluent water by surface 
water may be very small. Following these findings, I have revised the model. As a screening 
approach the environmental exposure levels are to be expected at the water concentration in 
the fish tank.  
 
Grazing animals. The concentration in dung was a critical component in the Phase I 
assessment proposed by the CVMP Note for Guidance, since all concentrations greater than 
10 microgram per kilogram would trigger a Phase II assessment. Alternative methods to 






The validation of the model for the concentration in dung (produced by grazing 
animals) shows that the worst-case calculations are overestimating actual concentrations, 
which suits the objective to err on the safe side, but fails the objective of realism. The 
proposed exposure assessment based on concentrations derived with actual excretion profiles 
and empirical dung production data appeared to lead to quite accurate results compared to 
field measurements. The trigger value was deemed, however, inappropriate: too low to 
discriminate between different dosages of substances (all would lead to higher 
concentrations), and too high to protect for the potent ivermectins. In the VICH Note for 
Guidance, the trigger value has been abandoned, and a Phase II assessment is warranted for 
all applications of anti-parasitic substances in grazing animals. 
The Phase II assessment will have to answer to the question whether field populations 
of insects and possibly higher trophic levels will be reduced due to the use of the medicine. 
The effect of anthelminthic treatments in grazing livestock on dung insects, worms, and 
organic matter breakdown in Europe, has been debated several times (Madsen et al., 1988; 
Madsen et al., 1990; Wratten and Forbes, 1996; McKellar, 1997; Montforts, 1997b; Suarez, 
2002; Svendsen et al., 2002; Sommer and Bibby, 2002; Lumaret and Errouissi, 2002; 
Svendsen et al., 2003; Floate et al., 2005). Contaminated dung may support some species, but 
may hypothetically function as an ecological trap for dung-dependent species that produce 
offspring only once, or feed on dung fauna (Donovan and Thompson III, 2001; Ries and 
Fagan, 2003). All papers address the population issues qualitatively, in the sense that short 
excretion periods, or availability of dung from untreated herds, are reasoned to sustain 
populations of dung dependent species. Exclusive use of these products, long excretion 
periods or use during reproductive seasons, are expected to seriously impact populations. 
However, no solutions for a quantitative approach of exposure and effect dynamics, with a 
concurrent level of acceptability were presented. Sherrat et al. (1998) demonstrated the 
impact of periodically contaminated dung on population levels of selected dung insects over 
longer periods using population modelling. To my opinion, this type of modelling is very 
useful in the registration procedure. A further development of the model approach, 
incorporating food-web modelling and the identification of indicator species and their life-
cycle strategies is needed (Petney, 1997).  
 
Slurry from stabled animals. The emission from slurry to soil and water is 
unmistakably an important and complex route. Given the many animal categories and slurry 
qualities, storage conditions and fertilising regimes, a realistic worst-case approach in a 
deterministic model is a choice that is well to understand. The actual use pattern of the 
product should be explored since repetitive use, season-related use, or concurrent uses over 
large areas, in relation to the timing and scale of emission to the environment (i.e. spreading 
of manure), have a significant impact on the actual exposure. The importance of storage of 
slurry has been noted in the guidance, but no clear guidance on the most relevant conditions 
for this parameter could be given. Therefore, scenarios for the risk assessment under different 
European conditions, incorporating information on realistic agricultural and veterinarian 





The CVMP Note for Guidance issued in 1997 contained relatively straightforward 
deterministic exposure models for soil. These models, as proposed by Spaepen et al. (1997), 
are capacity models based on fixed volumes and masses. Time windows are fixed in the 
parameter dimensions. The volumes of administered substances and produced slurry were 
based on a full year and the emission to soil was modelled as a single event. I hypothesised 
that the practice of slurry management, with repetitive spreading on grassland, would change 
soil exposure significantly. The influence of changes in values of parameters such as 
phosphate content of the slurry, mixing depth, and degradation rate, was also incorporated in 
the validation. The comparison of the CVMP models with the RIVM models demonstrated 
that differences in predicted exposure concentrations could be as high as a factor of 40. It was 
obvious that arbitrarily chosen values concerning for example the percentage of the herd 
treated, and variation in national nutrient immission standards or nutrient contents of the 
slurry, would lead to further deviating results.  
There are indications that the soil model by Spaepen et al. (1997) is under-protective 
when compared to the results of German and UK field experiments, since several field 
measurements were higher (Figure 1, Chapter 4). The model I have conceived for a single 
spreading event was more successful, although some field measurements were still higher. 
Since the slurry volume that dilutes the residue strongly determines the concentrations, slurry 
concentrations should be related to a realistic short time frame for the production and the 
dilution of the contaminated slurry in order to optimise the realistic worst case predictions. I 
also concluded that the available field data did not allow for validation of separate parameters 
in the soil exposure models. The screening models calculate homogeneous distributions of 
the residue, which represent the median concentration in soil. The field data provided some 
estimates on variability in the slurry-soil model results: not only may field concentrations 
vary a factor 30 between samples within one field (Boxall et al., 2002); also patches of slurry 
may contain concentrations 30 times above those found in more homogeneous soil 
(Hamscher et al., 2002). This variation is unavoidable, but results in a situation where the 
modelled concentration in half of the area is 1 to 10 times (or more) lower than the actual 
concentration. The risk due to a higher concentration in one spot is however not compensated 
by the absence of risk in another.  
 
The empirical validations of the CVMP and RIVM models on field data of 
(oxy)tetracycline and sulphonamides indicated that it is impossible to analyse the 
contribution of every single model parameter to the variability in the model predictions. The 
validation of the models was complicated by not only variation in doses (a function of dosage 
and animal body weight at the moment of treatment), excretion factors, dilution and 
degradation, slurry application rates and soil variability, but also factors such as 
representative sampling in slurry and soil, and field residue history. 
Surface water and groundwater models generated high deviation in results compared 
to the controlled field results. The common element of all models is that soil porewater 
concentrations are over-estimated compared to the measurements for sandy soils. Again, 





the environment will be secured. However, there is also evidence that surface water and 
groundwater contamination is not controlled by equilibrium sorption between soil and 
porewater, but also by non-equilibrium sorption, preferential flow, and movement of 
particles, run-off and soil erosion. Hence, cut-off values based on sorption properties that 
determine whether a risk assessment is performed do not guarantee sufficient protection of 
surface- and groundwater. This is further elaborated below. 
The degree of surface water contamination calculated in the screening level exposure 
models is not related to the physical transport processes taking place (erosion, run-off, 
drainage), the possible incorporation of the slurry into the soil, or the distance to the surface 
water. The soil-surface water models are merely simple transport coefficients that express the 
assumed mass transfer from soil to water. Models that describe these transport processes in 
physical terms are however available (FOCUS, 2001). Both screening and advanced level 
models share the presupposition that the area of land that connects to the ditch or stream is 
proportional to the size of the water body. In all models used in pesticide registration, the 
drainage model contains a single soil column from which drains, or run-off, discharge into 
the surface water. This single soil column makes it impossible to assess the impact of 
spatially restricted manure spreading on the surface water concentration. More advanced 
distribution models are needed to yield better judgements for differentiated land use and 
spatial risk mitigation measures.  
 
Based on the validation performed, I propose realistic worst case conditions in a 
simple scenario assuming: 
- single treatment,  
- standard European nitrogen production values,  
- an accumulated manure production volume of 1 month (30 days) containing the full 
residue,  
- no dissipation during storage, and no after-treatment of slurry. 
- a nitrogen application rate of 600 kg N/ha/year in one time onto agricultural land, which 
is distributed over 5 cm soil with a bulk density of 1500 kg.m-3, 
If the exposure calculation in Phase I according to this scenario does not exceed the 
trigger for further testing, safe use in all member states is possible. If the exposure meets the 
trigger, then realistic best case conditions, characterising a possible safe use in vulnerable 
areas under the Nitrate Directive in the European Union, are needed. I propose a similar 
scenario, now assuming active incorporation of slurry into 20 cm of soil, at a nitrogen 
application rate of 170 kg N/ha/year in one time. If the trigger is exceeded, then a phase II 
assessment should be compulsory for all member states. If the trigger is met, further 
assessments should be made at the member state level, since national environmental concerns 
may be a reason to refuse (mutual recognition of) marketing authorisation.  
The resulting concentrations in soil can be used in conjunction with the discussed 
screening level models that assume a certain mass transfer to groundwater and surface water, 
preferably without triggers on substance properties or exposure concentrations (Chapter 4 of 





However, I consider the mechanistic models provided by FOCUS equally suitable for both 
veterinary drugs and pesticides. The simple fact that this methodology applies to the same 
agricultural fields that are relevant for manure application and for pesticide use, predestined 
the accompanying scenarios to be applicable to residues spread by manure as well (FOCUS, 
2000; FOCUS, 2001). 
 
Interestingly, the difference between the results of this local soil modelling approach 
and of a mass balance at national scale appears rather small. The predicted initial soil 
concentration using the proposed scenario in conjunction with Dutch default conditions, for a 
veterinary medicine that is used in large quantities, like (oxy)tetracycline used in pigs or 
broilers, amounts to 200 µg/kg soil, with a possible maximum of 1000 µg/kg soil (Montforts, 
2003). The average concentration in soil, based on the total annual consumption of antibiotics 
of 402 tonnes, and the total capacity of the agricultural area to utilise manure in the 
Netherlands, amounts to approximately 100 µg/kg soil (Van Staalduinen et al., 2001; 
MARAN, 2002). The difference between the model and the mass balance is just one order of 
magnitude, which suggests that regional scale modelling of soil concentrations may provide 
alternative approaches for protective risk assessments in areas with intensive animal 
husbandry and manure surplus. 
 
8.3. The validation of precautionary labelling 
 
Two possible management options in response to an identified environmental risk 
were discussed in Chapter 7. The first is to eliminate the risk by denying marketing 
authorisation of the veterinary medicine in question. The second is to mitigate the predicted 
risk to an acceptable level by special precautions included in the information that 
accompanies the product. The intention then is to establish a code of conduct that is reaching 
further than the Good Agricultural Practice observed in the risk assessment.  
If risk mitigation measures are ineffective, they are unsuitable for labelling and 
packaging. The risk mitigation measures are considered effective, when the risk model can 
demonstrate their efficacy, and when the precautions have legal force. However, precautions 
are not legally binding through the Directive on its own. In that sense, no precaution can be 
considered an effective risk reduction measure. It is imperative that the legality of the 
precautions and the subjects and objects of the precautions are defined in national regulation, 
and that this is harmonised between Member States. Otherwise differences in national 
legislation may obstruct mutual recognition of registrations where this is not needful. 
Further, the wording of the precautions in relation to the national legislation 
determines the legal status. Under Dutch law, precautions can be used to control the fate of 
the treated animal and the manure containing excreted residues, provided that the legal person 
addressed is in fact the keeper of the treated animals. If the product is to be administered by 
the veterinarian, environmental precautions regarding the treated animals or manure are not 





medicines that are administered by the keeper of the animals, the current legislation does not 
transfer precautions regarding the treated animals and the manure to third parties (when the 
animals or the manure is sold). The solution to these shortcomings is to prohibit both trade 
and use of the animals and manure in the precaution. Another option is to transfer all 
responsibilities to the keeper and to other parties, either in the precautions, in EU legislation, 
or in the national regulation. 
Precautions forbidding release of treated animals or manure containing residues into 
the environment, when addressing the keeper of the animals, are not only legally, but also 
technically effective: the impact can be demonstrated with the methodology. Whether or not 
the prohibition of spreading the manure (for a time period or infinitely) leaves the farmer 
with a real alternative for the disposal of this contaminated manure, is an issue of 
proportionality. The alternative for the farmer would be to resort to alternative products. 
The impact of temporary storage of manure cannot be quantified however, because of 
a lack of standardised conditions. Likewise, the precise effect of the precautions prohibiting 
the spreading of manure within a certain distance to the surface water could not be expressed 
in terms of the exposure assessment methodology. In order to avoid marketing authorisations 
that would not comply in a legal sense with the Directive, because precautions are not 
demonstrably effective, the capacity of the risk assessment methodology to deal with 
temporal and spatial differentiation should be improved.  
 
8.4. The use of science in the registration framework 
 
In the introduction, I stated that there are potential controversies that require a 
carefully designated playing field, where science can be impartial and authoritative. One is at 
the demarcation line between science and regulation when deciding what should be 
investigated or protected, and when this protection goal is achieved. The second is the choice 
of scientific disciplines: what science is allowed and who selects the scientists? The third is 
the actual weight that science is given in the decision-making. A critical appraisal (Chapters 
2, 5, and 6 in this thesis) of the settings of the development of the guidance documents and of 
the risk assessment at registration has dealt with these aspects.  
The interconnections between science and regulation require some elucidation here. 
In the organisation of the European registration process of veterinary medicines, regulatory, 
administrative, and scientific responsibilities are separated. The Directorate-General (DG) 
Enterprise is responsible for the European policy and legislation on veterinary medicines. The 
European Medicines Agency (EMEA)36 handles the administration, and the CVMP provides 
scientific opinions. According to the European Court of Justice (case C212-91 
Angelopharm): "the Scientific Committee is the only party involved in the policy-making 
                                                 
36 In a 1987 Council decision (87/373/EEC) the phenomenon of comitology was formalised, through which the EU sought 
to ensure that Commission decisions would be taken with due regard for the political preferences of the Member States, 





process that is competent to make those scientific and technical assessments on which the 
legal validity of the measures depends" (Heyvaert, 1999a). To my opinion, both the technical 
guidance and the risk assessment at registration resort under the responsibility of science. 
CVMP and VICH have issued Notes for Guidance. These scientific guidance documents are 
crucial in the registration process.  
 
In the underpinning of the soil concentration value that triggers a Phase II assessment, 
science had been applied. This strategic effect assessment I have critically validated in this 
research. Validation is used here in the meaning of establishing whether the trigger value is 
‘well founded and applicable’ (Addiscot et al., 1995). I drew a number of conclusions on the 
data and arguments to support a soil concentration trigger in Chapter 5.  
Before the effect and risk assessment for substances spread with slurry from stabled 
animals is performed in Phase II, the concentration in soil because of this spreading is 
compared to a trigger value. The exposure trigger in soil, that determines whether a full risk 
assessment for all environmental compartments is performed, has been raised by a factor of 
10 in the VICH Note for Guidance. This new trigger value was based on an effect assessment 
performed on a data set of existing veterinary medicines. The original data set was based on 
dossiers that have been submitted to the US authorities for the registration of veterinary 
medicines (Zeeman, 1987; AHI, 1997; Nidel, 2003).  
If the data would have been assessed in the same way as the risk model for 
registration does, then the threshold will certainly be valid for the substances in the data set. 
For other compounds and for other risk models, this is not straightforward. The data set was 
very limited in the number of substances and types of endpoints. More substances and more 
discriminating properties were considered required for a case based reasoning that extends 
from substances with identified common characteristics to substances that yet have to be 
developed.  
Next to the selection of the data, the selection of ecotoxicological tools determined the 
outcome of the scientific assessment. In order to derive ‘no effect’ concentrations from a 
limited number of effect endpoints from a small group of species, assessment factors are 
applied. The argumentation presented by the VICH on the redundancy of assessment factors 
did not comply with the EU-guidance given on these matters (EC, 2003). Moreover, the 
argumentation deviates from the risk characterisation performed in the CVMP Note for 
Guidance, which constitutes the risk assessment component of the risk model.  
Because of these diverging methodologies, the predicted ‘no effect’ concentrations 
derived in Phase II may be found below the trigger value of Phase I. Consequently, the 
trigger in Phase I is not protective for its own risk model in Phase II. The trigger is not even 
protective for the compounds that were in the reference set. Applications that result in 
predicted exposure concentrations below the trigger, are not further assessed, but may cause 
damage to the terrestrial and aquatic ecosystem. Based on the distributions built from the 
                                                                                                                                                        
the European Commission (EC) through Decree 2309/93 and began its activities in 1995. The name was changed by the 





experimental evidence, the soil exposure trigger value of 100 µg/kg may already affect soil 
microbial species by 80% of the substances covered by its data set. 
I took the validation of the soil trigger value a step further by introducing other readily 
available effect data. In contrast to the reference data set discussed above, the risk model 
under consideration has not generated these data. It was demonstrated that further 
consideration of available effect data would lower the trigger. In combination with alternative 
interpretations of the given arguments for the abandonment of assessment factors, a case was 
made to set a threshold at 1 µg/kg. It should be kept in mind that the exposure trigger based 
on the soil compartment determines whether a further assessment of the surface and 
groundwater compartments is performed in Phase II. The trigger was, however, solely based 
on soil data and was not harmonised with the possible quality criteria in these other 
compartments. Even if the soil compartment would be protected at the trigger value, 
protection of groundwater and surface water quality may not have been secured. In fact, this 
may not have been the case after all. Harmonisation of effect endpoints between 
compartments, using the equilibrium partitioning method, gives reasons for soil triggers as 
low as 0.0125 µg/kg.  
The technical guidance documents not only elaborate on the requirement set in the 
legislation but also effectively define the protection goals, as argued in Chapter 2 and 6. From 
a regulatory point of view, a transparent input of scientists, Member States and interested 
parties (other regulatory authorities, manufacturers, users and consumers) is expected, in 
order to agree on protection goals and assessment methodology for the guidance documents 
(ESC, 2001). These protection goals were however not laid down in the legislation on 
product registration, quite to the opposite for the feed additives, pesticides and biocides, 
where protection goals and standards were incorporated in the EU Directives themselves, 
subjected to regulatory and political supervision. The VICH had appointed a working group 
for the drafting of the guidance documents. This working group was in my perception a 
scientific committee, but not a representation of all interested parties. The selection of 
protection goals is not the prerogative of science, and groundwater as a protection goal has 
unjustly been omitted from the risk model.  
Addiscot et al. (1995) stated that some form of critical evaluation procedure is 
essential both to maintain the integrity of modelling and to ensure that the use of models by 
regulators does not result in the propagation of misleading information. Although models for 
exposure were meant, it is clear that this statement also applies to the use of effect models 
and to the use of risk models. Both the definition of protection goals and the underpinning of 
the soil exposure trigger were not well founded.  
 
Should the development of resistance in bacterial communities due to the 
environmental exposure to antibiotics have been identified as a hazard? And what kind of 
hazard are we dealing with? Is it a hazard for the ecosystem integrity or also a hazard for 
public health in general? How can we express the degree of anticipated damage? Currently 
both molecular and ecological methods are investigated. Pollution-induced community 





there is a genetic basis for these shifts is to be explored. Shifts in community tolerance caused 
by soil pollution have been shown to have impacts on e.g. extinction of sensitive species, 
competitive abilities, and metabolic diversities. Resistance development occurs already at the 
Minimum Effect Concentration (MEC) at which growth is reduced, that is tenfold below the 
Minimum Inhibitory Concentration (MIC), the endpoint used to derive the soil concentration 
trigger discussed in Chapter 5. Thus, even at concentrations below the Phase I trigger, 
resistance genes may be favoured. The survival of adapted bacteria in absence of the 
compound that the bacteria have adapted to is limited, but the acquired functionality (e.g. 
resistance genes) remains present at low levels. The costs for resistance can even be 
compensated for. Horizontal transmission of genetic information occurs for example in the 
gut of soil arthropods. Resistance genes can be transferred from manure to soil and 
groundwater, where low levels of antibiotics may be present (Rysz and Alvarez, 2004). Since 
this hazard, that is not yet addressed in the risk model, also applies to antimicrobial products 
used as pesticide and biocide, a harmonised approach for all antibiotic use should be 
developed. 
 
8.5. Concluding remarks 
 
In conclusion, I have outlined and discussed several technical and conceptual flaws in 
the use of risk assessment in the registration process. Foremost, and perhaps for the better, the 
formalisation of the protection goals by the Note for Guidance has no legal status. The VICH 
Phase I guidance does not contain all European environmental quality criteria and includes a 
trigger for the full risk assessment that was not well founded. Screening level exposure 
models are not always protective and lack standardised scenarios for uniform assessment. 
Risk mitigation measures are not validated, and give a false impression that the risk to the 
environment is reduced to acceptable levels. Some products have been registered with 
precautions that are not in agreement with the Directive. Products that pose a threat to 
environmental quality at or after use may now be registered and be used. Authorities 
responsible for water and land quality cannot infer from the registration of a veterinary 
medicine that the use complies with the quality standards set by environmental legislation. 
This legislation now obliges these authorities to regulate and enforce product use and slurry 
use on a case by case basis through permits or letters of consent. 
All of the shortcomings identified above undermine, to a greater or to a lesser extent, 
the legitimacy of the registration process and the use of scientific opinions. Particularly the 
variability in outcomes for the soil concentration trigger is troublesome, since it gives the 
impression that science may produce information that will not lead to better judgement. The 
respectable efforts made by the regulators and scientists within CVMP and VICH need to be 
founded on clear policy decisions and embedded in a uniform and transparent decision-
making procedure. A further elaboration on European agricultural and environmental 





warranted. It should take relatively little effort to postulate European decision-making criteria 
together with their levels of acceptability, some of which this research has exemplified.   
The recently adopted Directive 2004/28/EC amends the 2001/82/EC Directive and 
will have to be implemented at member state level by October 30th, 2005. In this new 
Directive, any risk of undesirable effects on the environment has been added to the definition 
of risks relating to the use of the product. Marketing authorisation is to be denied if the risk-
benefit balance of the product is, under the authorised conditions of use, unfavourable. 
Compared to the text in the previous Directive, it is noteworthy that the qualification 
‘harmful’ has been replaced by ‘unfavourable risk-benefit balance’, meaning ‘an evaluation 
of the positive therapeutic effects of the veterinary medicinal product in relation to the risks’.  
Policy makers, regulators, and scientists should engage in a reconnaissance of 
regulatory goals, assessment scales, model approaches, and uncertainty and variability of data 
associated with the assessment. Only then, a risk model (with or without triggers) can be 
applicable to the situation of interest and provide a solid framework for making risk-benefit 
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1. Veterinary medicines are pharmacologically active substances. This property categorises 
them under substances that are denoted as pesticides or biocides. Likewise, the use of 





2. The collection of protection goals, exposure and effect models, and the conventions to 
apply and harmonise their results constitutes a risk model. The risk model is a tool to 
make scientific assessments of the environmental risks of the use of veterinary medicines. 
The selection of hazard based criteria (thus not based on the risk of the use of the 
veterinary medicine) that trigger formal risk assessment is also part of the risk model and 
hence part of the scientific domain.  
3. Present European legislation regulating the registration of veterinary medicines does not 
specify environmental protection goals. The risk model employed at the registration of 
veterinary medicines does not systematically address all environmental concerns 
identified in EU environmental legislation. The neglect of the risk to surface water and in 




4. Actual excretion profiles of residues in dung from grazing animals provide reliable input 
for modelling of concentrations of veterinary medicines excreted in dung. Contaminated 
dung may act as an ecological trap for dung dependent species, it attracts invertebrates 
without providing them the opportunity for reproduction. Population models need to be 
developed for indicator species in dynamic agro-ecosystems, taking different 
reproduction strategies and dependency relationships into account. 
5. Variation in common agricultural practices with respect to slurry storage time and the use 
of slurry on land throughout the year gives rise to a variation in soil exposure 




6. The original exposure assessment model suggested for concentrations in soil suggested is 
not worst case. Dilution of residues by clean slurry and degradation during storage are the 
main parameters that control the concentrations of residues in slurry. Environmental 





levels, are highly variable in the field. No degradation of residues represents a realistic 
worst case. Concentrations on slurry should be related to a realistic time frame in which 
the contaminated slurry is produced and diluted in order to optimise the worst case 
predictions.  
7. Distribution of slurry in the field generates a considerable spatial variability. Actual 
concentrations may be an order of magnitude above or below the averaged concentration.  
8. The complete slurry-soil distribution model cannot be validated by merely field soil 
measurements, due to the complexity and variability of all environmental and agricultural 
parameters involved.  
9. Realistic worst case conditions for protective risk assessment are hence proposed in a 
simple scenario assuming a single treatment per animal place, standard European nitrogen 
production values, a manure production volume of 1 month (30 days) containing the full 
residue, and a nitrogen application rate of 600 kg N/ha/year in one time onto agricultural 
land, which is distributed over 5 cm soil with a bulk density of 1500 kg.m-3, no 
dissipation during storage, and no after-treatment of slurry. If the exposure calculation in 
Phase I according to this scenario fails the trigger for further testing, safe use in all 
member states is possible.  
10. Realistic best case conditions, characterising a possible safe use in vulnerable areas under 
the Nitrate Directive in the European Union, are created in a scenario assuming active 
incorporation of slurry into 20 cm of soil, at a nitrogen application rate of 170 kg 
N/ha/year in one time. If the trigger were exceeded, then a phase II assessment would be 
compulsory for all member states. Further assessments should be made at the member 
state level, since environmental concerns can be a reason to refuse (mutual recognition of) 
marketing authorisation. 
11. The original surface water and groundwater distribution models are not founded on 
empirical data or on physical relationships. Consequently, trigger values for aquatic risk 
assessment following spreading of slurry to soil, based on substance properties, are not 
justified. The simple fact that the groundwater and surface water exposure methodology 
applied at the registration of plant protection products encompasses the same agricultural 
fields that are relevant for manure application predestines these models and scenarios to 
be applicable to residues spread by manure as well. In areas with intensive animal 
husbandry and manure surplus, simplified regional scale modelling of surface water 
contamination over larger time windows may well prove to be sufficiently protective.  
12. Settlement tanks for coarse soil particles in wash water do not contribute to the removal 
of pesticide from the total load in water phase. 
13. For the aquatic risk assessment of the use of veterinary medicines in aquaculture the 
worst-case environmental exposure levels are to be expected at the therapeutic 








14. For the underpinning of the value of the soil concentration trigger a reference dataset was 
used. The terrestrial ecosystem was not investigated in great detail, both with respect to 
the representation of test species and with respect to the selection of testing conditions 
and endpoints. Not all information that was available was presented.  
15. Resistance development occurs already at the Minimum Effect Concentration (MEC) at 
which growth is reduced, which is tenfold below the Minimum Inhibitory Concentration 
(MIC), the endpoint used to derive the trigger under discussion. This indicates that at the 
MIC level used in the reference dataset, a selection pressure for resistance development is 
present.  
16. For the underpinning of the value of the soil concentration trigger, the case that sorption 
reduces bioavailability, hence removing the need for assessment factors, has not been 
argued correctly. In the derivation of the value of the soil concentration trigger, the effect 
values have not been corrected for the argued influence of test conditions compared to 
standard conditions, or for the relative molar weight of the tested substance. 
17. The concept of functional redundancy does not provide an argument to refrain from using 
assessment factors to extrapolate laboratory results with model species to vulnerable 
species. 
18. For the underpinning of the value of the soil concentration trigger, the case that 
degradation in the field may mitigate effects, hence removing the need for assessment 
factors, has not been argued correctly. Not only may degradation have been reflected in 
the test result, also the risk may be increased due to persistency of the substance. 
19. For the underpinning of the value of the soil concentration trigger, harmonisation with 
protection levels in water and groundwater was not observed. A soil trigger that is not 
harmonised with protection levels for water might result in violation of water quality 
standards. 
20. Based on a statistical analysis of the reference data set, there is 45% likelihood that a 
substance represented by the reference data set will affect plant species and 80% 
likelihood that bacterial species are affected. The soil trigger is not even protective for the 
substances in the dataset under discussion.  
21. For a hypothetical substance, with a mode of action covered in the reference data set 
under discussion, and a strong preference for the water phase, the predicted MIC depends 
on the molar mass and will typically range between 1 and 15 µg/kg. The trigger for 
antibiotics can be based on other experimental bacterial test results, yielding no-effect-
levels at 100, 30, 28, 16, 4, or 2 µg/l, depending on the preference for a given community 
process, a specific single species, an certain inoculum density, or a specific endpoint.  
22. For the underpinning of the value of the soil concentration trigger, the representation of 
different mode of actions of veterinary medicines was acknowledged to be insufficient to 
set a trigger for parasiticides administered to grazing animals. The trigger value is 
however applied to these and other ill-represented compounds, spread with slurry. More 





reasoning for a soil concentration trigger that extends from substances with identified 




23. The technical guidance documents on the environmental risk assessment contain 
environmental protection goals and acceptability standards. Unlike the protection goals 
and standards codified in the directives on feed additives, biocides and pesticides, the 
goals and standards for veterinary medicines have not been subject to regulatory and 
political scrutiny. Since scientists developed the technical guidance documents, 
regulatory powers have been unobtrusively transferred to the scientific community. 
Implementation of the ERA procedure is an act that will have legal consequences for 
stakeholders (producers, users, and third parties). Formalisation of the contents and the 
procedure should be transparent and open to input by regulators, scientists, industry and 
other interested parties. 
24. Registration authorities and scientific panels should reflect in their composition the fact 
that environmental concerns are to be taken into account in the risk/benefit profile. 
25. Not all veterinary medicines are subjected to an environmental risk assessment at 
registration. 
26. A positive opinion on the environmental risk at registration is by no means a charter for 
the use of the product with respect to liabilities set by environmental legislation to the 
emission of residues.  
27. Communautarian decision-making criteria together with their levels of acceptability are 
needed. These will provide a solid basis for the implementation of the existing risk 
assessment methodologies, and subsequently help to clarify the (compulsory) data 
requirements and (realistic) risk mitigation measures. These five elements (criteria, 
standards, methodology, data requirements, and mitigation measures) will then provide a 





28. The registration framework has created an obligation for applicant and authority to assess 
the environmental risk of both the use and the disposal of the product. Potential risks 
arising from indirect exposure, i.e. by the spreading of contaminated matrices such as 
dung and manure, are within the scope of the EU Directive 2001/82/EC. At the European 
level, the CVMP is competent to make those scientific and technical assessments on 
which the marketing authorisation depends. At national level national scientific bodies 
are. The scientific body may decide what information is to be generated and when the 
assessment is conclusive on the risk/benefit profile. The dossier, to be delivered by the 
applicant, should contain all the information needed to perform the assessment, else the 





constitute a reason to deny (mutual) recognition of a marketing authorisation. The 
alternative option is to mitigate the risk to an acceptable level by special precautions in 
the information that accompanies the product.  
29. Precautions are not legally binding through the Directive 2001/82/EC on its own. In that 
sense, no precaution can be considered an effective risk reduction measure. National 
legislation concerning the veterinary practice must turn these recommendations into legal 
injunctions, in order to make the precautions work. This is realised under the Dutch 
legislation. Precautions can then be used to control the fate of the treated animal and the 
manure containing excreted residues, provided the legal person addressed is the keeper of 
the treated animals. The Dutch legislation at hand does not transfer precautions regarding 
the treated animals and the manure to third parties. The solution to these shortcomings is 
to include a transfer of responsibilities, either in the precautions themselves or in the 
national legislation, to second and third parties, and to prohibit both trade and use of the 
animals and manure in the precautions during the time that the precaution is operative. 
30. Precautions are only acceptable under the Directive if their potential effect can be 
demonstrated using the risk assessment methodology. The flexibility of the risk 
assessment methodology to deal with temporal and spatial differentiation in exposure 
should be improved accordingly. 
31. With respect to liabilities set by environmental legislation to the emission of residues to 
soil, water and groundwater, alternative solutions to the use of precautions in the product 
information may be found in establishing precautions in permits, or in codes of Good 
Agricultural Practices, issued in these legislative frameworks. Inevitably, the scientific 
and juridical underpinning of the precautions in these frameworks should be as 
meticulous as in the framework of registration, and will also require a flexible risk 






Validatie van de Europese milieurisicobeoordeling voor diergeneesmiddelen 
Samenvatting 
Diergeneesmiddelen en risico’s voor het milieu 
In de loop van de jaren zestig werd een verband gelegd tussen het gebruik van 
landbouwbestrijdingsmiddelen en de achteruitgang van de roofvogelstand. Ook waren er 
meldingen van massale sterfte van vogels ten gevolge van het gebruik van met 
bestrijdingsmiddelen behandeld zaad en lokmiddelen voor knaagdieren. De overheid 
reageerde hierop met een verbod op het gebruik van verschillende middelen, en met de 
invoering van een beoordeling van het risico voor het milieu bij de registratie van 
bestrijdingsmiddelen. Enkele incidenten met vogels en vissen waren echter te wijten aan het 
gebruik van diergeneesmiddelen. 
Diergeneesmiddelen zijn middelen die in potentie ziekte bij dieren kunnen genezen of 
afwenden, of middelen die gebruikt kunnen worden om ziekten vast te stellen, of om 
lichaamsfuncties te beïnvloeden. Wanneer we ons beperken tot de chemische stoffen, dan 
kunnen we vaststellen dat we te maken hebben met een groep van stoffen die biologisch 
actief is. Duidelijk is dat een deel van de stoffen die gebruikt worden om parasieten te 
bestrijden, ook in gebruik is als bestrijdingsmiddel. Daarnaast blijken diverse families van 
chemische verbindingen zowel diergeneesmiddelen als bestrijdingsmiddelen te omvatten. 
Een recent voorbeeld betreft de dramatische achteruitgang van populaties van verschillende 
soorten gieren in Pakistan aan het einde van jaren negentig, waardoor deze met uitsterven 
bedreigd worden. Deze achteruitgang kan verklaard worden door het gebruik van een 
ontstekingsremmer in runderen. Dit diergeneesmiddel is bij de concentratie die bij zoogdieren 
therapeutisch is, al dodelijk voor deze aaseters.  
 
De Europese Unie streeft een hoge kwaliteit van het milieu na, zoals verwoord in het 
Verdrag van Europa. Er is daarom voldoende reden voor het uitvoeren van een 
risicobeoordeling voor het milieu bij de registratie van diergeneesmiddelen. 
Risicobeoordeling voor het milieu is een wetenschappelijke activiteit, waarbij onderzocht 
wordt welke mogelijke schade een activiteit of een handeling aan het milieu kan toebrengen. 
Daarbij wordt informatie over eigenschappen en de wijze van gebruik van het geneesmiddel 
bijeengebracht, zodat een nieuw soort informatie ontstaat: een schatting van de kans op, en de 
ernst van, effecten. In de praktijk wordt gezocht naar het niveau van blootstelling, of 
concentratie, waarbij geen effecten meer optreden. In feite wordt dus een ‘geen-effect’ 
concentratie gezocht en een ‘geen-risico’ beoordeling uitgevoerd. Daarbij wordt de 
risicobeoordeling doorgaans zo uitgevoerd, dat in eerste instantie zoveel mogelijk 
onzekerheid en variatie wordt afgedekt. Op deze wijze kan men er zeker van zijn, dat een 
toepassing die leidt tot een blootsteling die lager is dan de concentratie van ‘geen-effect’, niet 
verder onderzocht hoeft te worden. Is hieraan niet voldaan, dan zal de risicobeoordeling met 
inachtneming van meer informatie over blootstelling en effecten moeten worden herhaald, 





Voordat diergeneesmiddelen verhandeld en gebruikt mogen worden in de Europese 
Unie, moeten ze geregistreerd worden. Bij de registratie worden kwaliteit, veiligheid en 
werkzaamheid van het middel nauwkeurig beoordeeld. Het risico voor het milieu is een van 
de onderdelen van deze beoordeling. Het milieu wordt beschouwd als een verzameling van 
compartimenten, zoals water, bodem, grondwater en lucht, en organismen, zoals planten, 
dieren, en bacteriën. Het milieu wordt op verschillende manieren blootgesteld aan 
diergeneesmiddelen en het kan op verschillende manieren op deze blootstelling reageren. Ten 
behoeve van deze risicobeoordeling is er een wetenschappelijke beoordelingsmethodiek 
voorhanden, die is vastgelegd in een aantal leidraden. 
 
De vraag is nu voor welke milieucompartimenten, op welke wijze en met welke 
nauwkeurigheid, deze risicobeoordeling uitgevoerd moet worden. Dit onderzoek wordt 
validatie genoemd. Valideren van een methode of een model levert inzicht op in de betekenis 
van de risicovoorspellingen. 
Ten eerste zijn daar de rekenkundige modellen waarmee blootstellingconcentraties 
worden berekend. Deze modellen kunnen beoordeeld worden op de wijze waarop zij 
geconstrueerd zijn, wat hun vermogen bepaalt om de werkelijkheid na te bootsen, of op de 
wijze waarop de relevante processen wiskundig benaderd worden, maar ook door 
proefondervindelijke resultaten te vergelijken met de voorspellingen. Indien 
modelvoorspellingen weinig nauwkeurig of beperkt relevant zijn, moeten de resultaten met 
grote voorzichtigheid gebruikt worden. Testen met organismen in het laboratorium zijn in 
feite ook modellen. Er kan slechts een beperkt aantal soorten getest worden; daarom dienen 
deze soorten alle andere organismen in het milieu te vertegenwoordigen. Daarnaast is men 
ingeval van het milieu niet zozeer bezorgd om de effecten op individuen, maar om de invloed 
op populaties en het functioneren van het grotere geheel van het ecosysteem. Deze 
samenhang is niet aanwezig in eenvoudige laboratoriumproeven, waarvan de uitkomsten 
gepaard gaan met grote onzekerheden. 
Ten tweede is daar het proces van de uitvoering van de beoordeling en de 
daarbijbehorende afspraken over het gebruik van gegevens en interpretatiewijzen van de 
grote verzameling van modeluitkomsten. Aangezien er vele soorten van gebruik van 
diergeneesmiddelen zijn, bij vele soorten doeldieren, zijn er ook diverse routes van 
blootstelling en verspreiding. In samenhang met een verscheidenheid aan beschermdoelen 
(denk bijvoorbeeld aan de kwaliteit van oppervlaktewater, sediment, grondwater, drinkwater, 
en bodem, de bescherming van soorten en van gebieden) zal de methodologie van de 
risicobeoordeling bij registratie bestaan uit een verzameling beschermdoelen, normen, 
aannames, rekenregels en conventies. Dit noem ik het risicomodel; het model dat het risico 
van het gebruik van diergeneesmiddelen voorspelt. Dit model moet worden toegepast bij de 
registratie en de uitkomsten moeten worden begrepen. Deze interpretatie van het risico wordt 
vervolgens gebruikt bij de besluitvorming. 
Bij de interpretatie van het risico komen de wereld van de wetenschap en die van het 
beleid bijeen. Op vragen als: ‘Wat moet beschermd worden?’ ‘Hoeveel risico is 





risicobeoordeling geen antwoord geven. Het moge duidelijk zijn dat het antwoord op deze 
vragen aan de basis van de risicovoorspelling moet liggen, en niet omgekeerd. Het zou ideaal 
zijn als het antwoord in de samenspraak van wetenschap en beleid ontwikkeld wordt.  
 
Zoals hierboven aangegeven, zijn er wetenschappelijke leidraden beschikbaar die de 
toepassing van het risicomodel ondersteunen en die in het registratieproces gehanteerd 
worden. De ontwikkeling van deze leidraden en het gebruik van de risicoinformatie, de 
toepasselijkheid van het risicomodel voor het milieu, de betekenis van de resultaten van de 
blootstellingmodellen en de rol van gebruiksvoorschriften op de bijsluiter van het 
diergeneesmiddel in de risicobeheersing, vormen het onderwerp van dit proefschrift. Meer 
concreet waren de vraagstellingen de volgende: 
1) Over de overeenstemming tussen beschermdoelen en risicomodel. 
a) Welke beschermdoelen zouden beoordeeld moeten worden? 
b) Richt het risicomodel zich op deze beschermdoelen? 
2) Over de validatie van de rekenmodellen en de gebruiksvoorschriften. 
a) Zijn de blootstellingmodellen voor water bij gebruik in de viskweek, voor mest bij 
gebruik in grazers, en voor bodem en water bij gebruik in de intensieve veehouderij, 
deugdelijk onderbouwd en toegepast? 
b) Is de drempelwaarde voor de bodemconcentratie, die gebaseerd is op effectgegevens, 
functioneel en deugdelijk onderbouwd? 
c) Kan de effectiviteit van gebruiksvoorschriften met het oog op risicobeheersing 
worden aangetoond met de beschikbare modellen? 
3) Over het van gebruik wetenschap in het kader van de productregistratie. 
a) Wordt de wetenschap inzichtelijk en onpartijdig toegepast in de ontwikkeling van de 
risicobeoordelingsmethodologie, en in het besluitvormingsproces bij 
productregistratie? 
Deze vragen zullen nu achtereenvolgens behandeld worden. 
 
De overeenstemming tussen beschermdoelen en risicomodel 
Het risicomodel dat gebruikt wordt bij de registratiebeoordeling bestaat uit een aantal 
fasen en stappen. De eerste fase is beperkt tot een verkenning van enkele belangrijke 
eigenschappen van het diergeneesmiddel en een berekening van de blootstelling. Hoewel in 
principe elke blootstelling een zekere schade kan opleveren, is een met wetenschappelijke 
redenen omklede drempelwaarde voor de concentratie in de bodem vastgesteld, waaronder 
een risicobeoordeling niet noodzakelijk wordt geacht. In het risicomodel is daardoor het 
milieu in eerste instantie beperkt tot het compartiment bodem.  
Uit mijn analyse blijkt dat het risicomodel voor de risicobeoordeling niet gefundeerd 
is op gemeenschappelijke Europese beschermdoelen, maar dat de beschermdoelen 
geformuleerd zijn vanuit de overeenkomsten tussen de beschermdoelen in de Verenigde 
Staten, Japan en de Europese Unie. De bescherming van grondwater en oppervlaktewater 





van grondwater en oppervlaktewater, zoals vastgelegd in Europese wetgeving, is 
onvoldoende onderkend in de voorbereidingen van de leidraden, en vervolgens ook niet in de 
uitvoeringspraktijk in Europa. Er ontstaat een probleem wanneer de beoordelingsprocedure 
voor de registratie wordt geharmoniseerd op een internationaal niveau, terwijl lokale of 
regionale autoriteiten verantwoordelijk zijn voor het bereiken en handhaven van de gewenste 
milieukwaliteit. De beoordeling bij registratie zal onvoldoende functioneren als een filter ten 
dienste van het milieukwaliteitsbeleid, en het bevoegde gezag zal ter plekke de emissie van 
diergeneesmiddelen moeten beperken middels vergunningen omdat de milieuwetgeving op 
het gebied van de waterkwaliteit dit vereist. Niettegenstaande het gegeven dat de 
registratiewetgeving geen milieuwetgeving is, moeten beschermdoelen, normen en 
methodologie tussen deze toelatings- en milieubeschermings-kaders in overeenstemming met 
elkaar zijn. Ik ben van mening dat het niet beoordelen van de blootstelling van grondwater in 
de eerste fase van het risicomodel een conceptuele fout in het risicomodel is. Immers, 
wanneer in de eerste fase de concentratie in de bodem beneden de drempelwaarde wordt 
berekend, stopt de risicobeoordeling. De blootstelling van grondwater en oppervlaktewater 
hebben geen rol gespeeld bij het vaststellen van de drempelwaarde in de bodem. De 
drempelwaarde is niet geharmoniseerd met de beschermingsniveaus voor water en 
grondwater. Een bodemconcentratie beneden de drempelwaarde kan dus risico opleveren 
voor het grond- en oppervlaktewater, die immers in contact staan met de bodem.  
Op basis van de bescherming die Europese wetgeving biedt aan grondwater en 
oppervlaktewater, is het hanteren van dit risicomodel naar mijn mening onjuist, temeer omdat 
in deze wetgeving voor enkele stofgroepen, waartoe diergeneesmiddelen ook kunnen 
behoren, al normen opgenomen zijn. De Gezondheidsraad heeft de overheid geadviseerd 
geneesmiddelen op een vergelijkbare wijze als bestrijdingsmiddelen te behandelen, en 
volgens het Nederlandse beleid betekent dat, dat de concentratie in het grondwater niet hoger 
dan 0,1 microgram per liter mag zijn. Deze concentratie kan al bereikt worden indien enkele 
grammen per hectare op het land gebracht worden. Het gebruik van een geregistreerd 
diergeneesmiddel zou daarmee een aanvaardbaar risico voor de bodem kunnen hebben, maar 
desondanks in strijd zijn met de waterkwaliteitswetgeving. 
 
Validatie van blootstellingmodellen en gebruiksvoorschriften 
De beoordeling van de blootstelling start met het gebruik van het middel: hoe wordt 
het middel gebruikt, met welke frequentie, wat komt er vrij bij gebruik of na uitscheiding 
door de dieren? De emissie is het startpunt van de modellering van de verspreiding, de 
verdeling, de ophoping en de afbraak door en in de milieucompartimenten die met elkaar in 
verbinding staan.  
De vraag die bij validatie gesteld wordt is in hoeverre het gehanteerde model 
deugdelijk en toepasselijk is. We hebben er immers mee te maken dat het onmogelijk is om 
alle processen die in de werkelijkheid plaatsvinden, in het model te vangen. Een model is per 
definitie een vereenvoudiging, en deze vereenvoudiging levert onzekerheid op over de 





De modellen bestaan in feite uit rekenregels en variabele of constante grootheden. 
Een grootheid heeft een waarde met een eenheid (of dimensie) die gekozen moet worden uit 
de werkelijkheid die het model beschrijft. De waarden worden gekozen uit specifieke 
bereiken die typisch zijn voor de situatie die het model dient te beschrijven. Bij de keuze van 
de waarde hebben we dus te maken met een zekere variabiliteit. In plaats van een waarde te 
selecteren, kan een model met behulp van kansberekeningen gebruik maken van het volledige 
bereik van waarden. Het model levert dan een verdeling van uitkomsten op, die inzicht geeft 
in het spectrum van mogelijke gevolgen. Welke modelbenadering ook gevolgd wordt, het is 
belangrijk dat bij het gebruik van modeluitkomsten duidelijk is hoe valide deze zijn in het 
licht van het oorspronkelijke doel.  
De uitdaging is om die waarde te kiezen, in samenhang met de keuze die voor andere 
waarden gemaakt moet worden, waardoor het model een voorspelling levert die het doel 
dient. De verzameling van waarden voor de landbouw- en milieukundige grootheden die 
samen een relevante modelsituatie vormen, noemen we een scenario. Afhankelijk van de 
onzekerheid in de waarden, de variabiliteit in de werkelijkheid en de complexiteit van de 
modellen, representeert de combinatie van een scenario en een model een deel van de 
werkelijkheid, en bevatten de uitkomsten een (on)zekere onnauwkeurigheid.  
 
Voor de blootstellingbeoordeling van oppervlaktewater door viskwekerijen, van mest 
van grazers en van bodem en water door het uitrijden van gier met daarin resten van 
diergeneesmiddelen, heb ik een aantal modellen ontwikkeld en deze samen met bestaande 
modellen vergeleken en gevalideerd. 
De kweek van vis in Nederland vindt voornamelijk plaats in bedrijven met 
kweekbakken. Van geneesmiddelen die toegevoegd worden aan het water of aan het voer, 
kunnen resten het milieu bereiken via het afvalwater. Concentraties in het milieu worden 
daarom bepaald door de concentratie in het afvalwater, het volume van het afvalwater, de 
verdunning door uitstroom in het ontvangende oppervlaktewater, en de aan- of afwezigheid 
van waterzuivering. De concentratie in het afvalwater hangt af van de dosering, de opname en 
uitscheiding van de stoffen door de vissen, de afbraak in de kweekbakken, de wijze waarop 
de kweekbakken ververst worden en de wijze waarop het afvalwater behandeld wordt. 
Afhankelijk van de eigenschappen van het geneesmiddel speelt de aanwezigheid van 
bezinkers, filters en rioolwaterzuivering een grote rol.  
Een bezinker is bedoeld om organische resten en slibvlokken af te vangen, waardoor 
het water hergebruikt kan worden en het afvalwater minder belastend voor het milieu is. In 
het model is de retentie van opgeloste diergeneesmiddelen in de bezinker gebaseerd op een 
interpretatie van gegevens van bestrijdingsmiddelen die in de champignonkweek en de 
bloembollenteelt gebruikt worden. Bij nadere beschouwing van deze gegevens is gebleken 
dat de interpretatie dat de helft van de opgeloste bestrijdingsmiddelen in de bezinker 
achterbleef, onjuist was. Daarnaast is het bezinksel in de viskweek, dat voornamelijk uit 
organisch materiaal bestaat, niet vergelijkbaar met bezinksel uit de champignon- of 





Afhankelijk van de stofeigenschappen kunnen concentraties van een 
diergeneesmiddel in het oppervlaktewater met een factor 30 verlaagd worden door afvoer via 
een rioolwaterzuivering.  
Tenslotte is de menging tussen afvalwater en ontvangend oppervlaktewater van 
belang. Indien er weinig stroming is, kan er weinig verdunning optreden. Meetgegevens bij 
een tropische viskwekerij tonen aan dat er sprake is van een verdunning met slechts een 
factor 2.  
Deze gegevens in aanmerking nemend, heb ik moeten concluderen dat het door mij 
voorgestelde model niet verantwoord is. Als een eerste stap in de beoordeling moet de 
concentratie in het milieu gelijkgesteld worden aan de (therapeutische) concentratie in de 
kweekbakken. Voor een verdere beoordeling is het noodzakelijk dat het blootstellingmodel 
wordt gebaseerd op een representatieve procesbeschrijving. 
 
Het tweede voorbeeld betreft residuen van diergeneesmiddelen in mest van grazende 
dieren. Dergelijke residuen kunnen grote invloed hebben op de mestfauna. Er zijn ongeveer 
250 soorten geleedpotigen bekend die afhankelijk zijn van mest, als voedselbron of als 
verblijfplaats van prooidieren. Daarnaast is er een scala aan wormen, nematoden, schimmels 
en bacteriën aangewezen op mest, en diverse vogels en zoogdieren zijn deels aangewezen op 
de insecten die aangetrokken worden door en voortkomen uit de mest37. Voor de concentratie 
in de mest was in de eerste leidraad een drempelwaarde van 10 microgram per kilogram 
voorgesteld voor de verdere risicobeoordeling. De berekening van deze concentratie was 
daarvoor cruciaal. Bij een vergelijking met veldwaarnemingen bleek dat de voorgestelde 
rekenwijze veel te hoge concentraties gaf, waardoor deze in ieder geval beschermend was. 
Met behulp van een eenvoudig model waarin de uitscheiding als functie van de tijd berekend 
werd, kon ik voorspellingen doen van concentraties in de mest op gegeven momenten, die 
redelijk nauwkeurig overeenstemden met de meetgegevens.  
 
Het derde voorbeeld betreft de verspreiding van diergeneesmiddelen met het inwerken 
van gier in de bodem. Deze emissieroute van de gier van de intensieve veehouderij via de 
bodem naar water is onmiskenbaar een belangrijke route, maar ook een ingewikkelde. Gezien 
de vele soorten doeldieren, mest, opslag, en bemestingsschema’s, stel ik voor gebruik te 
maken van een model met gekozen waarden zonder volledige kansverdelingen, met 
scenario’s toegesneden op verschillende doeldieren. De belangrijkste argumenten voor deze 
keuze zijn de inzichtelijkheid van deze scenario’s, naast het gebrek aan beschikbare 
informatie om zinvol met kansverdelingen te rekenen.  
Uit een vergelijking van de beschikbare modellen is gebleken dat de keuze van het 
aantal momenten dat gier uitgereden wordt een grote invloed heeft op de concentratie van het 
geneesmiddel in de bodem. Afhankelijk van de afbreekbaarheid van het diergeneesmiddel 
zijn verschillen in voorspelde concentraties in de bodem van een factor 40 te verwachten. 
Vergeleken met gemeten concentraties in mestkelders bleken de voorspellingen van het 
                                                 





model van de leidraad niet toereikend. De modellen die ik heb voorgesteld slaagden hier 
beter in, maar niet in alle gevallen. De afspraken over de hoeveelheid mest die op het land 
gebracht wordt, blijken van groot belang te zijn. Als er veel tijd is tussen het moment van 
toedienen van het diergeneesmiddel en het moment van uitrijden, is het residu sterk verdund, 
of verregaand afgebroken. In de modellen mag de tijd tussen toediening en uitrijden daarom 
niet te groot gekozen worden. Ook is aan het licht gekomen dat de omstandigheden voor 
afbraak van een diergeneesmiddel in een opslagbekken een bijzonder grote variatie kennen. 
De verschillen in temperatuur, zuurgraad, en gehalte aan zuurstof, vocht en voedingsstoffen 
binnen opslagsystemen en tussen opslagsystemen zijn groot, en de invloed op de omzetting 
hiervan is onbekend. Het gevolg is dat het onduidelijk is hoe afbraak in de gier gemodelleerd 
moet worden, en welke situatie als realistische ‘worst case’ zou moeten worden aangemerkt.  
Vergelijkingen tussen gemeten concentraties van een diergeneesmiddel in de bodem 
lieten zien, dat concentraties in de bodem met wel een factor 30 kunnen variëren. Deze 
variatie is niet te vermijden. De berekende concentraties gaan echter uit van een gelijkmatige 
verdeling, die in de helft van het areaal 1 tot 10 keer lager kan zijn dan de werkelijke 
concentratie. Door te rekenen met een gemiddelde concentratie kunnen risico’s onderschat 
worden. Het risico ten gevolge van een hogere concentratie op de ene plek wordt immers niet 
gecompenseerd door de lagere concentratie op een andere plek. 
Meetresultaten van concentraties diergeneesmiddelen in drainagewater en 
bodemwater, nadat deze met gier op het land gebracht waren, bleken niet voorspelbaar te zijn 
met de eenvoudige modellen die beschikbaar waren. Daarom heb ik voorgesteld gebruik te 
maken van het modelinstrumentarium voor de beoordeling van gewasbeschermingsmiddelen; 
niet alleen beschrijven deze de transportprocessen in groter detail, maar deze modellen 
beschikken ook over scenario’s voor combinaties van bodemgesteldheid en klimaat, die 
relevant zijn voor stoffen die over akkers verspreid worden. 
Ten behoeve van de beoordeling op Europees niveau, heb ik voorgesteld de 
blootstellingberekening voor de bodem na toepassing van diergeneesmiddelen bij gestalde 
dieren te beperken tot de verspreiding van een eenmalige dosis van het diergeneesmiddel, 
zonder afbraak, in de totale mestproductie van 30 dagen met een vastgesteld gehalte aan 
stikstof, over een bodemlaag van 5 centimeter landbouwgrond. Als ‘worst case’ aanname 
wordt een hoeveelheid gier gelijk aan 600 kilogram stikstof per hectare uitgereden. Indien de 
berekende concentratie in de bodem beneden de drempelwaarde is, dan is het gebruik van het 
diergeneesmiddel aanvaardbaar in alle EU landen. Is dat niet zo, dan wordt de berekening 
herhaald met een verdeling over een bodemlaag van 20 centimeter en een vracht van 170 
kilogram stikstof per hectare. Indien de drempelwaarde nog steeds wordt overschreden, is een 
verdere risicobeoordeling noodzakelijk voor alle EU landen, zo niet, dan zal op het niveau 
van de lidstaat de beoordeling uitgevoerd moeten worden. 
 Opmerkelijk is dat het quotiënt van de jaarconsumptie van antibiotica (circa 400 ton) 
en het totale areaal aan landbouwgrond in Nederland, ongeveer dezelfde bodemconcentratie 
oplevert als het model van de leidraad. In Nederland wordt méér mest geproduceerd wordt 
dan er feitelijk plaatsingsruimte is op het land. In deze situatie, waarbij het voorkomen van 





bacteriën, zou de risicobeoordeling voor de grotere watergangen op regionaal niveau gedaan 
kunnen worden. Het voordeel hiervan is dat gebruik gemaakt kan worden van modellen die 
de blootstelling van oppervlaktewater in stroomgebieden nabootsen. 
 
 Wanneer een risico voor het milieu is vastgesteld, staan er twee mogelijkheden open 
voor de besluitvormer: de toelating afwijzen, of maatregelen treffen die het risico 
verminderen tot een aanvaardbaar niveau. De laatste optie bestaat in de praktijk uit het 
opnemen van speciale aanwijzingen op de bijsluiter en verpakking van het middel. Diegene 
die het middel gebruikt is verplicht deze voorschriften te volgen, mits deze persoon daar 
redelijkerwijs toe in staat is. Voorschriften betreffende de behandelde dieren of 
verontreinigde mest missen hun uitwerking indien de veearts het middel toedient, omdat deze 
noch het lot van de dieren noch dat van de mest bepaalt. Daardoor blijft de veearts formeel 
buiten schot. Als de eigenaar van de dieren of de mest de middelen toedient, is deze wel 
gehouden aan de betreffende voorschriften. Als de eigenaar de dieren of de mest verkoopt, is 
de derde partij echter opnieuw tot niets verplicht. Zodra een van deze situaties aan de orde is, 
is het voorschrift geen effectieve maatregel, omdat in dat geval het milieu onverminderd 
blootgesteld wordt.  
Een andere beperking van voorschriften op een bijsluiter betreft de verplichting dat 
alle informatie op de bijsluiter moet worden gestaafd door het dossier. Maatregelen waarvan 
het effect niet aangetoond kan worden door de modelberekeningen, zijn niet in 
overeenstemming met de bepalingen in de wet. Zo kan het effect van de mogelijke afbraak 
van een diergeneesmiddel in de mest door een verplichting de mest tijdelijk op te slaan, niet 
worden uitgerekend, omdat in de scenario’s geen waarden voorhanden zijn voor de 
parameters die de afbraak controleren. Evenmin kan het effect van een verplichting de mest 
niet binnen een afstand van 10 meter van de slootkant uit te rijden niet aangetoond worden, 
omdat geen van de beschikbare modellen dit kan uitrekenen. Bij het opstellen van een 
risicobeoordeling en het voorstellen van voorschriften dient dus rekening gehouden te 
worden met deze haken en ogen, om te voorkomen dat oneigenlijke maatregelen opgenomen 
worden of dat technisch zinvolle maatregelen hun uitwerking missen. 
 
De rol van de wetenschap in het proces van registratie 
Wetenschap en beleid zijn met elkaar verbonden door een groot aantal geschreven en 
ongeschreven spelregels. Voor zover het de Europese registratie van diergeneesmiddelen 
betreft, zijn beleidsmatige, uitvoerende en wetenschappelijke verantwoordelijkheden 
gescheiden. De Europese Commissie, de Raad, en het Parlement zijn verantwoordelijk voor 
beleid en regelgeving. Het Europese Geneesmiddelenbureau behandelt de aanvraag en is 
daarmee verantwoordelijk voor de uitvoering. Het Comité voor geneesmiddelen voor 
diergeneeskundig gebruik levert de wetenschappelijke opinie. Ten behoeve van de 
beoordeling van het milieurisico heeft het Comité, zoals eerder opgemerkt, leidraden 
uitgevaardigd. Deze leidraden zijn cruciaal in het proces van registratie, omdat ze uitwerking 





de wetgeving zelf. In dat verband is het opmerkelijk dat voor veevoederadditieven, voor 
bestrijdingsmiddelen, en voor biociden, waaronder stoffen vallen die ook als 
diergeneesmiddel gebruikt worden, de beschermdoelen benoemd en gekwantificeerd zijn in 
de wetgeving, onder supervisie van het beleid, en niet in leidraden. Volgens het Europees 
Sociaal Comité is vanuit beleidsmatig oogpunt voor het vaststellen van Europese 
beschermdoelen en methodologie een samenwerking van beleidsmakers, uitvoerders, 
wetenschappers en belanghebbenden gewenst. Vervolgens is evenwel, volgens het Europese 
Hof van Justitie, het opstellen van wetenschappelijke en technische beoordelingen waarop de 
rechtmatigheid van maatregelen steunt, voorbehouden aan de wetenschappelijke comités. 
Naar mijn mening vallen zowel de leidraden voor de milieubeoordelingen, als de 
beoordelingen zelf, onder de verantwoordelijkheid van de wetenschap. Het vaststellen van 
beschermdoelen is echter niet een zaak van wetenschappers alleen. De meest recente leidraad 
is opgesteld door een groep wetenschappers afkomstig uit overheden en industrie. Deze groep 
kan als een wetenschappelijk comité worden aangemerkt, maar kent geen 
vertegenwoordiging van alle betrokken partijen.  
In de leidraad die door de wetenschappelijke werkgroep van de Veterinaire 
Internationale Conferentie voor de Harmonisatie (VICH) is opgesteld, is het risicomodel 
veranderd ten opzichte van de oudere leidraad van het Comité voor geneesmiddelen voor 
diergeneeskundig gebruik. De drempelwaarde voor de concentratie in de bodem ten gevolge 
van verspreiding van mest van gestalde dieren is bovendien verhoogd van 10 naar 100 
microgram per kilogram bodem. Deze verandering was gemotiveerd met een 
wetenschappelijke beoordeling van beschikbare effectgegevens door de Amerikaanse 
branchevereniging van de industrie. Deze motivering heb ik gevalideerd. De gebruikte 
gegevens bleken afkomstig te zijn uit de registratieprocedure in de Verenigde Staten. 
Wanneer alleen deze gegevens van deze stoffen in beschouwing genomen worden, betekent 
dat, dat indien overschrijding van de drempelwaarde leidt tot het produceren en beoordelen 
van deze gegevens, de drempelwaarde inderdaad beschermend zal blijken voor deze stoffen. 
De beoordeling zal immers exact dezelfde informatie genereren. Voor andere stoffen, en voor 
andere risicomodellen, is deze wederkerigheid echter afwezig. De verzameling gegevens was 
zodanig beperkt, zowel voor wat betreft het aantal stoffen, als voor wat betreft het aantal 
soorten en effecten, dat hij niet kan dienen om het risico van nog onbekende stoffen af te 
wegen. De gegeven argumenten voor het afzien van veiligheidsfactoren (die dienen om de 
onzekerheid in effecten, en de vergelijkbaarheid met andere soorten, in acht te nemen) 
voldeden niet aan de leidraden die de Europese Commissie heeft uitgevaardigd. De 
argumenten stroken echter evenmin met de beoordelingswijze van de effectgegevens die 
uitgevoerd moet worden bij overschrijding van de drempelwaarde. Als gevolg hiervan kan de 
effectwaarde in de risicobeoordeling lager zijn dan de drempelwaarde. De drempelwaarde is 
daardoor zelfs niet valide voor de stoffen waarop de drempelwaarde gebaseerd is. Gebaseerd 
op deze gegevens, met behulp van gangbare methodieken voor effectbeoordeling, voorspel ik 
dat 80% van de diergeneesmiddelen bij de drempelwaarde schade kunnen veroorzaken aan de 
microbiële levensgemeenschap in de bodem. Wanneer overige vrij beschikbare informatie in 





maar op 0,1 microgram per kilogram vastgesteld moet worden. Zou nog in aanmerking 
worden genomen, dat de concentratie in de bodem nooit mag leiden tot een overschrijding 
van een drempelwaarde in oppervlaktewater, dan zou de drempelwaarde voor bodem met nog 
een factor 8 moeten dalen. Deze enorme variatie in uitkomsten is zorgelijk, aangezien het de 
indruk wekt dat wetenschap alle gewenste antwoorden kan formuleren.  
 
Tenslotte 
Ik heb diverse technische en principiële tekortkomingen in het gebruik de 
risicobeoordeling in het proces van registratie aangeroerd. Als belangrijkste merk ik op dat 
het vastleggen van beschermdoelen in de leidraad niet bindend is. Dat is in deze situatie 
wellicht een voordeel, aangezien de meest recente leidraad niet op alle Europese 
milieucriteria aanstuurt (in het bijzonder ontbreken grondwater en water), en de 
risicobeoordeling afhangt van een onvoldoende onderbouwde drempelwaarde voor de bodem. 
De modellen die in eerste instantie gebruikt worden om de blootstelling van het milieu in te 
schatten blijken niet altijd beschermend te zijn tengevolge van het ontbreken van 
gestandaardiseerde scenario’s voor doeldieren en mest. Sommige gebruiksvoorschriften 
wekken ten onrechte de indruk dat het milieurisico tot een aanvaardbaar niveau teruggebracht 
wordt, terwijl daar geen wettelijke basis voor aanwezig is. Als gevolg van deze 
tekortkomingen kunnen milieugevaarlijke diergeneesmiddelen geregistreerd worden, 
waardoor de regionale of lokale overheid, die verantwoordelijk is voor de plaatselijke 
milieukwaliteit, gedwongen is het gebruik van diergeneesmiddelen, het uitrijden van mest, of 
het weiden van vee, middels vergunningen te reguleren. Dit zal in de praktijk een uitermate 
omvangrijke administratieve last betekenen. 
Over de wijze waarop de ontwikkeling van resistentie tegen antibiotica betrokken 
moet worden in de beoordeling is nog onvoldoende kennis ontwikkeld.  
De beschreven tekortkomingen ondermijnen in meer of mindere mate de 
rechtmatigheid van het registratieproces en van de wetenschap. De recente Richtlijn 
2004/28/EC, die voor 30 oktober 2005 in nationale wetgeving omgezet moet worden, gaat 
voor de beoordeling van een registratie uit van de verhouding voordelen/risico's. Met relatief 
weinig inspanning zouden gemeenschappelijke besluitvormingscriteria vastgesteld kunnen 
worden, waartoe in dit proefschrift een eerste aanzet gegeven is. Het belangrijke werk van 
wetenschappers moet gefundeerd worden op heldere besluiten van beleidsmakers, en 
verankerd in een uniform en inzichtelijk besluitvormingsysteem. Een verdergaande 
uitwerking van scenario's betreffende de Europese landbouw- en milieukundige 
omstandigheden, van beleidsmatige en wettelijke beperkingen, en van een integraal 
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